



(86) Date de dépôt PCT/PCT Filing Date: 2010/01/28

(87) Date publication PCT/PCT Publication Date: 2010/08/05

(45) Date de délivrance/Issue Date: 2017/10/17

(85) Entrée phase nationale/National Entry: 2011/06/28

(86) N° demande PCT/PCT Application No.: AU 2010/000080

(87) N° publication PCT/PCT Publication No.: 2010/085844

(30) Priorité/Priority: 2009/01/29 (US61/148,271)

(51) Cl.Int./Int.Cl. *G01N 33/53* (2006.01),
C07K 14/705 (2006.01), *C12N 15/09* (2006.01),
G01N 21/64 (2006.01), *G01N 21/76* (2006.01)


(72) Inventeurs/Inventors:
TROWELL, STEPHEN CHARLES, AU;
HORNE, IRENE MARY, AU;
DACRES, HELEN, AU;
LEITCH, VIRGINIA, AU

(73) Propriétaire/Owner:
COMMONWEALTH SCIENTIFIC AND INDUSTRIAL
RESEARCH ORGANISATION, AU

(74) Agent: SMART & BIGGAR


(54) Titre : MESURE DE L'ACTIVATION D'UN RECEPTEUR COUPLE AUX PROTEINES G

(54) Title: MEASURING G PROTEIN COUPLED RECEPTOR ACTIVATION



(57) **Abrégé/Abstract:**

The present invention relates to methods and polypeptides for detecting a compound in a sample. In particular, the present invention relates to the use of a cell- free composition comprising at least one G protein coupled receptor embedded in a lipid bilayer which when expressed in a cell the N-terminus of the G protein coupled receptor, or subunits thereof, is outside the cell and the C-terminus is inside the cell, and which is capable of binding the compound. Optionally, the composition also comprises at least one accessory molecule that directly or indirectly binds an intracellular loop and/or the C-terminus of the G protein coupled receptor. The G protein coupled receptor, and/or accessory molecule when present, in combination comprise a bioluminescent protein and an acceptor molecule, which enables bioluminescent resonance energy transfer (BRET) to be used to detect the compound binding the receptor.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
5 August 2010 (05.08.2010)(10) International Publication Number
WO 2010/085844 A1

(51) International Patent Classification:

G01N 33/53 (2006.01) *C07K 14/705* (2006.01)
C12N 15/09 (2006.01) *G01N 21/64* (2006.01)
G01N 21/76 (2006.01)

(21) International Application Number:

PCT/AU2010/000080

(22) International Filing Date:

28 January 2010 (28.01.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/148,271 29 January 2009 (29.01.2009) US

(71) Applicant (for all designated States except US): **COMMONWEALTH SCIENTIFIC INDUSTRIAL RESEARCH ORGANISATION** [AU/AU]; Limestone Avenue, Campbell, Australian Capital Territory 2612 (AU).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **TROWELL, Stephen, Charles** [GB/AU]; 3 Farrelly Close, Oxley, Australian Capital Territory 2903 (AU). **HORNE, Irene, Mary** [AU/AU]; 81 Rossi Street, Yass, New South Wales 2582 (AU). **DACRES, Helen** [GB/AU]; 10 Tarraleah Crescent, Lyons, Australian Capital Territory 2606 (AU). **LEITCH, Virginia** [AU/AU]; 5 Moulden Court, Belconnen, Australian Capital Territory 2617 (AU).

(74) Agent: **FB RICE & CO**; Level 23, 200 Queen Street, Melbourne, Victoria 3000 (AU).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: MEASURING G PROTEIN COUPLED RECEPTOR ACTIVATION

Figure 1



(57) Abstract: The present invention relates to methods and polypeptides for detecting a compound in a sample. In particular, the present invention relates to the use of a cell-free composition comprising at least one G protein coupled receptor embedded in a lipid bilayer which when expressed in a cell the N-terminus of the G protein coupled receptor, or subunits thereof, is outside the cell and the C-terminus is inside the cell, and which is capable of binding the compound. Optionally, the composition also comprises at least one accessory molecule that directly or indirectly binds an intracellular loop and/or the C-terminus of the G protein coupled receptor. The G protein coupled receptor, and/or accessory molecule when present, in combination comprise a bioluminescent protein and an acceptor molecule, which enables bioluminescent resonance energy transfer (BRET) to be used to detect the compound binding the receptor.



WO 2010/085844 A1

MEASURING G PROTEIN COUPLED RECEPTOR ACTIVATION

FIELD OF THE INVENTION

The present invention relates to methods and polypeptides for detecting a compound in a sample. In particular, the present invention relates to the use of a cell-free composition comprising at least one G protein coupled receptor embedded in a lipid bilayer which when expressed in a cell the N-terminus of the G protein coupled receptor, or subunits thereof, is outside the cell and the C-terminus is inside the cell, and which is capable of binding the compound. Optionally, the composition also comprises at least one accessory molecule that directly or indirectly binds an intracellular loop and/or the C-terminus of the G protein coupled receptor. The G protein coupled receptor, and/or accessory molecule when present, in combination comprise a bioluminescent protein and an acceptor molecule, which enables bioluminescent resonance energy transfer (BRET) to be used to detect the compound binding the receptor.

BACKGROUND OF THE INVENTION

G protein coupled receptors (GPCRs) are a family of transmembrane receptors that sense molecules outside the cell and activate inside signal transduction pathways and, ultimately, cellular responses. GPCRs are found only in eukaryotes including yeast and animals. The ligands that bind and activate GPCRs include light-sensitive compounds, odors, pheromones, hormones, and neurotransmitters, and vary in size from small molecules to peptides to large proteins. G protein-coupled receptors are involved in many diseases, and are also the target of therapeutic drugs.

Vertebrate and *C. elegans* odorant receptors (ORs) are members of the G-protein coupled receptor (GPCR) family (Buck et al., 1991; Troemel et al., 1995). GPCRs are characterised by their seven transmembrane spanning domains with ligand binding domains inferred to be on the extracellular side of the membrane and G-protein binding domains on the intracellular side. When a receptor binds the ligand, a conformational change occurs in the receptor allowing it to activate a heterotrimeric G-protein (Kobilka et al., 2007). The activated G-protein can then activate signal transduction pathways such as the guanyl cyclase or phospholipase C pathways, transducing the signal to higher processing centres (Gaillard et al., 2004).

Forster resonance energy transfer, or simply resonance energy transfer (RET), is the non-radiative transfer of energy from an excited state donor molecule to a ground state acceptor molecule (Ghanouni et al., 2001). Energy transfer efficiency is

dependent on the distance between the donor and acceptor, the extent of the spectral overlap and the relative orientation of the acceptor and donor dipoles. Previous cases where intramolecular RET has been used to monitor GPCR activation have employed a fluorescent donor and acceptor, a method referred to as fluorescence resonance energy transfer (FRET). In most cases both the fluorescent donor and acceptor are engineered variants of green fluorescent protein (GFP) from *Aequoria victoria* (Tsien, 1998). The most widely used FRET pair is cyan fluorescent protein (CFP) as the donor alongside yellow fluorescent protein (YFP) as the acceptor (Piston and Kremers, 2007) and this FRET system has previously been used to quantify direct ligand binding by a number of GPCRs (Lohse et al., 2003 and 2007; Vilardaga et al., 2003; Rochais et al., 2007; Lisenbee et al., 2007).

One method for monitoring receptor activation involves dual labelling a single GPCR with CFP and YFP at insertion sites within the third intracellular loop and C-terminus, respectively. Excitation of CFP with light at 436 nm causes CFP emission at 480 nm and FRET to YFP, which emits at 535 nm. The efficiency of FRET varies with the sixth power of the distance between donor and acceptor, providing an exquisitely sensitive indication of conformational changes in the GPCR. This was demonstrated with α 2AR, parathyroid hormone receptor (PTHr), β 1-AR and secretin receptors in intact cells. Interaction of the agonists noreadrenaline with α 2AR (Lohse et al., 2003), parathyroid hormone with PTHr (Vilardaga et al., 2003), norepinephrine with β 1-AR (Rochais et al., 2007) and secretin with secretin receptors (Lisenbee et al., 2007) changed the distance between CFP and YFP thus causing a change in FRET signal.

Replacement of the YFP acceptor with FAsH, a fluorescein arsenical hairpin binder, in a FRET system (Hoffman et al., 2005; Nakanishi et al., 2006) resulted in a five-fold greater increase in agonist-induced FRET signal compared with the CFP/YFP system when used to monitor α 2-adrenergic receptor activation (Nakanishi et al., 2006). However, FAsH involves a more difficult labelling and washing procedure which has limited use in the wider research community. The CFP/YFP system remains the most frequently reported FRET system for monitoring intramolecular conformational change. A major disadvantage associated with FRET is the need for a light source to energise the donor fluorophore (Piston and Kremers, 2007). This causes unwanted direct excitation of the acceptor at the donor excitation wavelength (a problem referred to as 'cross-talk').

In bioluminescence resonance energy transfer (BRET), the donor fluorophore of FRET is replaced with a luciferase and the acceptor can be any suitable fluorophore. The use of a luciferase avoids the need for illumination as the addition of a substrate

initiates bioluminescent emission and hence, RET. Two common implementations of BRET comprise *Renilla* luciferase (RLuc) with either coelenterazine *h* (BRET¹; $\lambda_{em} = \sim 475$ nm) or coelenterazine 400a (Clz400a) substrate (BRET²; $\lambda_{em} = \sim 395$ nm) as the donor system coupled to either of the GFP mutants, YFP (BRET¹; $\lambda_{em} = \sim 530$ nm) or GFP² (BRET²; $\lambda_{em} = \sim 510$ nm). The BRET² system offers superior spectral separation between the donor and acceptor emission peaks of ~ 115 nm compared to ~ 55 nm for the BRET¹ system at the expense of the quantum yield (Pfleger and Eidne et al., 2006).

FRET with odorant receptors has only previously been demonstrated for Class A (α_2 -adrenergic and parathyroid hormone, (Vilardaga et al., 2003)) and Class B (secretin, (Lisenbee et al., 2007)) GPCRs. Unlike mammalian ORs, which belong to GPCR Class A, nematode ORs (Robertson, 1998 and 2001) belong to neither of these classes and are evolutionarily and structurally distinct. Furthermore, all ORs, including mammalian ORs, which sit within Class A of the GPCR superfamily, are atypical in respect of their expression. Generally these proteins cannot be functionally expressed other than in neurons derived from the chemosensory lineage. A number of accessory proteins have been identified whose presence is required for proper expression of mammalian and nematode ORs.

Thus, there is a need for suitably sensitive methods and molecules which enable the detection of compounds which bind G protein coupled receptors for use in, for example, biosensors.

SUMMARY OF THE INVENTION

The present inventors have surprisingly found that cell-free bioluminescence resonance energy transfer (BRET) using chimeric G protein coupled receptors (GPCRs), such as odorant receptors (ORs), to detect a target compound is more sensitive than other detection methods such as BRET using whole cells or FRET.

Thus, in a first aspect the present invention provides a method of detecting a compound, the method comprising,

- i) contacting a sample with a cell-free composition comprising
 - a) at least one G protein coupled receptor embedded in a lipid bilayer, and which is capable of binding the compound, and
 - b) optionally at least one accessory molecule that directly or indirectly binds an intracellular loop and/or the C-terminus of the G protein coupled receptor, wherein the G protein coupled receptor comprises one or more subunits that are the same or different, and wherein the G protein coupled receptor, and/or accessory

molecule when present, in combination comprise a bioluminescent protein and an acceptor molecule,

ii) simultaneously or sequentially with step i) providing a substrate of the bioluminescent protein, and allowing the bioluminescent protein to modify the substrate,

iii) determining if step ii) modulates bioluminescent resonance energy transfer (BRET) between the bioluminescent protein and the acceptor molecule,

wherein the spatial location and/or dipole orientation of the bioluminescent protein relative to the acceptor molecule is altered when the compound binds the G protein coupled receptor, and wherein when expressed in a cell the N-terminus of the G protein coupled receptor, or subunits thereof, is outside the cell and the C-terminus inside the cell.

In one embodiment, a subunit of the G protein coupled receptor which is capable of binding the compound comprises

- i) the bioluminescent protein, and
- ii) the acceptor molecule,

and wherein the spatial location and/or dipole orientation of the bioluminescent protein relative to the acceptor molecule is altered when the compound binds the subunit. For example, the subunit may comprise

- i) an amino acid sequence provided as SEQ ID NO:13, 15, 52 or 54, or
- ii) an amino acid sequence which is at least 40% identical to any one or more of SEQ ID NO:13, 15, 52 or 54.

In an alternate embodiment, the G protein coupled receptor comprises

- i) a first subunit comprising
 - a) the bioluminescent protein, and
 - b) the acceptor molecule, and
- ii) a second subunit which is capable of binding the compound,

and wherein the spatial location and/or dipole orientation of the bioluminescent protein relative to the acceptor molecule is altered when the compound binds the second subunit.

In a further embodiment,

- i) the bioluminescent protein forms part of the third non-transmembrane loop of the subunit, and the acceptor molecule forms part of the fifth non-transmembrane loop, or

ii) the acceptor molecule forms part of the third non-transmembrane loop of the subunit, and the bioluminescent protein forms part of the fifth non-transmembrane loop, or

iii) the bioluminescent protein forms part of the first non-transmembrane loop of the subunit, and the acceptor molecule forms part of the third non-transmembrane loop, or

iv) the acceptor molecule forms part of the first non-transmembrane loop of the subunit, and the bioluminescent protein forms part of the third non-transmembrane loop, or

v) the bioluminescent protein forms part of the fifth non-transmembrane loop of the subunit, and the acceptor molecule forms part of the C-terminus, or

vi) the acceptor molecule forms part of the fifth non-transmembrane loop of the subunit, and the bioluminescent protein forms part of the C-terminus.

In yet another alternate embodiment, the G protein coupled receptor comprises

i) a first subunit comprising the bioluminescent protein, and

ii) a second subunit comprising the acceptor molecule. For example, the first or second subunit may comprise:

i) an amino acid sequence provided as SEQ ID NO: 17 or 19, or

ii) an amino acid sequence which is at least 40% identical to SEQ ID NO: 17 and/or 19.

In an embodiment,

i) the bioluminescent protein forms part of the third non-transmembrane loop of the first subunit, and the acceptor molecule forms part of the fifth non-transmembrane loop of the second subunit, or

ii) the acceptor molecule forms part of the third non-transmembrane loop of the first subunit, and the bioluminescent protein forms part of the fifth non-transmembrane loop of the second subunit, or

iii) the bioluminescent protein forms part of the first non-transmembrane loop of the first subunit, and the acceptor molecule forms part of the third non-transmembrane loop of the second subunit, or

iv) the acceptor molecule forms part of the first non-transmembrane loop of the first subunit, and the bioluminescent protein forms part of the third non-transmembrane loop of the second subunit, or

v) the bioluminescent protein forms part of the fifth non-transmembrane loop of the first subunit, and the acceptor molecule forms part of the C-terminus of the second subunit, or

vi) the acceptor molecule forms part of the fifth non-transmembrane loop of the first subunit, and the bioluminescent protein forms part of the C-terminus of the second subunit.

In a further alternate embodiment,

i) the G protein coupled receptor comprises a subunit comprising the bioluminescent protein, and the accessory molecule comprises the acceptor molecule, or

ii) the G protein coupled receptor comprises a subunit comprising the acceptor molecule, and the accessory molecule comprises the bioluminescent protein.

In another alternate embodiment, the accessory molecule comprises

i) the bioluminescent protein, and

ii) the acceptor molecule.

In a further alternate embodiment, the composition comprises at least two accessory molecules, and wherein a first accessory molecule comprises the bioluminescent protein and a second accessory molecule comprises the acceptor molecule.

The present inventors were particularly surprised to find how superior the present invention is when compared to FRET-cellfree and BRET-whole cell detection systems. Thus, in a preferred embodiment, the method of the invention is at least 2 fold, 3 fold or 4 fold more sensitive than if a non-bioluminescent protein is used as a donor molecule and a modulation of fluorescence resonance energy transfer (FRET) is determined. In a further preferred embodiment, the method of the invention provides at least a 10 fold, 20 fold, 30 fold or 40 fold more intense BRET signal than if the method used the same G protein coupled receptor present in an intact cell instead of being in a cell-free composition.

Given the atypical nature of Class A GPCRs, ORs generally and nematode ORs in particular, it was surprising that a chimera comprising a Class A GPCR with BRET donor and acceptor tags would a) retain structural integrity and b) be capable of transducing receptor activation by an odorant into an optical signal. Thus, in a preferred embodiment, the G protein coupled receptor is a Class A GPCR. In a further preferred embodiment, the class A GPCR is an odorant receptor. The odorant receptor can be from any source as long as when expressed in a cell the N-terminus of the receptor is outside the cell and the C-terminus is inside the cell. Examples include, but are not limited to, a chordate receptor, a nematode receptor, or a biologically active variant or fragment of any one thereof. Examples of chordate receptors include, but are not limited to mammalian receptors, avian receptors and fish receptors. In a preferred

embodiment, the odorant receptor is a nematode receptor or biologically active variant or fragment thereof. In an embodiment, the nematode receptor is a *Caenorhabditis elegans* receptor, or biologically active variant or fragment thereof.

In an embodiment, the odorant receptor comprises:

- i) an amino acid sequence as provided in any one of SEQ ID NOs 1 to 6, and
- ii) an amino acid sequence which is at least 40% identical to any one or more of SEQ ID NO:1 to 6.

In another embodiment, the subunit is a chimera of a portion of two or more different G protein coupled receptor subunits.

The accessory molecule can be any molecule that directly or indirectly associates with the G protein coupled receptor. Examples include, but are not limited to, G protein and arrestin.

The effect of changing compound concentrations on the amplitude of the change in BRET has provided the first demonstration that the response is dose-dependent. Thus, in a preferred embodiment the level of BRET is indicative of the relative amount of the compound in the sample.

Examples of bioluminescent proteins include, but are not limited to, a luciferase, a β -galactosidase, a lactamase, a horseradish peroxidase, an alkaline phosphatase, a β -glucuronidase or a β -glucosidase.

Examples of luciferases include, but are not limited to, a *Renilla* luciferase, a Firefly luciferase, a Coelenterate luciferase, a North American glow worm luciferase, a click beetle luciferase, a railroad worm luciferase, a bacterial luciferase, a *Gaussia* luciferase, Aequorin, a *Arachnocampa* luciferase, or a biologically active variant or fragment of any one, or chimera of two or more, thereof.

Examples of substrates include, but are not limited to, beetle luciferin, other luciferins, coelenterazine, or a derivative of coelenterazine. Also, in the case of some luminescent proteins such as aequorin, the substrate may be a cofactor such as calcium ions.

In one embodiment, the acceptor molecule is a protein, examples of which include, but are not limited to, green fluorescent protein (GFP), blue fluorescent variant of GFP (BFP), cyan fluorescent variant of GFP (CFP), yellow fluorescent variant of GFP (YFP), enhanced GFP (EGFP), enhanced CFP (ECFP), enhanced YFP (EYFP), GFPS65T, Emerald, Topaz, GFPuv, destabilised EGFP (dEGFP), destabilised ECFP (dECFP), destabilised EYFP (dEYFP), HcRed, t-HcRed, DsRed, DsRed2, t-dimer2, t-dimer2(12), mRFP1, pocilloporin, *Renilla* GFP, Monster GFP, paGFP, Kaede protein or a Phycobiliprotein, or a biologically active variant or fragment of any one thereof.

In an alternate embodiment, the acceptor molecule is a non-protein, examples of which include, but are not limited to, an Alexa Fluor dye, Bodipy dye, Cy dye, fluorescein, dansyl, umbelliferone, fluorescent microsphere, luminescent microsphere, fluorescent nanocrystal, Marina Blue, Cascade Blue, Cascade Yellow, Pacific Blue, Oregon Green, Tetramethylrhodamine, Rhodamine, Texas Red, rare earth element chelates, or any combination or derivatives thereof.

In another embodiment, the methods further comprise simultaneously or sequentially with step i) or step ii) providing a co-factor of the bioluminescent protein. Examples include, but are not limited to, ATP, magnesium, oxygen, FMNH₂, calcium, or a combination of any two or more thereof.

In an embodiment, the cell-free composition was obtained by producing the G protein coupled receptor in a recombinant cell and disrupting the membrane of the cell.

In an embodiment, the recombinant cell does not produce any non-endogenous proteins which associate with the G protein coupled receptor.

The cell from which the cell-free composition can be obtained is any cell type capable of expressing the G protein coupled receptor and incorporating the receptor into its cell membrane. In a particularly preferred embodiment, the recombinant cell is a yeast cell.

In an alternate embodiment, the G protein coupled receptor is embedded in the lipid bilayer of a liposome.

In a further embodiment, the method is preformed using microfluidics.

In another aspect, the present invention provides a purified and/or recombinant polypeptide for detecting a compound, the polypeptide comprising,

- i) a subunit of a G protein coupled receptor, and
- ii) a bioluminescent protein and/or an acceptor molecule,

wherein when expressed in a cell the N-terminus of the subunit is outside the cell and the C-terminus inside the cell.

In an embodiment, the polypeptide forms part of a protein complex which is a G protein coupled receptor comprising one or more different G protein coupled receptor subunits, and optionally one or more different accessory molecules.

In an embodiment,

- i) the bioluminescent protein forms part of the third non-transmembrane loop of the subunit, and the acceptor molecule forms part of the fifth non-transmembrane loop,
- or

ii) the acceptor molecule forms part of the third non-transmembrane loop of the subunit, and the bioluminescent protein forms part of the fifth non-transmembrane loop, or

iii) the bioluminescent protein forms part of the first non-transmembrane loop of the subunit, and the acceptor molecule forms part of the third non-transmembrane loop, or

iv) the acceptor molecule forms part of the first non-transmembrane loop of the subunit, and the bioluminescent protein forms part of the third non-transmembrane loop, or

v) the bioluminescent protein forms part of the fifth non-transmembrane loop of the subunit, and the acceptor molecule forms part of the C-terminus, or

vi) the acceptor molecule forms part of the fifth non-transmembrane loop of the subunit, and the bioluminescent protein forms part of the C-terminus, or

vii) the bioluminescent protein or the acceptor molecule forms part of the first non-transmembrane loop of the subunit, or

viii) the bioluminescent protein or the acceptor molecule forms part of the third non-transmembrane loop of the subunit, or

ix) the bioluminescent protein or the acceptor molecule forms part of the fifth non-transmembrane loop of the subunit, or

x) the bioluminescent protein or the acceptor molecule forms part of the C-terminus of the subunit.

In a further embodiment, the polypeptide comprises the bioluminescent protein and the acceptor molecule, and wherein the spatial location and/or dipole orientation of the bioluminescent protein relative to the acceptor molecule is altered when the compound binds the polypeptide.

In an alternate embodiment, the polypeptide comprises the subunit and the bioluminescent protein, and the polypeptide is directly or indirectly bound to a second polypeptide comprising an acceptor molecule, and wherein the spatial location and/or dipole orientation of the bioluminescent protein relative to the acceptor molecule is altered when the compound binds the polypeptide and/or the second polypeptide.

In a further alternate embodiment, the polypeptide comprises the subunit and the acceptor molecule, and the polypeptide is directly or indirectly bound to a second polypeptide comprising a bioluminescent protein, and wherein the spatial location and/or dipole orientation of the bioluminescent protein relative to the acceptor molecule is altered when the compound binds the polypeptide and/or the second polypeptide.

In the above two embodiments, the second polypeptide either comprises an G protein coupled receptor subunit (to form a homo- or hetero-dimer or higher multimer as defined herein) or an accessory molecule.

In a further aspect, the present invention provides a purified and/or recombinant polypeptide for detecting a compound, the polypeptide comprising,

i) an accessory molecule that directly or indirectly binds an intracellular loop and/or the C-terminus of the G protein coupled receptor, and

ii) a bioluminescent protein and/or an acceptor molecule,

wherein when expressed in a cell the N-terminus of the G protein coupled receptor, or subunits thereof, is outside the cell and the C-terminus inside the cell.

As the skilled reader will appreciate, many of the above embodiments relating to the methods of detection also apply to the polypeptide aspects of the invention.

Also provided is an isolated and/or exogenous polynucleotide encoding a polypeptide of the invention.

In an embodiment, the polynucleotide comprises:

i) a nucleotide sequence as provided in any one of SEQ ID NO's 7 to 12, 14, 16, 18, 20, 51 or 53, or

ii) a nucleotide sequence which is at least 40% identical to any one or more of SEQ ID NO's 7 to 12, 14, 16, 18, 20, 51 or 53.

In another aspect, provided is a vector comprising a polynucleotide of the invention. In a preferred embodiment, the polynucleotide is operably linked to a promoter.

In a further aspect, provided is a host cell comprising the polynucleotide of the invention and/or the vector of the invention.

Preferably, the host cell produces, and hence comprises, a polypeptide of the invention.

The host cell can be any cell type.

The present inventors are also the first to show the functional expression of a nematode odorant receptor, which are evolutionarily different to mammalian odorant receptors, in yeast membranes. Thus, in a preferred embodiment the host cell is a yeast cell.

In a further aspect, the present invention provides a composition comprising the polypeptide of the invention, the polynucleotide of the invention, the vector of the invention, and/or the host cell of the invention.

Preferably, the polypeptide is embedded in a lipid bilayer.

Also provided is a cell-free composition comprising,

i) the polypeptide of the invention comprising a G protein coupled receptor subunit, wherein the polypeptide is embedded in a lipid bilayer, and/or

ii) the polypeptide of the invention comprising an accessory molecule which is directly or indirectly bound to an intracellular loop and/or the C-terminus of a G protein coupled receptor, wherein the G protein coupled receptor is embedded in a lipid bilayer, and wherein when expressed in a cell the N-terminus of the G protein coupled receptor, or subunits thereof, is outside the cell and the C-terminus inside the cell.

Preferably, the lipid bilayer is a yeast lipid bilayer.

In an embodiment, the cell-free composition further comprises a substrate of the bioluminescent protein and/or a co-factor of the bioluminescent protein.

As the skilled reader will appreciate, many of the above embodiments relating to the methods of detection also apply to the cell-free aspect of the invention.

In a further aspect, the present invention provides a method of producing a cell-free composition of the invention, the method comprising obtaining a cell of the invention and disrupting the membrane of the cells.

In an embodiment, the cells are permeabilized or lysed.

In an embodiment, the cells are lysed in a French press.

In another aspect, the present invention provides a biosensor comprising a polypeptide of the invention, a host cell of the invention, a composition of the invention and/or a cell-free composition of the invention.

In a further aspect, the present invention provides a method for screening for a compound that binds a G protein coupled receptor, the method comprising,

i) contacting a candidate compound with a cell-free composition comprising

a) at least one G protein coupled receptor embedded in a lipid bilayer, and which is capable of binding the compound, and

b) optionally at least one accessory molecule that directly or indirectly binds an intracellular loop and/or the C-terminus of the G protein coupled receptor, wherein the G protein coupled receptor comprises one or more subunits that are the same or different, and wherein the G protein coupled receptor, and/or accessory molecule when present, in combination comprise a bioluminescent protein and an acceptor molecule,

ii) simultaneously or sequentially with step i) providing a substrate of the bioluminescent protein, and allowing the bioluminescent protein to modify the substrate,

iii) determining if step ii) modulates bioluminescent resonance energy transfer (BRET) between the bioluminescent protein and the acceptor molecule,

81732212

12

wherein a modulation of BRET indicates that the compound binds the G protein coupled receptor, and wherein when expressed in a cell the N-terminus of the G protein coupled receptor, or subunits thereof, is outside the cell and the C-terminus inside the cell.

As the skilled reader will appreciate, many of the above embodiments relating
5 to the methods of detection also apply to the method of screening aspect of the invention.

In a further aspect, the present invention provides a kit comprising a polypeptide of the invention, a polynucleotide of the invention, a vector of the invention, a host cell of the invention, a composition of the invention, a cell-free composition of the invention, and/or a biosensor of the invention.

10 The present invention as claimed relates to:

- a method of detecting a compound, the method comprising, i) contacting a sample with a cell-free composition comprising at least one G protein coupled receptor embedded in a lipid bilayer, and which is capable of binding the compound, wherein the G protein coupled receptor comprises one or more subunits that are the same or different, each
15 subunit being a G protein coupled receptor, and wherein the G protein coupled receptor comprises a bioluminescent protein and an acceptor molecule, and wherein the bioluminescent protein is a *Renilla* luciferase or a biologically active variant or fragment thereof, and the acceptor molecule is green fluorescent protein 2 (GFP²), ii) simultaneously or sequentially with step i) providing a substrate of the bioluminescent protein, and allowing the
20 bioluminescent protein to modify the substrate, wherein the substrate is Coelenterazine 400a, iii) determining if step ii) modulates bioluminescent resonance energy transfer (BRET) between the bioluminescent protein and the acceptor molecule, wherein the spatial location and/or dipole orientation of the bioluminescent protein relative to the acceptor molecule is altered when the compound binds the G protein coupled receptor, and wherein when
25 expressed in a cell the N-terminus of the G protein coupled receptor, or subunits thereof, is outside the cell and the C-terminus inside the cell, and wherein the level of BRET is indicative of the relative amount of the compound in the sample, and wherein 1) a subunit of the G protein coupled receptor which is capable of binding the compound comprises the

81732212

12a

bioluminescent protein and the acceptor molecule, and wherein the spatial location and/or dipole orientation of the bioluminescent protein relative to the acceptor molecule is altered when the compound binds the subunit, or 2) the G protein coupled receptor comprises a first subunit comprising the bioluminescent protein and the acceptor molecule, and a second
 5 subunit which is capable of binding the compound, and wherein the spatial location and/or dipole orientation of the bioluminescent protein relative to the acceptor molecule is altered when the compound binds the second subunit, and wherein in 1) and 2) a) the bioluminescent protein forms part of the fifth non-transmembrane loop of the subunit, and the acceptor molecule forms part of the C-terminus, or b) the acceptor molecule forms part of the fifth non-
 10 transmembrane loop of the subunit, and the bioluminescent protein forms part of the C-terminus; and

- a method for screening for a compound that binds a G protein coupled receptor, the method comprising, i) contacting a candidate compound with a cell-free composition comprising at least one G protein coupled receptor embedded in a lipid bilayer,
 15 and which is capable of binding the compound, wherein the G protein coupled receptor comprises one or more subunits that are the same or different, each subunit being a G protein coupled receptor, and wherein the G protein coupled receptor comprises a bioluminescent protein and an acceptor molecule, and wherein the bioluminescent protein is a *Renilla* luciferase or a biologically active variant or fragment thereof, and the acceptor molecule is
 20 green fluorescent protein 2 (GFP²), ii) simultaneously or sequentially with step i) providing a substrate of the bioluminescent protein, and allowing the bioluminescent protein to modify the substrate, wherein the substrate is Coelenterazine 400a, iii) determining if step ii) modulates bioluminescent resonance energy transfer (BRET) between the bioluminescent protein and the acceptor molecule, wherein a modulation of BRET indicates that the compound binds the G
 25 protein coupled receptor, and wherein when expressed in a cell the N-terminus of the G protein coupled receptor, or subunits thereof, is outside the cell and the C-terminus inside the cell, and wherein the level of BRET is indicative of the relative amount of the compound in the sample, and wherein 1) a subunit of the G protein coupled receptor which is capable of binding the compound comprises the bioluminescent protein, and the acceptor molecule, and

01/32212

12b

wherein the spatial location and/or dipole orientation of the bioluminescent protein relative to the acceptor molecule is altered when the compound binds the subunit, or 2) the G protein coupled receptor comprises a first subunit comprising the bioluminescent protein, and the acceptor molecule, and a second subunit which is capable of binding the compound, and

5 wherein the spatial location and/or dipole orientation of the bioluminescent protein relative to the acceptor molecule is altered when the compound binds the second subunit, and wherein in 1) and 2), a) the bioluminescent protein forms part of the fifth non-transmembrane loop of the subunit, and the acceptor molecule forms part of the C-terminus, or b) the acceptor molecule forms part of the fifth non-transmembrane loop of the subunit, and the bioluminescent protein

10 forms part of the C-terminus.

As will be apparent, preferred features and characteristics of one aspect of the invention are applicable to many other aspects of the invention.

Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element,

15 integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

The invention is hereinafter described by way of the following non-limiting Examples and with reference to the accompanying figures.

BRIEF DESCRIPTION OF THE ACCOMPANYING DRAWINGS

20 **Figure 1.** Principle of resonance energy transfer in ODR-10 receptor fused to GFP² and RLuc. GFP² is inserted in the third intracellular loop of the GPCR and RLuc to the C-terminus. Diacetyl binding could result in a conformational change resulting in a decrease (top right), or increase (bottom right), in the distance between RLuc and GFP² or a change in the relative orientations of their chromophore dipoles, which would alter the BRET² signal in a dose-

25 dependent manner.

81732212

12c

Figure 2. The response of OGOR to (A) μM (mean $\pm$ SEM, $n=2$) and (B) nM (mean $\pm$ SEM, $n=6$) concentration of ligand or water (* denotes a significant different ($P \leq 0.05$) compared to water).

Figure 3. The change in BRET² ratio (%) of OGOR to (A) μM (mean $\pm$ SEM, $n=2$) and
5 (B) nM (mean $\pm$ SEM, $n=6$) concentration of ligand compared to water alone.

Figure 4. Diacetyl concentration dependence of the OGOR BRET² response (mean $\pm$ SEM, $n=12$).

Figure 5. Comparison of the response of OGOR (mean $\pm$ SEM, n=3) and the OGOR mutant (mean $\pm$ SEM, n=6) to water or one μ M of diacetyl in water.

Figure 6. Comparison of the response of OCOY (mean $\pm$ SEM, n=5) and OGOR (mean $\pm$ SEM, n=3) to water or one μ M of diacetyl in water.

Figure 7. Spectral scans of OCOY upon the addition of different concentrations of diacetyl. Top: Raw data. Bottom: Normalized (500 nm) data.

Figure 8. Normalized dose response curve for ODR-10 tagged with both FRET (mean $\pm$ SEM, n=5) and BRET² (mean $\pm$ SEM, n=12).

Figure 9. The response of TGTR to 10 μ L (mean $\pm$ SD, n=3) of OP50 bacterial supernatant (LB) or OP50 bacterial culture in LB compared to LB alone (* denotes a significant different ($P \leq 0.05$) compared to LB).

Figure 10. The response of TGTR to μ M (mean $\pm$ SD, n=3) concentration of ligand or water (* denotes a significant different ($P \leq 0.05$) compared to water).

Figure 11. ODR-10 transduction cassette. Dark – ODR-10 sequence, Light – variable receptor ligand binding domains. A) N-terminal fixed in cassette, B) N-terminal variable OR sequence. Rluciferase denoted as emitting at 410nm, and GFP² denoted as emitting at 515nm.

Figure 12. Co-expressed odr-10-Rluc and odr-10-GFP² yeast cells to show odr-10 receptor localization and tagged odr-10 expression level by confocal microscopy (Ex488 nm, Leica SP2 confocal laser scanning microscope).

Figure 13. Constitutive BRET² of nematode odr-10 in living Invscl yeast cells. All tested yeast strains were induced for expressing tagged odr-10 proteins for 24 hours at 15°C. Energy transfer measurements were performed in living cells by adding 10 μ M coelenterazine h (DeepBlueC) and measuring light emissions in a dual wavelength microplate reader with Rluc and GFP2 filter settings as described in the method. Data are means $\pm$ StD of two independent experiments. Insvc1/odr-10-RLuc – negative control.

Invsc1/odr-10-RLuc + Invsc1/odr-10-GFP2 – OR and OG in separate cells. Cells mixed together for plate reading – BRET is not expected because the two constructs were expressed in separate cells.

Invsc1/odr-10-RLuc; odr-10-GFP2 – both constructs expressed in same cell. BRET is present, therefore dimerisation is occurring.

Figure 14. Detection of Odr-10 oligomers by immunoprecipitation. Crude membrane from Invsc1 yeast cells co-expressing the indicated receptors were solubilised and adjusted to the same amount of luciferase activity. Receptors were then immunoprecipitated with anti-GFP antibody and luciferase activity determined in precipitates. Values are presented as % of maximal amount of precipitated luciferase activity. Data are mean of two biological repeats.

Figure 15. Measured light output in the BRET² channels upon the addition of 5 μ M of coelenterazine 400a to 100 μ L of a whole-cell assay sample of 100 μ L of the cell-free membrane preparations following ultracentrifugation.

Figure 16. BRET² signal upon incubation (45 minutes) with 1 μ M of diacetyl (mean $\pm$ S.D., n=3) monitored using a whole-cell and cell-free assay systems.

KEY TO THE SEQUENCE LISTING

SEQ ID NO:1 – *C. elegans* Odr10 receptor.

SEQ ID NO:2 – *C. elegans* Str112 receptor.

SEQ ID NO:3 – *C. elegans* Str113 receptor.

SEQ ID NO:4 – *C. elegans* Str114 receptor.

SEQ ID NO:5 – *C. elegans* Str115 receptor.

SEQ ID NO:6 – *C. elegans* Str116 receptor.

SEQ ID NO:7 – ORF encoding *C. elegans* Odr10 receptor.

SEQ ID NO:8 – ORF encoding *C. elegans* Str112 receptor.

SEQ ID NO:9 – ORF encoding *C. elegans* Str113 receptor.

SEQ ID NO:10 – ORF encoding *C. elegans* Str114 receptor.

SEQ ID NO:11 – ORF encoding *C. elegans* Str115 receptor.

SEQ ID NO:12 – ORF encoding *C. elegans* Str116 receptor.

SEQ ID NO:13 – Polypeptide of the invention comprising *C. elegans* Odr10 receptor, RLuc inserted into the third intracellular loop (fifth non-transmembrane loop) and GFP inserted at the C-terminus.

SEQ ID NO:14 – Open reading frame encoding polypeptide of the invention comprising *C. elegans* Odr10 receptor, RLuc inserted into the third intracellular loop (fifth non-transmembrane loop) and GFP inserted at the C-terminus.

SEQ ID NO:15 – Polypeptide of the invention comprising *C. elegans* Odr10 receptor, GFP inserted into the third intracellular loop (fifth non-transmembrane loop) and RLuc inserted at the C-terminus.

SEQ ID NO:16 – Open reading frame encoding polypeptide of the invention comprising *C. elegans* Odr10 receptor, GFP inserted into the third intracellular loop (fifth non-transmembrane loop) and RLuc inserted at the C-terminus.

SEQ ID NO:17 – Polypeptide of the invention comprising *C. elegans* Odr10 receptor and RLuc inserted at the C-terminus.

SEQ ID NO:18 – Open reading frame encoding polypeptide of the invention comprising *C. elegans* Odr10 receptor RLuc inserted at the C-terminus.

SEQ ID NO:19 – Polypeptide of the invention comprising *C. elegans* Odr10 receptor and GFP2 inserted at the C-terminus.

SEQ ID NO:20 – Open reading frame encoding polypeptide of the invention comprising *C. elegans* Odr10 receptor GFP2 inserted at the C-terminus.

SEQ ID NO's 21 to 44 – Oligonucleotide primers.

SEQ ID NO:45 – mCitrine derivative.

SEQ ID NO:46 – mCFP derivative.

SEQ ID NO:47 - Open reading frame encoding mCitrine derivative.

SEQ ID NO:48 - Open reading frame encoding mCFP derivative.

SEQ ID NO:49 - Open reading frame encoding Odr10 FRET dual labelled fusion protein.

SEQ ID NO:50 - Odr10 FRET dual labelled fusion protein.

SEQ ID NO:51 – Open reading frame encoding Str112 BRET dual labelled fusion protein.

SEQ ID NO:52 - Str112 BRET dual labelled fusion protein.

SEQ ID NO:53 – Open reading frame encoding mouse α_{2A} adrenergic receptor BRET dual labelled fusion protein.

SEQ ID NO:54 - Mouse α_{2A} adrenergic receptor BRET dual labelled fusion protein.

SEQ ID NO:55 - Open reading frame encoding mouse α_{2A} adrenergic receptor.

SEQ ID NO:56 - Mouse α_{2A} adrenergic receptor.

DETAILED DESCRIPTION OF THE INVENTION

General Techniques and Definitions

Unless specifically defined otherwise, all technical and scientific terms used herein shall be taken to have the same meaning as commonly understood by one of ordinary skill in the art (e.g., in cell culture, molecular genetics, biosensors, G-coupled protein receptor biology, immunology, immunohistochemistry, protein chemistry, and biochemistry).

Unless otherwise indicated, the recombinant protein, cell culture, and immunological techniques utilized in the present invention are standard procedures, well known to those skilled in the art. Such techniques are described and explained throughout the literature in sources such as, J. Perbal, *A Practical Guide to Molecular Cloning*, John Wiley and Sons (1984), J. Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbour Laboratory Press (1989), T.A. Brown (editor), *Essential Molecular Biology: A Practical Approach*, Volumes 1 and 2, IRL Press (1991), D.M. Glover and B.D. Hames (editors), *DNA Cloning: A Practical Approach*, Volumes 1-4, IRL Press (1995 and 1996), and F.M. Ausubel et al. (editors), *Current Protocols in Molecular Biology*, Greene Pub. Associates and Wiley-Interscience (1988, including all updates until present), Ed Harlow and David Lane (editors) *Antibodies: A Laboratory Manual*, Cold Spring Harbour Laboratory, (1988), and J.E. Coligan *et al.* (editors) *Current Protocols in Immunology*, John Wiley & Sons (including all updates until present).

As used herein, unless specified otherwise, the term "G protein coupled receptor" refers to a seven transmembrane receptor which signals through G proteins. The receptor may be a single subunit, or two or more receptor subunits. When two or more receptor subunits are present they may be the same, different, or a combination thereof (for example, two of one subunit and a single of another subunit). Furthermore, unless specified or implied otherwise the terms "G protein coupled receptor" and "subunit of a G protein coupled receptor", or variations thereof, are used interchangeably.

As used herein, the term "odorant receptor", "olfactory receptor", "OR" or variations thereof refers to a polypeptide which, when present in a cell of an organism, is involved in chemosensory perception. In an embodiment, the cell is a neuron. Furthermore, the term "odorant receptor" or "olfactory receptor" refers to a polypeptide which binds an odorant ligand, or forms part of a protein complex that binds to an odorant ligand, resulting in a physiologic response.

As used herein, the term "bioluminescent protein" refers to any protein capable of acting on a suitable substrate to generate luminescence.

As used herein, the term "substrate" refers to any molecule that can be used in conjunction with a bioluminescent protein to generate or absorb luminescence.

As used herein, the phrase "allowing the bioluminescent protein to modify the substrate" refers to any enzymatic activity of the bioluminescent protein on the substrate that produces energy.

As used herein, the term "acceptor molecule" refers to any compound which can accept energy emitted as a result of the activity of a bioluminescent protein, and re-emit it as light energy.

As used herein, bioluminescent resonance energy transfer (BRET) is a proximity assay based on the non-radioactive transfer of energy between the bioluminescent protein donor and the acceptor molecule.

As used herein, the terms "modulate" or "modulation" or variations thereof refer to an alteration in the intensity and/or emission spectra of the bioluminescent protein and/or acceptor molecule.

As used herein, the term "spatial location" refers to the three dimensional positioning of the bioluminescent protein relative to the acceptor molecule which changes as a result of the compound binding a polypeptide defined herein comprising a G protein coupled receptor.

As used herein, the term "dipole orientation" refers to the direction in three-dimensional space of the dipole moment associated either with the bioluminescent protein and/or the acceptor molecule relative their orientation in three-dimensional space. The dipole moment is a consequence of a variation in electrical charge over a molecule.

As used herein, the term "more sensitive" refers to a greater change in resonance energy transfer ratio between the ligand unbound form to the ligand bound form of one reporter system (for example, BRET) to another reporter system (for example, FRET). As used herein, the term "reporter system" refers to a system comprising a polypeptide of the invention containing an isolated and/or recombinant polypeptide of the invention comprising a G protein coupled receptor subunit. Preferably, the cell-free composition comprises no live cells, whether they comprise a polypeptide of the invention or not.

As used herein, the term "contacting" refers to the addition of a sample comprising, or which may comprise, the compound to be detected in a way that the compound is capable of binding the G protein coupled receptor.

As used herein, the term "lipid bilayer" refers to two layers of, typically amphiphilic, molecular arrays arranged opposite to each other with a common

hydrophobic bilayer interior and two hydrophilic surfaces. The lipid bilayer can be naturally occurring or artificial. Most preferably, the lipid bilayer is a cellular or bio-membrane into which a polypeptide defined herein comprising an G protein coupled receptor is inserted, for example a mammalian, insect, plant or yeast cell membrane, most preferably of a yeast cell membrane.

As used herein, the term "yeast lipid bilayer" refers to the lipid bilayer being derived from a yeast cell expressing a polypeptide defined herein comprising an G protein coupled receptor. The skilled person can readily determine if a lipid bilayer is derived from a yeast by detecting proteins naturally occurring in yeast which are embedded in the membrane such as, but not limited to, Fus1p protein (Trueheart and Fink, 1989), SNARE complex which comprises the Sso1/2p, Sncip and Sec9p proteins (Strop et al., 2007), pheromone receptor Ste2p (Celic et al., 2003), and/or Alr1 (Graschopf et al., 2001).

As used herein, the term "simultaneously or sequentially" means that the substrate can be provided before, during or after the sample is contacted with a polypeptide as defined herein. Preferably, the substrate is provided at the same time or after the sample.

The "sample" can be any substance or composition suspected of comprising a compound to be detected. Examples of samples include air, liquid, biological material and soil. The sample may be obtained directly from the environment or source, or may be at least partially purified by a suitable procedure before a method of the invention is performed.

As used herein, the term "G protein coupled receptor, and/or accessory molecule when present, in combination comprise a bioluminescent protein and an acceptor molecule" means that the bioluminescent protein is associated, preferably covalently attached, more preferably produced as a fusion protein, with a subunit of the G protein coupled receptor or with an accessory molecule, and the acceptor molecule is associated, preferably covalently attached, more preferably produced as a fusion protein, with a subunit of the G protein coupled receptor or with an accessory molecule. The bioluminescent protein and accessory molecule may be associated, preferably covalently attached, more preferably produced as a fusion protein, with the same or different subunits of the G protein coupled receptor or the same or different accessory molecules. Furthermore, one of the bioluminescent protein and accessory molecule may be associated, preferably covalently attached, more preferably produced as a fusion protein, with a subunit of the G protein coupled receptor, and the other of the bioluminescent protein and accessory molecule may be associated with an accessory

molecule. In addition, multiple bioluminescent protein and accessory molecule pairs may be present in the combination for multiplexing to detect different ligands, or increase the sensitivity of the detection of the same ligand.

As used herein, the term "forms part of" refers to the bioluminescent protein or acceptor molecule being located within the specified region of the G protein coupled receptor, or subunit thereof. This term also includes the possibility that the bioluminescent protein and/or acceptor molecule is attached to or binds the G protein coupled receptor but does not form a continuous chain of amino acids. In one embodiment, the bioluminescent protein or acceptor molecule completely replaces the specified region of the G protein coupled receptor. In another embodiment, some, but not all, of the specified region of the G protein coupled receptor is replaced. In yet another embodiment, none of the specified region of the G protein coupled receptor is replaced. As the skilled addressee will appreciate, the bioluminescent protein or acceptor molecule will not be inserted such that it makes the G protein coupled receptor portion of a polypeptide of the invention incapable of binding the target compound to result in a spatial change to the location and/or dipole orientation of the bioluminescent protein relative to the acceptor molecule.

As used herein, the term "at least a majority" of a specified portion (domain) of a G protein coupled receptor, refers to at least 51%, more preferably at least 75% and even more preferably at least 90% of the specified region.

By "substantially purified" or "purified" we mean a polypeptide that has been separated from one or more lipids, nucleic acids, other polypeptides, or other contaminating molecules with which it is associated in its native state. It is preferred that the substantially purified polypeptide is at least 60% free, more preferably at least 75% free, and more preferably at least 90% free from other components with which it is naturally associated. However, at present there is no evidence that the polypeptides of the invention exist in nature.

The term "recombinant" in the context of a polypeptide refers to the polypeptide when produced by a cell, or in a cell-free expression system, in an altered amount or at an altered rate compared to its native state. In one embodiment, the cell is a cell that does not naturally produce the polypeptide. However, the cell may be a cell which comprises a non-endogenous gene that causes an altered, preferably increased, amount of the polypeptide to be produced. A recombinant polypeptide of the invention includes polypeptides which have not been separated from other components of the transgenic (recombinant) cell, or cell-free expression system, in which it is produced,

and polypeptides produced in such cells or cell-free systems which are subsequently purified away from at least some other components.

The terms "polypeptide" and "protein" are generally used interchangeably and refer to a single polypeptide chain which may or may not be modified by addition of non-amino acid groups. It would be understood that such polypeptide chains may associate with other polypeptides or proteins or other molecules such as co-factors. The terms "proteins" and "polypeptides" as used herein also include variants, mutants, biologically active fragments, modifications, analogous and/or derivatives of the polypeptides described herein.

The % identity of a polypeptide is determined by GAP (Needleman and Wunsch, 1970) analysis (GCG program) with a gap creation penalty=5, and a gap extension penalty=0.3. The query sequence is at least 25 amino acids in length, and the GAP analysis aligns the two sequences over a region of at least 25 amino acids. More preferably, the query sequence is at least 50 amino acids in length, and the GAP analysis aligns the two sequences over a region of at least 50 amino acids. More preferably, the query sequence is at least 100 amino acids in length and the GAP analysis aligns the two sequences over a region of at least 100 amino acids. Even more preferably, the query sequence is at least 250 amino acids in length and the GAP analysis aligns the two sequences over a region of at least 250 amino acids. Even more preferably, the GAP analysis aligns the two sequences over their entire length.

As used herein, a "biologically active fragment" is a portion of a polypeptide as described herein which maintains a defined activity of the full-length polypeptide. For example, a biologically active fragment of a G protein coupled receptor must be capable of binding the target compound resulting in a conformational change. Biologically active fragments can be any size as long as they maintain the defined activity. Preferably, biologically active fragments are at least 150, more preferably at least 250 amino acids in length.

As used herein, a "biologically active variant" is a molecule which differs from a naturally occurring and/or defined molecule by one or more amino acids but maintains a defined activity, such as defined above for biologically active fragments. Biologically active variants are typically least 50%, more preferably at least 80%, more preferably at least 90%, more preferably at least 95%, more preferably at least 97%, and even more preferably at least 99% identical to the naturally occurring and/or defined molecule.

With regard to a defined polypeptide or polynucleotide, it will be appreciated that % identity figures higher than those provided above will encompass preferred

embodiments. Thus, where applicable, in light of the minimum % identity figures, it is preferred that the polypeptide or polynucleotide comprises an amino acid sequence which is at least 50%, more preferably at least 60%, more preferably at least 70%, more preferably at least 80%, more preferably at least 85%, more preferably at least 90%, more preferably at least 91%, more preferably at least 92%, more preferably at least 93%, more preferably at least 94%, more preferably at least 95%, more preferably at least 96%, more preferably at least 97%, more preferably at least 98%, more preferably at least 99%, more preferably at least 99.1%, more preferably at least 99.2%, more preferably at least 99.3%, more preferably at least 99.4%, more preferably at least 99.5%, more preferably at least 99.6%, more preferably at least 99.7%, more preferably at least 99.8%, and even more preferably at least 99.9% identical to the relevant nominated SEQ ID NO.

By an "isolated polynucleotide", including DNA, RNA, or a combination of these, single or double stranded, in the sense or antisense orientation or a combination of both, we mean a polynucleotide which is at least partially separated from the polynucleotide sequences with which it is associated or linked in its native state. Preferably, the isolated polynucleotide is at least 60% free, preferably at least 75% free, and most preferably at least 90% free from other components with which they are naturally associated.

The term "exogenous" in the context of a polynucleotide refers to the polynucleotide when present in a cell, or in a cell-free expression system, in an altered amount compared to its native state. In one embodiment, the cell is a cell that does not naturally comprise the polynucleotide. However, the cell may be a cell which comprises a non-endogenous polynucleotide resulting in an altered, preferably increased, amount of production of the encoded polypeptide. An exogenous polynucleotide of the invention includes polynucleotides which have not been separated from other components of the transgenic (recombinant) cell, or cell-free expression system, in which it is present, and polynucleotides produced in such cells or cell-free systems which are subsequently purified away from at least some other components.

Furthermore, the term "polynucleotide" is used interchangeably herein with the term "nucleic acid". Polynucleotides of the present invention may possess, when compared to molecules provided herewith, one or more mutations which are deletions, insertions, or substitutions of nucleotide residues, or modified residues. Mutants can be either naturally occurring (that is to say, isolated from a natural source) or synthetic (for example, by performing site-directed mutagenesis on the nucleic acid). Usually,

monomers of a polynucleotide are linked by phosphodiester bonds or analogs thereof. Analogs of phosphodiester linkages include: phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoranilidate and phosphoramidate.

Compositions of the present invention may include an "acceptable carrier". Examples of such acceptable carriers include water, saline, Ringer's solution, dextrose solution, Hank's solution, and other aqueous physiologically balanced salt solutions. Nonaqueous vehicles, such as fixed oils, sesame oil, ethyl oleate, or triglycerides may also be used. The exact nature of the "acceptable carrier" will depend on the use of the composition. Considering the uses described herein, and the nature of the component of the invention in the composition, the skilled person can readily determine suitable a "acceptable carrier(s)" for a particular use.

Bioluminescent Proteins

It is understood in the art that a bioluminescent protein is an enzyme which converts a substrate into an activated product which then releases energy as it relaxes. The activated product (generated by the activity of the bioluminescent protein on the substrate) is the source of the bioluminescent protein-generated luminescence that is transferred to the acceptor molecule.

There are a number of different bioluminescent proteins that can be employed in this invention (see, for example, Table 1). Given the size of bioluminescent proteins it was surprising that functional polypeptides useful for the present invention could be produced. Light-emitting systems have been known and isolated from many luminescent organisms including bacteria, protozoa, coelenterates, molluscs, fish, millipedes, flies, fungi, worms, crustaceans, and beetles, particularly click beetles of genus *Pyrophorus* and the fireflies of the genera *Photinus*, *Photuris*, and *Luciola*. Additional organisms displaying bioluminescence are listed in WO 00/024878, WO 99/049019 and Viviani (2002).

One very well known example is the class of proteins known as luciferases which catalyze an energy-yielding chemical reaction in which a specific biochemical substance, a luciferin (a naturally occurring fluorophore), is oxidized by an enzyme having a luciferase activity (Hastings, 1996). A great diversity of organisms, both prokaryotic and eukaryotic, including species of bacteria, algae, fungi, insects, fish and other marine forms can emit light energy in this manner and each has specific luciferase activities and luciferins which are chemically distinct from those of other organisms. Luciferin/luciferase systems are very diverse in form, chemistry and

function. Bioluminescent proteins with luciferase activity are thus available from a variety of sources or by a variety of means. Examples of bioluminescent proteins with luciferase activity may be found in US 5,229,285, 5,219,737, 5,843,746, 5,196,524, and 5,670,356. Two of the most widely used luciferases are: (i) *Renilla* luciferase (from *R. reniformis*), a 35 kDa protein, which uses coelenterazine as a substrate and emits light at 480 nm (Lorenz et al., 1991); and (ii) Firefly luciferase (from *Photinus pyralis*), a 61 kDa protein, which uses luciferin as a substrate and emits light at 560 nm (de Wet et al., 1987).

Table 1. Exemplary bioluminescent proteins.

<u>Species</u>	<u>Name</u>	<u>Organism</u>	<u>MW</u> <u>kDa x 10⁻³</u>	<u>Emission</u> <u>(nm)</u>	<u>Substrate</u>
Insect	FFluc	Photinus pyralis (North American Firefly)	~61	560	D-(-)-2-(6'-hydroxybenzothiazolyl)- Δ^2 -thiazoline-4-carboxylic acid, HBTTCa (C ₁₁ H ₈ N ₂ O ₃ S ₂) (luciferin)
Insect	FF'luc	Luciola cruciata (Japanese Firefly)		560-590 (many mutants)	Luciferin
Insect		Phengodid beetles (railroad worms)			
Insect		Arachnocampa sp.			Luciferin
Insect		Orphelia fultoni (North American glow worm)			
Insect	Clluc	Pyrophorus plagiophthalmus (click beetle)		546, 560, 578 and 593	Luciferin
Jellyfish	Aequorin	Aequorea	44.9	460-470	Coelenterazine
Sea pansy	Rluc	Renilla Reniformis	36	480	Coelenterazine
Sea pansy	Rluc8	Renilla reniformis	36	487	Coelenterazine

(modified)		(modified)		(peak)	/Deep Blue C
Sea pansy	Rmluc	Renilla mullerei	36.1	~480	Coelenterazine
Sea pansy		Renilla kollikeri			
Crustacea (shimp)	Vluc	Vargula hilgendorffii	~62	~460	coelenterazine *
Crustacea		Cypridina (sea firefly)	75	460	coelenterazine **
Dinoflagellate (marine alga)		Gonyaulax polyedra	130	~475	Tetrapyrrole
Mollusc		Latia (fresh water limpet)	170	500	Enol formate, terpene, aldehyde
Hydroid		Obelia bicuspidata	~20	~470	Coelenterazine
Shrimp		Oplophorus graciliorostris	31	462	Coelenterazine
Others	Ptluc	Ptilosarcus		~490	Coelenterazine
	Gluc	Gaussia	~20	~475	Coelenterazine
	Plluc	Pleuromamma	22.6	~475	Coelenterazine

Gaussia luciferase (from *Gaussia princeps*) has been used in biochemical assays (Verhaegen et al., 2002). *Gaussia* luciferase is a 20 kDa protein that oxidises coelenterazine in a rapid reaction resulting in a bright light emission at 470 nm.

Luciferases useful for the present invention have also been characterized from *Anachnocalpa* sp (WO 2007/019634). These enzymes are about 59 kDa in size and are ATP-dependent luciferases that catalyze luminescence reactions with emission spectra within the blue portion of the spectrum.

Alternative, non-luciferase, bioluminescent proteins that can be employed in this invention are any enzymes which can act on suitable substrates to generate a luminescent signal. Specific examples of such enzymes are β -galactosidase, lactamase, horseradish peroxidase, alkaline phosphatase, β -glucuronidase and β -glucosidase. Synthetic luminescent substrates for these enzymes are well known in the art and are commercially available from companies, such as Tropix Inc. (Bedford, MA, USA).

An example of a peroxidase useful for the present invention is described by Hushpalian et al. (2007).

In a preferred embodiment, a bioluminescent protein with a small molecular weight is used to prevent an inhibition of the interaction due to steric hindrance. The

bioluminescent protein preferably consists of a single polypeptide chain. Also the bioluminescent proteins preferably do not form oligomers or aggregates. The bioluminescent proteins *Renilla* luciferase, *Gaussia* luciferase and Firefly luciferase meet all or most of these criteria.

Substrates

The choice of the substrate can impact on the wavelength and the intensity of the light generated by the bioluminescent protein.

A widely known substrate is coelenterazine which occurs in cnidarians, copepods, chaetognaths, ctenophores, decapod shrimps, mysid shrimps, radiolarians and some fish taxa (Greer and Szalay, 2002). For *Renilla* luciferase for example, coelenterazine analogues/derivatives are available that result in light emission between 418 and 512 nm (Inouye et al., 1997). A coelenterazine analogue/derivative (400A, DeepBlueC) has been described emitting light at 400 nm with *Renilla* luciferase (WO 01/46691). Other examples of coelenterazine analogues/derivatives are EnduRen and ViviRen.

As used herein, the term “luciferin” refers to a class of light-emitting biological pigments found in organisms capable of bioluminescence, which are oxidised in the presence of the enzyme luciferase to produce oxyluciferin and energy in the form of light. Luciferin, or 2-(6-hydroxybenzothiazol-2-yl)-2-thiazoline-4-carboxylic acid, was first isolated from the firefly *Photinus pyralis*. Since then, various forms of luciferin have been discovered and studied from various different organisms, mainly from the ocean, for example fish and squid, however, many have been identified in land dwelling organisms, for example, worms, beetles and various other insects (Day et al., 2004; Viviani, 2002).

There are at least five general types of luciferin, which are each chemically different and catalysed by chemically and structurally different luciferases that employ a wide range of different cofactors. First, is firefly luciferin, the substrate of firefly luciferase, which requires ATP for catalysis (EC 1.13.12.7). Second, is bacterial luciferin, also found in some squid and fish, that consists of a long chain aldehyde and a reduced riboflavin phosphate. Bacterial luciferase is FMNH-dependent. Third, is dinoflagellate luciferin, a tetrapyrrolic chlorophyll derivative found in dinoflagellates (marine plankton), the organisms responsible for night-time ocean phosphorescence. Dinoflagellate luciferase catalyses the oxidation of dinoflagellate luciferin and consists of three identical and catalytically active domains. Fourth, is the imidazolopyrazine vargulin, which is found in certain ostracods and deep-sea fish, for example,

Porichthys. Last, is coelenterazine (an imidazopyrazine), the light-emitter of the protein aequorin, found in radiolarians, ctenophores, cnidarians, squid, copepods, chaetognaths, fish and shrimp.

Acceptor Molecules

There are a number of different acceptor molecules that can be employed in this invention. The acceptor molecules may be a protein or non-proteinaceous. Examples of acceptor molecules that are protein include, but are not limited to, green fluorescent protein (GFP), blue fluorescent variant of GFP (BFP), cyan fluorescent variant of GFP (CFP), yellow fluorescent variant of GFP (YFP), enhanced GFP (EGFP), enhanced CFP (ECFP), enhanced YFP (EYFP), GFPS65T, Emerald, Topaz, GFPuv, destabilised EGFP (dEGFP), destabilised ECFP (dECFP), destabilised EYFP (dEYFP), HcRed, t-HcRed, DsRed, DsRed2, t-dimer2, t-dimer2(12), mRFP1, pocilloporin, *Renilla* GFP, Monster GFP, paGFP, Kaede protein or a Phycobiliprotein, or a biologically active variant or fragment of any one thereof. Examples of acceptor molecules that are not proteins include, but are not limited to, Alexa Fluor dye, Bodipy dye, Cy dye, fluorescein, dansyl, umbelliferone, fluorescent microsphere, luminescent microsphere, fluorescent nanocrystal, Marina Blue, Cascade Blue, Cascade Yellow, Pacific Blue, Oregon Green, Tetramethylrhodamine, Rhodamine, Texas Red, rare earth element chelates, or any combination or derivatives thereof.

One very well known example is the group of fluorophores that includes the green fluorescent protein from the jellyfish *Aequorea victoria* and numerous other variants (GFPs) arising from the application of molecular biology, for example mutagenesis and chimeric protein technologies (Tsien, 1998). GFPs are classified based on the distinctive component of their chromophores, each class having distinct excitation and emission wavelengths: class 1, wild-type mixture of neutral phenol and anionic phenolate: class 2, phenolate anion : class 3, neutral phenol : class 4, phenolate anion with stacked s-electron system: class 5, indole : class 6, imidazole : and class 7, phenyl.

A naturally occurring acceptor molecule which has been mutated (variants) can also be useful for the present invention. One example of an engineered system which is suitable for BRET is a *Renilla* luciferase and enhanced yellow mutant of GFP (EYFP) pairing which do not directly interact to a significant degree with one another alone in the absence of a mediating protein(s) (in this case, the G protein coupled receptor) (Xu et al., 1999).

In another embodiment, the acceptor molecule is a fluorescent nanocrystal. Nanocrystals, or “quantum dots”, have several advantages over organic molecules as fluorescent labels, including resistance to photodegradation, improved brightness, non-toxicity, and size dependent, narrow emission spectra that enables the monitoring of several processes simultaneously. Additionally, the absorption spectrum of nanocrystals is continuous above the first peak, enabling all sizes, and hence all colors, to be excited with a single excitation wavelength.

Fluorescent nanocrystals may be attached, or “bioconjugated”, to proteins in a variety of ways. For example, the surface cap of a “quantum dot” may be negatively charged with carboxylate groups from either dihydrolipoic acid (DHLA) or an amphiphilic polymer. Proteins can be conjugated to the DHLA–nanocrystals electrostatically, either directly or via a bridge consisting of a positively charged leucine zipper peptide fused to recombinant protein. The latter binds to a primary antibody with specificity for the intended target. Alternatively, antibodies, streptavidin, or other proteins are coupled covalently to the polyacrylate cap of the nanocrystal with conventional carbodiimide chemistry.

There are colloidal methods to produce nanocrystals, including cadmium selenide, cadmium sulfide, indium arsenide, and indium phosphide. These quantum dots can contain as few as 100 to 100,000 atoms within the quantum dot volume, with a diameter of 10 to 50 atoms. Some quantum dots are small regions of one material buried in another with a larger band gap. These can be so-called core-shell structures, for example, with CdSe in the core and ZnS in the shell or from special forms of silica called ormosil. The larger the dot, the redder (lower energy) its fluorescence spectrum. Conversely, smaller dots emit bluer (higher energy) light. The coloration is directly related to the energy levels of the quantum dot. Quantitatively speaking, the bandgap energy that determines the energy (and hence color) of the fluoresced light is inversely proportional to the square of the size of the quantum dot. Larger quantum dots have more energy levels which are more closely spaced. This allows the quantum dot to absorb photons containing less energy, i.e. those closer to the red end of the spectrum.

In an alternate embodiment, the acceptor molecule is a fluorescent microsphere. These are typically made from polymers, and contain fluorescent molecules (for example fluorescein GFP or YFP) incorporated into the polymer matrix, which can be conjugated to a variety of reagents. Fluorescent microspheres may be labelled internally or on the surface. Internal labelling produces very bright and stable particles with typically narrow fluorescent emission spectra. With internal labelling, surface groups remain available for conjugating ligands (for example, proteins) to the surface

of the bead. Internally-labelled beads are used extensively in imaging applications, as they display a greater resistance to photobleaching.

Carboxylate-modified fluorescent microspheres are suitable for covalent coupling of proteins using water-soluble carbodiimide reagents such as 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDAC). Sulfate fluorescent microspheres are relatively hydrophobic and will passively and nearly irreversibly adsorb almost any protein. Aldehyde-sulfate fluorescent microspheres are sulfate microspheres that have been modified to add surface aldehyde groups, and react with proteins.

In another embodiment, the acceptor molecule is a luminescent microsphere. These are typically made from polymers, which contain luminescent molecules (for example complexes of europium or platinum) incorporated into the polymer matrix, which can be conjugated to a variety of reagents.

Bioluminescent Protein and Acceptor Molecule Pairs

A criteria which should be considered in determining suitable pairings for BRET is the relative emission/fluorescence spectrum of the acceptor molecule compared to that of the bioluminescent protein. The emission spectrum of the bioluminescent protein should overlap with the absorbance spectrum of the acceptor molecule such that the light energy from the bioluminescent protein luminescence emission is at a wavelength that is able to excite the acceptor molecule and thereby promote acceptor molecule fluorescence when the two molecules are in a proper proximity and orientation with respect to one another. For example, it has been demonstrated that an *Renilla* luciferase/EGFP pairing is not as good as an *Renilla* luciferase/EYEF pairing based on observable emission spectral peaks (Xu, 1999; Wang, et al. (1997) in *Bioluminescence and Chemiluminescence : Molecular Reporting with Photons*, eds. Hastings et al. (Wiley, New York), pp. 419-422). To study potential pairing, protein fusions are prepared containing the selected bioluminescent protein and acceptor molecule and are tested, in the presence of an appropriate substrate.

It should also be confirmed that the bioluminescent protein and acceptor molecule do not spuriously associate with each other. This can be accomplished by separate co-expression of the bioluminescent protein and acceptor molecule in the same cells and then monitoring the luminescence spectrum in order to determine if BRET occurs. This may be achieved, for example, using the method of Xu et al. (1999). The selected bioluminescent protein and acceptor molecule form a suitable BRET pair if little or no BRET is observed.

The bioluminescent protein emission can be manipulated by modifications to the substrate. In the case of luciferases the substrate is coelenterazine. The rationale behind altering the bioluminescent protein emission is to improve the resolution between donor emission and acceptor emissions. The original BRET system uses the *Renilla* luciferase as donor, EYFP (or Topaz) as the acceptor and coelenterazine h derivative as the substrate. These components when combined in a BRET assay, generate light in the 475-480 nm range for the bioluminescent protein and the 525-530 nm range for the acceptor molecule, giving a spectral resolution of 45-55 nm.

Unfortunately, *Renilla* luciferase generates a broad emission peak overlapping substantially the GFP emission, which in turn contributes to decrease the signal to noise of the system. One BRET system of the present invention, using coel400a as the *Renilla* luciferase substrate, provides broad spectral resolution between donor and acceptor emission wavelengths (-105nm). *Renilla* luciferase with coel400a generates light between 390-400 nm and a GFP was prepared which absorbs light in this range and re-emits light at 505-508 nm. Because of this increase in spectral resolution between *Renilla* luciferase and GFP emissions, this BRET system provides an excellent biological tool to monitor small changes in conformation of a polypeptide of the invention. This is a significant improvement over the system described previously using the coelenterazine h derivative and EYFP, which has a wavelength difference between donor and acceptor of approximately 51 nm.

Various coelenterazine derivatives are known in the art, including coel400a, that generate light at various wavelengths (distinct from that generated by the wild type coelenterazine) as a result of *Renilla* luciferase activity. A worker skilled in the art would appreciate that because the light emission peak of the donor has changed, it is necessary to select an acceptor molecule which will absorb light at this wavelength and thereby permit efficient energy transfer. This can be done, for example by altering a GFP class 4 such that it becomes a class 3 or 1 GFP. Spectral overlapping between light emission of the donor and the light absorption peak of the acceptor is one condition among others for an efficient energy transfer. Class 3 and 1 GFPs are known to absorb light at 400 nm and re-emit between 505-511 nm. This results in a wavelength difference between donor and acceptor emissions of approximately 111 nm.

Examples of further bioluminescent proteins and acceptor molecule pairs are provided in Table 2.

Table 2. Exemplary BRET bioluminescent proteins and acceptor molecule pairs.

<u>BDP</u>	<u>Substrate</u>	<u>Substrate wavelength (peak)</u>	<u>Fluorescence acceptor molecule (FAM)</u>	<u>Wavelength of acceptor (Ex/Em)</u>
Rluc	Coelenterazine Wild type	470nm	Fluorescein	490/525nm
Rluc	Coelenterazine Wild type	470nm	Acridine yellow	470/550 nm
Rluc	Coelenterazine Wild type	470nm	Nile red	485/525 nm
Rluc	Coelenterazine cp	442nm	Lucifer yellow	428/540 nm
Rluc	Coelenterazine 400	400nm	Quin-2	365/490 nm
Rluc	Coelenterazine 400	400nm	Dansylchloride	380/475 nm
Firefly luciferase	Luciferin	560nm	Cyanine Cy3	575/605
Firefly luciferase	Luciferin	560nm	Texas red	590/615

G Protein Coupled Receptors

G protein-coupled receptors (GPCRs) are also known as seven transmembrane receptors, 7TM receptors, heptahelical receptors, and G protein linked receptors (GPLR). GPCRs are a large protein family of transmembrane receptors that sense molecules outside the cell and activate inside signal transduction pathways and, ultimately, cellular responses. The ligands that bind and activate these receptors include light-sensitive compounds, odors, pheromones, hormones, and neurotransmitters, and vary in size from small molecules to peptides to large proteins. GPCRs are involved in many diseases, but are also the target of around half of all modern medicinal drugs. GPCRs can be grouped into at least 5 classes based on sequence homology and functional similarity:

- Class A rhodopsin-like,
- Class B secretin-like,
- Class C metabotropic/pheromone,

Class D fungal pheromone, and

Class E cAMP receptors.

Class A Rhodopsin like receptors include: Amine receptors: Acetylcholine, Alpha Adrenoceptors, Beta Adrenoceptors, Dopamine, Histamine, Serotonin, Octopamine, and Trace amine; Peptide receptors: Angiotensin, Bombesin, Bradykinin, C5a anaphylatoxin, Fmet-leu-phe, APJ like, Interleukin-8, Chemokine receptors (C-C Chemokine, C-X-C Chemokine, BONZO receptors (CXC6R), C-X3-C Chemokine, and XC Chemokine), CCK receptors, Endothelin receptors, Melanocortin receptors, Neuropeptide Y receptors, Neurotensin receptors, Opioid receptors, Somatostatin receptors, Tachykinin receptors, (Substance P (NK1), Substance K (NK2), Neuromedin K (NK3), Tachykinin like 1, and Tachykinin like 2), Vasopressin-like receptors (Vasopressin, Oxytocin, and Conopressin), Galanin like receptors (Galanin, Allatostatin, and GPCR 54), Proteinase-activated like receptors (e.g., Thrombin), Orexin & neuropeptide FF, Urotensin II receptors, Adrenomedullin (G10D) receptors, GPR37/endothelin B-like receptors, Chemokine receptor-like receptors, and Neuromedin U receptors; Hormone protein receptors: Follicle stimulating hormone, Lutropin-choriogonadotropic hormone, Thyrotropin, and Gonadotropin; (Rhod)opsin receptors; Olfactory receptors; Prostanoid receptors: Prostaglandin, Prostacyclin, and Thromboxane; Nucleotide-like receptors: Adenosine and Purinoceptors; Cannabis receptors; Platelet activating factor receptors; Gonadotropin-releasing hormone receptors; Thyrotropin-releasing hormone & Secretagogue receptors: Thyrotropin-releasing hormone, Growth hormone secretagogue, and Growth hormone secretagogue like; Melatonin receptors; Viral receptors; Lysosphingolipid & LPA (EDG) receptors; Leukotriene B4 receptor: Leukotriene B4 receptor BLT1 and Leukotriene B4 receptor BLT2; and Class A Orphan/other receptors: Platelet ADP & KI01 receptors, SREB, Mas proto-oncogene, RDC1, ORPH, LGR like (hormone receptors), GPR, GPR45 like, Cysteinyl leukotriene, Mas-related receptors (MRGs), and GP40 like receptors.

Class B (the secretin-receptor family) of the GPCRs includes receptors for polypeptide hormones (Calcitonin, Corticotropin releasing factor, Gastric inhibitory peptide, Glucagon, Glucagon-like peptide-1,-2, Growth hormone-releasing hormone, Parathyroid hormone, PACAP, Secretin, Vasoactive intestinal polypeptide, Diuretic hormone, EMR1, Latrophilin), molecules thought to mediate intercellular interactions at the plasma membrane (Brain-specific angiogenesis inhibitor (BAI)) and a group of *Drosophila* proteins (Methuselah-like proteins) that regulate stress responses and longevity.

Class C Metabotropic glutamate/pheromone receptors include Metabotropic glutamate, Metabotropic glutamate group I, Metabotropic glutamate group II, Metabotropic glutamate group III, Metabotropic glutamate other, Extracellular calcium-sensing, Putative pheromone Receptors, GABA-B, GABA-B subtype 1, GABA-B subtype 2, and Orphan GPRC5 receptors.

GPCRs are involved in a wide variety of physiological processes, including the visual sense, the sense of smell, behavioral and mood regulation, regulation of immune system activity and inflammation, autonomic nervous system transmission, cell density sensing, and many others. It is known that the inactive G protein is bound to the receptor in its inactive state. Once the ligand is recognized, the receptor or a subunit thereof shifts conformation and thus mechanically activates the G protein, which detaches from the receptor. The receptor can now either activate another G protein, or switch back to its inactive state. It is believed that a receptor molecule exists in a conformational equilibrium between active and inactive biophysical states. The binding of ligands to the receptor may shift the equilibrium toward the active receptor states.

Polypeptides of the invention comprise G protein coupled receptors which, when expressed in a cell the N-terminus of the receptor is outside the cell and the C-terminus is inside the cell. The person skilled in the art is aware of suitable techniques for detecting the orientation of a transmembrane protein. Such techniques comprise but are not limited to crystallography, NMR-studies, modeling studies as well as microscopy techniques, like immunolabeling combined with detergent permeabilisation controls for light or electron microscopy preparation, fragment complementation tagging of two polypeptides and the like.

In a preferred embodiment, the G protein coupled receptor is a Class A GPCR. In a further preferred embodiment, the class A (rhodopsin-like) GPCR is an odorant receptor or an adrenergic receptor, more preferably an odorant receptor. The odorant receptor can be from any source as long as when expressed in a cell the N-terminus of the receptor is outside the cell and the C-terminus is inside the cell. Examples include, but are not limited to, a chordate receptor, a nematode receptor, or a biologically active variant or fragment of any one thereof. Examples of chordate receptors include, but are not limited to mammalian receptors, avian receptors and fish receptors. In a preferred embodiment, the odorant receptor is a nematode receptor or biologically active variant or fragment thereof. In an embodiment, the nematode receptor is a *Caenorhabditis elegans* receptor, or biologically active variant or fragment thereof. Examples of odorant receptors that can be used to produce polypeptides of the invention and/or used in the methods of the invention are described in Buck and Axel (1991), Robertson

(1998 and 2001), Aloni et al. (2006), Feldmesser (2006), Olender et al. (2004a and b), Glusman et al. (2000a, 2000b and 2001), Fuchs et al. (2001), Pilpel and Lancet (1999), Sharon et al. (1998), Zozulya et al. (2001), Niimura and Nei (2003), Lander et al. (2001), Zhang and Firestein (2002), Young et al. (2002). Furthermore, a comprehensive list of odorant receptors are available from the SenseLab website (<http://senselab.med.yale.edu>).

In other embodiments, the GPCR is a Class B or Class C receptor, with Class C being more preferred of these two embodiments.

In a particularly preferred embodiment, the G protein coupled receptor comprises seven transmembrane domains.

The bioluminescent protein can form part of the first, third, fifth non-transmembrane loops (domains) or the C-terminus of the G protein coupled receptor (or polypeptide of the invention). The acceptor molecule also can form part of the first, third, fifth non-transmembrane loops (domains) or the C-terminus of the G protein coupled receptor (or polypeptide of the invention). Each of these regions is intracellular when the G protein coupled receptor is expressed and present in a cell.

The acceptor molecule cannot be in the same region as the bioluminescent protein when part of the same molecule (namely, the same single polypeptide chain), however, the acceptor molecule can be in the equivalent region as the bioluminescent protein when the G protein coupled receptor is present as a dimer or higher multimer. For example, the bioluminescent protein can form part of the C-terminus of one subunit of the receptor, and the acceptor molecule can form part of the C-terminus of another subunit of the receptor. In this example, the subunit to which the label is associated can be the same or different, for instance the two subunits can be identical apart from one labelled with the bioluminescent protein and the other labelled with the acceptor molecule. In one embodiment, the bioluminescent protein forms part of the third non-transmembrane loop of the GPCR subunit, and the acceptor molecule forms part of the fifth non-transmembrane loop. In an alternate embodiment, the acceptor molecule forms part of the third non-transmembrane loop of the GPCR subunit, and the bioluminescent protein forms part of the fifth non-transmembrane loop.

In another embodiment, the bioluminescent protein forms part of the first non-transmembrane loop of the GPCR subunit, and the acceptor molecule forms part of the third non-transmembrane loop. In another embodiment, the acceptor molecule forms part of the first non-transmembrane loop of the GPCR subunit, and the bioluminescent protein forms part of the third non-transmembrane loop.

In a preferred embodiment, the bioluminescent protein forms part of the fifth non-transmembrane loop of the GPCR subunit, and the acceptor molecule forms part of the C-terminus. In an alternate embodiment, the acceptor molecule forms part of the fifth non-transmembrane loop of the GPCR subunit, and the bioluminescent protein forms part of the C-terminus.

In another embodiment, the G protein coupled receptor comprises at least two subunits, where the bioluminescent protein forms part of the third non-transmembrane loop of a first subunit, and the acceptor molecule forms part of the fifth non-transmembrane loop of a second subunit. In an alternate embodiment, the acceptor molecule forms part of the third non-transmembrane loop of a first subunit, and the bioluminescent protein forms part of the fifth non-transmembrane loop of a second subunit.

In another embodiment, the G protein coupled receptor comprises at least two subunits, where the bioluminescent protein forms part of the first non-transmembrane loop of a first subunit, and the acceptor molecule forms part of the third non-transmembrane loop of a second subunit. In another embodiment, the acceptor molecule forms part of the first non-transmembrane loop of a first subunit, and the bioluminescent protein forms part of the third non-transmembrane loop of a second subunit.

In another embodiment, the G protein coupled receptor comprises at least two subunits, where the bioluminescent protein forms part of the fifth non-transmembrane loop of a first subunit, and the acceptor molecule forms part of the C-terminus of a second subunit. In an alternate embodiment, the acceptor molecule forms part of the fifth non-transmembrane loop of a first subunit, and the bioluminescent protein forms part of the C-terminus of a second subunit.

In another embodiment, the G protein coupled receptor comprises at least two subunits and the donor and acceptor molecule are in the same site of the first and second subunits respectively.

In an embodiment, the bioluminescent protein or acceptor molecule is located after the second amino acid of the fifth transmembrane domain and before the second amino acid before the beginning of sixth transmembrane domain. In another embodiment, the bioluminescent protein or acceptor molecule is located after about amino acid 8 after the fifth transmembrane domain or after about amino acid 22 after the fifth transmembrane domain. In a further embodiment, the bioluminescent protein or acceptor molecule is inserted about 10 or 12 amino acids before the sixth

transmembrane domain. Most preferably, the bioluminescent protein or acceptor molecule is located in the middle of the third non-transmembrane loop (domain).

With regard to the C-terminus, it is preferred that about 5 to 25 amino acids of the natural C-terminus remain at the end of seventh transmembrane domain. Preferably, the bioluminescent protein or acceptor molecule is inserted after about the 16 or 20 amino acids after the seventh transmembrane.

Turning to the location of the bioluminescent protein or acceptor molecule in the first non-transmembrane loop (domain), it is preferred that said label is inserted about two amino acids after the end of first transmembrane domain and about two amino acids before the beginning of the second transmembrane domain. Most preferably, the bioluminescent protein or acceptor molecule is located in the middle of the first non-transmembrane loop (domain).

In a further embodiment, the bioluminescent protein can form part of the N-terminus, second, fourth, or sixth non-transmembrane loops (domains) of the G protein coupled receptor (or polypeptide of the invention). The acceptor molecule also can form part of the N-terminus, second, fourth, or sixth non-transmembrane loops (domains) of the G protein coupled receptor (or polypeptide of the invention), however, it cannot be in the same region as the bioluminescent protein when part of the same molecule. Each of these regions is extracellular when the G protein coupled receptor is expressed and present in a cell.

The GPCR may be a non-naturally occurring chimera of two or more different GPCRs. In particular, this enables a transduction cassette to be produced where portions of one receptor are always present in the chimera into which other portions of a wide variety of GPCRs are inserted depending on the compound to be detected.

In one embodiment, the subunit comprises the N-terminus and at least a majority of the first transmembrane domain of a first G protein coupled receptor subunit, at least a majority of the first non-transmembrane loop through to at least a majority of the fifth transmembrane domain of a second G protein coupled receptor subunit, and at least a majority of the fifth non-transmembrane loop through to the C-terminal end of the first G protein coupled receptor subunit.

In another embodiment, the subunit comprises the N-terminus through to at least a majority of the fifth transmembrane domain of a first G protein coupled receptor subunit, and at least a majority of the fifth non-transmembrane loop through to the C-terminal end of a second G protein coupled receptor subunit.

The skilled person can readily determine the N-terminal end, transmembrane domains, non-transmembrane loops (domains) and C-terminus of a G protein coupled.

For example, a variety of bioinformatics approaches may be used to determine the location and topology of transmembrane domains in a protein, based on its amino acid sequence and similarity with known transmembrane domain of G protein coupled receptors. Alignments and amino acid sequence comparisons are routinely performed in the art, for example, by using the BLAST program or the CLUSTAL W program. Based on alignments with known transmembrane domain-containing proteins, it is possible for one skilled in the art to predict the location of transmembrane domains. Furthermore, the 3 dimensional structures of some membrane-spanning proteins are known, for example, the seven transmembrane G-protein coupled rhodopsin photoreceptor structure has been solved by x-ray crystallography. Based on analyses and comparisons with such 3D structures, it may be possible to predict the location and topology of transmembrane domains in other membrane proteins. There are also many programs available for predicting the location and topology of transmembrane domains in proteins. For example, one may use one or a combination of the TMPred (Hofmann and Stoffel, 1993), which predicts membrane spanning proteins segments; TopPred (von Heijne et al., 1992) which predicts the topology of membrane proteins; PREDATOR (Frishman and Argos, 1997), which predicts secondary structure from single and multiple sequences; TMAP (Persson and Argos, 1994), which predicts transmembrane regions of proteins from multiply aligned sequences; and ALOM2 (Klien et al., 1984), which predicts transmembrane regions from single sequences.

In accordance with standard nomenclature, the numbering of the transmembrane domains and non-transmembrane loops (domains) is relative to the N-terminus of the polypeptide.

Amino acid sequence mutants/variants of naturally occurring G protein coupled receptors can be prepared by introducing appropriate nucleotide changes into the encoding polynucleotide, or by *in vitro* synthesis of the desired polypeptide. Such mutants include, for example, deletions, insertions or substitutions of residues within the amino acid sequence. A combination of deletion, insertion and substitution can be made to arrive at the final construct, provided that the final polypeptide product possesses the desired characteristics.

Mutant (variant) polypeptides can be prepared using any technique known in the art. For example, a polynucleotide described herein can be subjected to *in vitro* mutagenesis. Such *in vitro* mutagenesis techniques may include sub-cloning the polynucleotide into a suitable vector, transforming the vector into a "mutator" strain such as the *E. coli* XL-1 red (Stratagene) and propagating the transformed bacteria for a suitable number of generations. In another example, the polynucleotides encoding G

protein coupled receptors are subjected to DNA shuffling techniques as broadly described by Harayama (1998). Products derived from mutated/variant DNA can readily be screened using techniques described herein to determine if they are useful for the methods of the invention.

In designing amino acid sequence mutants, the location of the mutation site and the nature of the mutation will depend on characteristic(s) to be modified. The sites for mutation can be modified individually or in series, e.g., by (1) substituting first with conservative amino acid choices and then with more radical selections depending upon the results achieved, (2) deleting the target residue, or (3) inserting other residues adjacent to the located site.

Amino acid sequence deletions generally range from about 1 to 15 residues, more preferably about 1 to 10 residues and typically about 1 to 5 contiguous residues.

Substitution mutants have at least one amino acid residue in the G protein coupled receptor removed and a different residue inserted in its place. The sites of greatest interest for substitutional mutagenesis include sites identified as important for function. Other sites of interest are those in which particular residues obtained from various strains or species are identical. These positions may be important for biological activity. These sites, especially those falling within a sequence of at least three other identically conserved sites, are preferably substituted in a relatively conservative manner. Such conservative substitutions are shown in Table 3.

Furthermore, if desired, unnatural amino acids or chemical amino acid analogues can be introduced as a substitution or addition into a polypeptide described herein. Such amino acids include, but are not limited to, the D-isomers of the common amino acids, 2,4-diaminobutyric acid, α -amino isobutyric acid, 4-aminobutyric acid, 2-aminobutyric acid, 6-amino hexanoic acid, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, β -alanine, fluoro-amino acids, designer amino acids such as β -methyl amino acids, C α -methyl amino acids, N α -methyl amino acids, and amino acid analogues in general.

Also included within the scope of the invention are polypeptides which are differentially modified during or after synthesis, e.g., by biotinylation, benzylation, glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. These modifications may serve to increase the stability and/or bioactivity of the polypeptide.

Table 3. Exemplary substitutions.

Original Residue	Exemplary Substitutions
Ala (A)	val; leu; ile; gly
Arg (R)	lys
Asn (N)	gln; his
Asp (D)	glu
Cys (C)	ser
Gln (Q)	asn; his
Glu (E)	asp
Gly (G)	pro, ala
His (H)	asn; gln
Ile (I)	leu; val; ala
Leu (L)	ile; val; met; ala; phe
Lys (K)	arg
Met (M)	leu; phe
Phe (F)	leu; val; ala
Pro (P)	gly
Ser (S)	thr
Thr (T)	ser
Trp (W)	tyr
Tyr (Y)	trp; phe
Val (V)	ile; leu; met; phe; ala

Polypeptides described herein can be produced in a variety of ways, including production and recovery of recombinant polypeptides, and chemical synthesis of the polypeptides. In one embodiment, an isolated polypeptide of the present invention is produced by culturing a cell capable of expressing the polypeptide under conditions effective to produce the polypeptide, and recovering the polypeptide. A preferred cell to culture is a recombinant cell of the present invention. Effective culture conditions include, but are not limited to, effective media, bioreactor, temperature, pH and oxygen conditions that permit polypeptide production. An effective medium refers to any

medium in which a cell is cultured to produce a polypeptide of the present invention. Such medium typically comprises an aqueous medium having assimilable carbon, nitrogen and phosphate sources, and appropriate salts, minerals, metals and other nutrients, such as vitamins. Cells of the present invention can be cultured in conventional fermentation bioreactors, shake flasks, test tubes, microtiter dishes, and petri plates. Culturing can be carried out at a temperature, pH and oxygen content appropriate for a recombinant cell. Such culturing conditions are within the expertise of one of ordinary skill in the art.

Accessory Molecules

An accessory molecule is a protein which is involved in G coupled protein receptor signalling. Examples include G proteins and arrestins. Any labelled accessory molecule can be used in the methods of the present invention as long as they directly or indirectly associate with the G protein coupled receptor (and/or polypeptide defined herein) and following binding of the compound to the G protein coupled receptor there is a spatial alteration in the relative position of the two labels to allow for BRET detection.

The skilled person can readily identify accessory molecules that associate with a specific G protein coupled receptor using standard techniques in the art.

Details of mutants (variants) described above for G protein coupled receptors also apply to the accessory molecules.

The bioluminescent protein or acceptor molecule can be located anywhere in the accessory molecule as long as the accessory molecule is still able to directly or indirectly bind the receptor, and following binding of a compound of interest a change in BRET can be detected. In an embodiment, the bioluminescent protein or acceptor molecule is located at the C-terminus or N-terminus of the accessory molecule. The accessory molecule indirectly binds the receptor if it requires at least one other accessory molecule to form a complex with the GPCR, for instance a first accessory molecule binds the receptor and a second accessory molecule indirectly binds the receptor by directly binding to the first accessory molecule.

G proteins

G-proteins are a family of proteins involved in second messenger cascades for intracellular signaling. G proteins function as "molecular switches," alternating between an inactive guanosine diphosphate (GDP) bound state and an active guanosine triphosphate (GTP) bound state. Ultimately, G proteins regulate downstream cell

processes by initiating cascades of signal transduction networks Hofmann et al., 2009; Oldham and Hamm, 2008).

There are two distinct families of G proteins: Heterotrimeric G proteins, sometimes referred to as the "large" G proteins, that are activated by G protein-coupled receptors and made up of alpha (α), beta (β), and gamma (γ) subunits; and "small" G proteins (20-25kDa) that belong to the Ras superfamily of small GTPases. These proteins are homologous to the alpha (α) subunit found in heterotrimeric G proteins, and also bind GTP and GDP and are involved in signal transduction. In order to associate with the plasma membrane, many G proteins are covalently modified with lipids, for example heterotrimeric G protein subunits may be myristoylated, palmitoylated, or prenylated, while small G proteins may be prenylated.

As the skilled addressee will be aware, there are many known G-proteins. A number of heterotrimeric G proteins have been identified in nematodes, for example *C. elegans* has 21 $G\alpha$, 2 $G\beta$ and 2 $G\gamma$ genes (Jansen et al., 1999; Cuppen et al., 2003). Based on sequence similarity, mammalian $G\alpha$ subunits have been divided into four families: G_s , $G_{i/o}$, G_q and G_{12} (Neves et al., 2002). *C. elegans* expresses one ortholog of each of the mammalian families: GSA-1 (G_s), GOA-1 ($G_{i/o}$), EGL-30 (G_q) and GPA-12 (G_{12}). The remaining *C. elegans* α subunits (GPA-1-11, GPA-13-17 and ODR-3) do not share sufficient homology to allow classification. The conserved $G\alpha$ subunits, with the exception of GPA-12, are expressed broadly while 14 of the new $G\alpha$ genes are expressed in subsets of chemosensory neurons.

The $G\beta$ subunit, GPB-1, as well as the $G\gamma$ subunit, GPC-2, appear to function along with the α subunits in the classic G protein heterotrimer. The remaining $G\beta$ subunit, GPB-2, is thought to regulate the function of certain RGS proteins, while the remaining $G\gamma$ subunit, GPC-1, has a restricted role in chemosensation. The functional difference for most G protein pathways in *C. elegans*, therefore, resides in the α subunit.

Arrestins

Arrestins are one of the key proteins for the termination of G protein signaling. Activated GPCRs are specifically phosphorylated by G protein-coupled receptor kinases (GRKs) and then bind to arrestins to preclude the receptor/G protein interaction, resulting in quenching of the following signal transduction. Arrestins bind GPCRs, including those that have been agonist-activated and bind more tightly to those that have been phosphorylated by GRKs than those that are not.

Two distinct patterns of arrestin trafficking within the cell have been delineated resulting in the classification of GPCRs as follows: Class A where arrestin interacts with the receptor at the cell surface but does not endocytose into vesicles, thus showing a transient interaction with the receptor, and class B in which R-arrestins and receptor traffic together from the cell membrane to endocytic vesicles. These two classes of receptors also differ with regard to their affinity for different arrestin isoforms. In addition, Class A receptors preferentially bind R-arrestin2 whereas class B receptors bind to β -arrestin1 and H-arrestin2 with equal affinity.

R-arrestin-binding leads to the uncoupling of the receptor from its cognate G-proteins, causing dampening or desensitization of GPCR signaling via the downstream second messenger molecules.

While terminating G-protein signals, arrestin binding can initiate new signaling from GPCRs. For example, R-arrestins serve as adaptors, which bring non-receptor tyrosine kinases, such as Src, to form signaling complexes with the internalizing receptor. H-arrestins function as GPCR-regulated scaffolds for MAPK modules such as ASK-MKK4-JNK3 and RAF-MEK- ERK1/2. In addition, arrestins interact with proteins of the endocytic machinery, such as clathrin, β -adaptin subunit2 of the AP2 complex, and Arf-6 and thus promote internalization of receptors via clathrin-coated vesicles.

An example of a nematode arrestin is ARR-1 from *C. elegans*, which is primarily expressed in the nervous system, including the HSN neuron and various chemosensory neurons, involved in detecting soluble and volatile odorants. Over 20 putative arrestins have now been identified in the nematode *C. elegans*. Such arrestins are expressed throughout the nervous system and support receptor internalization, similarly to the vertebrate non-visual arrestins, yet participate in olfaction and vision, similarly to the visual/sensory subtypes.

Recombinant Vectors

One embodiment of the present invention includes a recombinant vector, which comprises at least one isolated/exogenous polynucleotide encoding a polypeptide as described herein, inserted into any vector capable of delivering the polynucleotide molecule into a host cell. Such a vector contains heterologous polynucleotide sequences, that are polynucleotide sequences that are not naturally found adjacent to polynucleotide molecules of the present invention and that preferably are derived from a species other than the species from which the polynucleotide molecule(s) are derived.

The vector can be either RNA or DNA, either prokaryotic or eukaryotic, and typically is a transposon (such as described in US 5,792,294), a virus or a plasmid.

One type of recombinant vector comprises the polynucleotide(s) operably linked to an expression vector. The phrase operably linked refers to insertion of a polynucleotide molecule into an expression vector in a manner such that the molecule is able to be expressed when transformed into a host cell. As used herein, an expression vector is a DNA or RNA vector that is capable of transforming a host cell and of effecting expression of a specified polynucleotide molecule. Preferably, the expression vector is also capable of replicating within the host cell. Expression vectors can be either prokaryotic or eukaryotic, and are typically viruses or plasmids. Expression vectors include any vectors that function (i.e., direct gene expression) in recombinant cells, including in bacterial, fungal, endoparasite, arthropod, animal, and plant cells. Vectors of the invention can also be used to produce the polypeptide in a cell-free expression system, such systems are well known in the art.

"Operably linked" as used herein refers to a functional relationship between two or more nucleic acid (e.g., DNA) segments. Typically, it refers to the functional relationship of transcriptional regulatory element to a transcribed sequence. For example, a promoter is operably linked to a coding sequence, such as a polynucleotide defined herein, if it stimulates or modulates the transcription of the coding sequence in an appropriate host cell and/or in a cell-free expression system. Generally, promoter transcriptional regulatory elements that are operably linked to a transcribed sequence are physically contiguous to the transcribed sequence, i.e., they are *cis*-acting. However, some transcriptional regulatory elements, such as enhancers, need not be physically contiguous or located in close proximity to the coding sequences whose transcription they enhance.

In particular, expression vectors of the present invention contain regulatory sequences such as transcription control sequences, translation control sequences, origins of replication, and other regulatory sequences that are compatible with the recombinant cell and that control the expression of polynucleotide molecules of the present invention. In particular, recombinant molecules of the present invention include transcription control sequences. Transcription control sequences are sequences which control the initiation, elongation, and termination of transcription. Particularly important transcription control sequences are those which control transcription initiation, such as promoter, enhancer, operator and repressor sequences. Suitable transcription control sequences include any transcription control sequence that can function in at least one of the recombinant cells of the present invention. A variety of

such transcription control sequences are known to those skilled in the art. Preferred transcription control sequences include those which function in bacterial, yeast, arthropod, nematode, plant or animal cells, such as, but not limited to, *tac*, *lac*, *trp*, *trc*, *oxy-pro*, *omp/lpp*, *rrnB*, bacteriophage lambda, bacteriophage T7, T7lac, bacteriophage T3, bacteriophage SP6, bacteriophage SP01, metallothionein, alpha-mating factor, *Pichia* alcohol oxidase, alphavirus subgenomic promoters (such as Sindbis virus subgenomic promoters), antibiotic resistance gene, baculovirus, *Heliothis zea* insect virus, vaccinia virus, herpesvirus, raccoon poxvirus, other poxvirus, adenovirus, cytomegalovirus (such as intermediate early promoters), simian virus 40, retrovirus, actin, retroviral long terminal repeat, Rous sarcoma virus, heat shock, phosphate and nitrate transcription control sequences as well as other sequences capable of controlling gene expression in prokaryotic or eukaryotic cells.

Host Cells

Another embodiment of the present invention includes a host cell transformed with one or more recombinant molecules described herein or progeny cells thereof. Transformation of a polynucleotide molecule into a cell can be accomplished by any method by which a polynucleotide molecule can be inserted into the cell. Transformation techniques include, but are not limited to, transfection, electroporation, microinjection, lipofection, adsorption, and protoplast fusion. A recombinant cell may remain unicellular or may grow into a tissue, organ or a multicellular organism. Transformed polynucleotide molecules of the present invention can remain extrachromosomal or can integrate into one or more sites within a chromosome of the transformed (i.e., recombinant) cell in such a manner that their ability to be expressed is retained.

Suitable host cells to transform include any cell that can be transformed with a polynucleotide of the present invention. Host cells of the present invention either can be endogenously (i.e., naturally) capable of producing polypeptides described herein or can be capable of producing such polypeptides after being transformed with at least one polynucleotide molecule as described herein. Host cells of the present invention can be any cell capable of producing at least one protein defined herein, and include bacterial, fungal (including yeast), parasite, nematode, arthropod, animal and plant cells. Examples of host cells include *Salmonella*, *Escherichia*, *Bacillus*, *Listeria*, *Saccharomyces*, *Spodoptera*, *Mycobacteria*, *Trichoplusia*, BHK (baby hamster kidney) cells, MDCK cells, CRFK cells, CV-1 cells, COS (e.g., COS-7) cells, and Vero cells. Further examples of host cells are *E. coli*, including *E. coli* K-12 derivatives;

Salmonella typhi; *Salmonella typhimurium*, including attenuated strains; *Spodoptera frugiperda*; *Trichoplusia ni*; and non-tumorigenic mouse myoblast G8 cells (e.g., ATCC CRL 1246). Particularly preferred host cells are yeast cells such as, but not limited to, *Saccharomyces spp.*, in particular, *Saccharomyces cerevisiae*, *Candida spp.*, *Hansenula spp.* or *Pichia spp.*

Recombinant DNA technologies can be used to improve expression of a transformed polynucleotide molecule by manipulating, for example, the number of copies of the polynucleotide molecule within a host cell, the efficiency with which those polynucleotide molecules are transcribed, the efficiency with which the resultant transcripts are translated, and the efficiency of post-translational modifications. Recombinant techniques useful for increasing the expression of polynucleotide molecules of the present invention include, but are not limited to, operatively linking polynucleotide molecules to high-copy number plasmids, integration of the polynucleotide molecule into one or more host cell chromosomes, addition of vector stability sequences to plasmids, substitutions or modifications of transcription control signals (e.g., promoters, operators, enhancers), substitutions or modifications of translational control signals (e.g., ribosome binding sites, Shine-Dalgarno sequences), modification of polynucleotide molecules of the present invention to correspond to the codon usage of the host cell, and the deletion of sequences that destabilize transcripts.

Cell-Free Compositions

Methods for preparing cell-free compositions from cells are well-known in the art and include repeated cycles of freezing and thawing, grinding, treatment of cells with ultrasound in a sonicator device, homogenization, the use of a French press, the addition of detergent and/or enzymes, glass-bead lysis, differential centrifugation, several density gradient procedures using a variety of gradient media. These techniques are familiar to the skilled worker and are dealt with in detail for example in "Current Protocols in Protein Science"; John E. Caligan; Ben M. Dunn; Hidde L. Ploegh; David W. Speicher; Paul T. Wingfield; Wiley and Sons).

For isolating or preparing cell membrane extracts, a combination of these methods is usually employed (Rieder and Emr, 2001). Generally, cells are lysed either by mechanical means, or using detergents, and the membrane fractions isolated via differential centrifugation, for example, as outlined in US 7,393,934. The method outlined in Moore (1994) is commonly used. An example of such a method can be found in US 7,320,875. Other methods are also available for the preparation of

membrane fractions, for example, aqueous two-phase affinity partitioning (Persson and Jergil, 1994).

There are also many commercial kits available for purifying cell membrane fractions, for example, Qiagen's Qproteome Plasma Membrane Protein Kit. Cells are incubated in a hypotonic buffer, causing them to swell. A mild detergent is added and the resulting cell suspension is homogenized by mechanical disruption. Intact cells, cell debris, nuclei and major organelles are removed by centrifugation. The resulting supernatant contains cytosolic proteins and microsomes, Golgi vesicles, and plasma membranes. A ligand specific for molecules on the cell membrane is added to the supernatant. The ligand binds to the cell membrane vesicles and the ligand-vesicle complexes are precipitated using magnetic beads that bind to the ligand. After washing, plasma membrane vesicles are eluted under native conditions and the ligand remains bound to the beads.

For yeast cells, a commonly used method for preparing cell membranes is to spheroplast the cells. This gives high yields, and is ideally suited to the large-scale isolation of plasma membranes. Such a method generally entails coating the negatively charged surfaces of the spheroplasts with dense cationic silica beads, which makes the membrane denser than any other membranous organelle of the cell. A washing procedure removes the excess cationic beads, followed by addition of polyacrylic acid to block the free cationic groups on the beads. The coated spheroplasts are subsequently lysed by hand homogenization in an EGTA-containing lysis buffer to prevent aggregation of membrane components. Centrifugation of the spheroplast lysate pellets the heavy plasma membrane-microbead assemblies, leaving intracellular membranous organelles in the supernatant.

Further examples of the production of cell-free composition comprising G protein coupled receptor-related polypeptides which can be used for the present invention are described in Kaiser et al. (2008).

In certain embodiments, a polypeptide of the invention comprising a GPCR are embedded in the lipid bilayer of a liposome preparation. As used herein, the term "liposome" refers to a closed vesicle comprising bilayers of amphiphilic phospholipids, for example phosphatidyl ethanolamine and cholesterol. Liposomes can be composed of naturally-derived phospholipids with mixed lipid chains (like phosphatidylethanolamine), or of pure surfactant components like DOPE (dioleoylphosphatidylethanolamine).

Liposomes containing polypeptides described herein may be created by disrupting the phospholipid membrane of cells expressing the protein in water, for

example by sonication. The phospholipids would reassemble into liposomal spheres containing a core of aqueous solution. Low shear rates would create multilamellar liposomes, which have many layers. Continued high-shear sonication would form smaller unilamellar liposomes, more suited to the application of the present invention. Experimentation to produce the optimal liposome size with optimal orientation and accessibility is within the routine capabilities of one of ordinary skill in the art.

Polypeptides described herein may also be produced and incorporated into liposomes by membrane reconstitution techniques involving dissociation in detergents, followed by their reconstitution in the presence of lipids and removal of the detergents. The liposome composition would be adjusted so as to ensure optimal orientation and accessibility of the polypeptides contained in the liposomes with binding partners (compounds). Such adjustments to achieve optimal liposome compositions are routine in the art.

Assays for BRET

In a preferred embodiment, the energy transfer occurring between the bioluminescent protein and acceptor molecule is presented as calculated ratios from the emissions measured using optical filters (one for the acceptor molecule emission and the other for the bioluminescent protein emission) that select specific wavelengths (see equation 1).

$$E_a/E_d = \text{BRET ratio} \quad (1)$$

where E_a is defined as the acceptor molecule emission intensity (emission light is selected using a specific filter adapted for the emission of the acceptor) and E_d is defined as the bioluminescent protein emission intensity (emission light is selected using a specific filter adapted for the emission of the bioluminescent protein).

It should be readily appreciated by those skilled in the art that the optical filters may be any type of filter that permits wavelength discrimination suitable for BRET. For example, optical filters used in accordance with the present invention can be interference filters, long pass filters, short pass filters, etc. Intensities (usually in counts per second (CPS) or relative luminescence units (RLU)) of the wavelengths passing through filters can be quantified using either a photo-multiplier tube (PMT) or a CCD camera. The quantified signals are subsequently used to calculate BRET ratios and represent energy transfer efficiency. The BRET ratio increases with increasing intensity of the acceptor emission.

Generally, a ratio of the acceptor emission intensity over the donor emission intensity is determined (see equation 1), which is a number expressed in arbitrary units

that reflects energy transfer efficiency. The ratio increases with an increase of energy transfer efficiency (see Xu et al., 1999).

Energy transfer efficiencies can also be represented using the inverse ratio of donor emission intensity over acceptor emission intensity (see equation 2). In this case, ratios decrease with increasing energy transfer efficiency. Prior to performing this calculation the emission intensities are corrected for the presence of background light and auto-luminescence of the substrate. This correction is generally made by subtracting the emission intensity, measured at the appropriate wavelength, from a control sample containing the substrate but no bioluminescent protein, acceptor molecule or polypeptide of the invention.

$$E_d/E_a = \text{BRET ratio} \quad (2)$$

where E_a and E_d are as defined above.

The light intensity of the bioluminescent protein and acceptor molecule emission can also be quantified using a monochromator-based instrument such as a spectrofluorometer, a charged coupled device (CCD) camera or a diode array detector. Using a spectrofluorometer, the emission scan is performed such that both bioluminescent protein and acceptor molecule emission peaks are detected upon addition of the substrate. The areas under the peaks represent the relative light intensities and are used to calculate the ratios, as outlined above. Any instrument capable of measuring lights for the bioluminescent protein and acceptor molecule from the same sample, can be used to monitor the BRET system of the present invention.

In an alternative embodiment, the acceptor molecule emission alone is suitable for effective detection and/or quantification of BRET. In this case, the energy transfer efficiency is represented using only the acceptor emission intensity. It would be readily apparent to one skilled in the art that in order to measure energy transfer, one can use the acceptor emission intensity without making any ratio calculation. This is due to the fact that ideally the acceptor molecule will emit light only if it absorbs the light transferred from the bioluminescent protein. In this case only one light filter is necessary.

In a related embodiment, the bioluminescent protein emission alone is suitable for effective detection and/or quantification of BRET. In this case, the energy transfer efficiency is calculated using only the bioluminescent protein emission intensity. It would be readily apparent to one skilled in the art that in order to measure energy transfer, one can use the donor emission intensity without making any ratio calculation. This is due to the fact that as the acceptor molecule absorbs the light transferred from

the bioluminescent protein there is a corresponding decrease in detectable emission from the bioluminescent protein. In this case only one light filter is necessary.

In an alternative embodiment, the energy transfer efficiency is represented using a ratiometric measurement which only requires one optical filter for the measurement. In this case, light intensity for the donor or the acceptor is determined using the appropriate optical filter and another measurement of the samples is made without the use of any filter (intensity of the open spectrum). In this latter measurement, total light output (for all wavelengths) is quantified. Ratio calculations are then made using either equation 3 or 4. For the equation 3, only the optical filter for the acceptor is required. For the equation 4, only the optical filter for the donor is required.

$$E_a/E_o - E_a = \text{BRET ratio or } = E_o - E_a/E_a \quad (3)$$

$$E_o - E_d/E_d = \text{BRET ratio or } = E_d/E_o - E_d \quad (4)$$

where E_a and E_d are as defined above and E_o is defined as the emission intensity for all wavelengths combined (open spectrum).

It should be readily apparent to one skilled in the art that further equations can be derived from equations 1 through 4. For example, one such derivative involves correcting for background light present at the emission wavelength for bioluminescent protein and/or acceptor molecule.

In performing a BRET assay, light emissions can be determined from each well using the BRETCount. The BRETCount instrument is a modified TopCount, wherein the TopCount is a microtiterplate scintillation and luminescence counter sold by Packard Instrument (Meriden, CT). Unlike classical counters which utilise two photomultiplier tubes (PMTs) in coincidence to eliminate background noise, TopCount employs single- PMT technology and time-resolved pulse counting for noise reduction to allow counting in standard opaque microtiterplates. The use of opaque microtiterplates can reduce optical crosstalk to negligible level. TopCount comes in various formats, including 1, 2, 6 and 12 detectors (PMTs) which allow simultaneous reading of 1, 2, 6 or 12 samples, respectively. Beside the BRETCount, other commercially available instrument are capable of performing BRET: the Victor 2 (Wallac, Finland (Perkin Elmer Life Sciences)) and the Fusion (Packard Instrument, Meriden). BRET can be performed using readers that can detect at least the acceptor molecule emission and preferably two wavelengths (for the acceptor molecule and the bioluminescent protein) or more.

In an embodiment of the invention, BRET is detected using a microfluidics device. Microfluidics devices conveniently require only an aliquot of the sample, generally not more than about 50 μL , to be transferred to the sample reservoir of the

microfluidics device. This is performed either manually or by pneumatic injection via a syringe, capillary or the like.

An automated luminescence biochip device using microfluidics may be used to perform all the necessary BRET reaction steps. Automating BRET reactions in a microfluidic biochip platform is desirable as this avoids multiple manual handling steps and reduces human time and effort in performing experiments. The microfluidics device may contain a self-contained disposable biochip with patterned microchannels and compartments having storage means for storing a plurality of samples, reagents, and substrates. The steps of transferring sequentially at least one of the samples, or reagents, and then luminescent substrate from compartments through microchannels to the reaction sites could be automated. The luminescent substrates would then react with the donor molecules resulting in luminescence, which would be detected by an optical detector. An example of a microfluidics device for detecting luminescence is described in US 6,949,377.

Uses

The present invention can be used to detect a wide variety of compounds, particularly odorants. Typically, the odorant will be a volatile organic or inorganic compound or inorganic gas that may be detected by chemosensory odorant receptors of at least one organism. These may include amine- and/or sulphydryl-containing compounds, carboxylic acids, alcohols, aldehydes, alkanes, alkenes, aromatic compounds, esters, terpenes or terpene-derivatives, ethers, CO₂ etc. as well as compounds bearing combinations of these features.

Odorants may be indicative of some biological or chemical state of value or of interest to humans. Such indications may include:

- The sensory appeal, quality or safety of food and beverages, pharmaceuticals or related materials.
- The health, nutritional or exercise status of humans or animals.
- The presence or absence of hazardous substances, including pathogens.
- The progress or status of industrial processes.
- An environmental contamination or state.
- The sensory appeal, quality or safety of perfumes, fragrances or other cosmetics.

In a particularly preferred embodiment, the compound only binds the receptor portion of a polypeptide described herein.

In a particularly preferred embodiment, the polypeptide defined herein comprising an odorant receptor is used in a biosensor to detect a compound(s) of

interest. A biosensor is a device for the detection of an analyte that combines a biological component with a physicochemical detector component. It typically consists of three parts, firstly at least one polypeptide defined herein comprising a G protein coupled receptor. Second, a transducer or detector element is required, which works in a physicochemical way (eg. optical, electrochemical) that transforms the signal resulting from the interaction of the compound with the polypeptide into another signal (i.e. transducers) that can be more easily measured and quantified. Third, an associated electronic or signal processor is required, which then displays the results of the interaction in a user-friendly way. An example of a biosensor involving BRET is described in Charest et al. (2005).

In another embodiment, the methods of screening are used for drug discovery and/or development. More specifically, the receptor is a target for potential therapeutics. Thus, in this embodiment it is preferred that the receptor is a clinically important molecule such as, but not limited to, an adrenergic receptor, a serotonin receptor, a dopamine receptor, metabotropic/glutamate receptor, a GABA receptor, a vomeronasal receptor, a taste receptor, or a secretin-like receptor.

Within the scope of the present invention are also methods for identifying, characterizing and for screening of molecules which are capable of interacting with an G protein coupled receptor which comprise so-called high-throughput screening methods and similar approaches which are known in the art (Spencer, 1998; Oldenburg, 1998; Milligan, 1999) carried out using 96-well, 384-well, 1536-well (and other) commercially available plates. Further methods to be employed in accordance with the present invention comprise, but are not limited to, homogenous fluorescence readouts in high-throughput screenings (as described, *inter alia*, in Pope, 1999).

As the skilled person would be aware, the present invention can also be multiplexed. In this system, two or more polypeptides comprising different G protein coupled receptors are provided which bind different compounds. Each different G protein coupled receptor is labelled with a different bioluminescent protein and/or acceptor molecule such that they emit at different wavelengths to enable the detection and quantification of different target compounds.

EXAMPLES**EXAMPLE 1 - DUAL LABELLED BRET ODR-10 (OGPR) CONSTRUCTS****MATERIALS AND METHODS****Design and Construction of Dual Labelled BRET OR Constructs**

BRET² receptor constructs were generated with BRET² components inserted into the third intracellular loop (IC3) and at the C-terminus. Two BRET constructs were made with; (1) GFP² in the middle of IC3 and RLuc(h) on the C-terminus; (2) OR with RLuc(h) in the middle of IC3 and GFP² on the C-terminus. The position of the third intracellular loop (IC3) was determined using TMAP on The Biology Workbench a web-based tool for prediction of transmembrane segments (<http://seqtool.sdsc.edu>). For ODR-10, the middle of the IC3 is amino acids 240-241. The amino acid sequence for this construct referred to as OGOR, is provided as SEQ ID NO:15 (encoding nucleotide sequence provided as SEQ ID NO:16).

ODR-10 was amplified from *C. elegans* cDNA, which was prepared with standard techniques using superscript II (Invitrogen). PCR conditions were as follows 94°C 2mins, 30 cycles of 94°C 15secs, 59°C 30secs, 68°C 70sec, and a final extension step of 68°C for 5min. Standard Pfx50 PCR ingredients were used with primers ODR-10Xba1F 5'-AGTCTAGAATGTCGGGAGAATTGTGGATTA-3' (SEQ ID NO: 21) and ODR-10-attb1-R 5'-GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATCACGTCGGAAGTTGAG-3' (SEQ ID NO:22). Amplified cDNA was cloned into pGEM-T (Promega) and sequenced.

The BRET components, GFP² and *Renilla* Luciferase, RLuc(h), were sourced from a commercially available plasmid pGFP²-MCS-Rluc(h) (PerkinElmer; Lot#6310051-6D1).

BRET constructs were constructed by PCR amplification of individual fragments of the construct (see Table 4 for primers and annealing temperatures). PCR was performed with Pfx50TM standard ingredients (Invitrogen) and conditions were as follows 94°C 2min, 30 cycles of 94°C 15sec, 59°C 30sec, 68°C 70sec, and a final extension step of 68°C for 5min. Separate components of the constructs were amplified using overlapping primers.

Table 4. Primers for dual tagged ODR-10 receptor constructs.

Construct	Fragment	cDNA Fragment size (bp)	Primers	Sequence	Oligo Anneal Temp (°C)
ODR-10::GFP ² @AA240-241::RLuc(h) (Cterm) (OGOR)	(5') ODR-10::GFP ²	1452	F: attB1 ODR-10Forward	AACCATGTCGGGAGAATTGTG (SEQ ID NO:23)	57.7
			R: ODR-10-MidIC3GFP ² Jt2R	TGTAGCGCTCGCTTGTACAGCTCGTCCAT (SEQ ID NO:24)	
	(3') ODR-10	321	F: ODR-10-MidIC3GFP ² Jt2F	GAGCTGTACAAGCGAGCGCTACAGAAACAA (SEQ ID NO:25)	57.3
			R: ODR-10-CtermRLuc(h)JtR	CTTGCTGGTCATCGTCGGAAGTTGAGACA (SEQ ID NO:26)	
	RLuc(h) (Cterm)	949	F: ODR-10-CtermRLuc(h)JtF	CAAGTTCGACGATGACCAGCAAGGTGTA (SEQ ID NO:27)	56.5
			R: attB2 RLuc(h)Reverse	GTTACTGCTCGTTCTTCA (SEQ ID NO:28)	
	(3') ODR-10::RLuc(h) (Cterm)	1246	F: ODR-10-MidIC3GFP ² Jt2F	GAGCTGTACAAGCGAGCGCTACAGAAACAA (SEQ ID NO:29)	55.3
			R: attB2 RLuc(h)Reverse	GTTACTGCTCGTTCTTCA (SEQ ID NO:30)	
	ODR-10::GFP ² @AA240-241::RLuc(h) (Cterm)	2675	F: attB1 ODR-10Forward	AACCATGTCGGGAGAATTGTG (SEQ ID NO:31)	53.7
			R: attB2 RLuc(h)Reverse	GTTACTGCTCGTTCTTCA (SEQ ID NO:32)	
ODR-10::RLuc(h)@AA240-241::GFP ² (Cterm) (OROG)	(5') ODR-10::RLuc(h)	1669	F: attB1 ODR-10Forward	AACCATGTCGGGAGAATTGTG (SEQ ID NO:33)	58

			R: ODR-10-MidIC3RLuc(h)Jt2R	CTGTAGCGCTCGCTGCTCGTTCTTCAG (SEQ ID NO:34)	
	(3') ODR-10	321	F: ODR-10-MidIC3RLuc(h)Jt2F	AAGAACGAGCAGCGAGCGCTACAGAAACA (SEQ ID NO:35)	57.9
			R: ODR-10-CtermGFP ² JtR	CTTGCTCACCATCGTCGGAAGTTGAGACA (SEQ ID NO:36)	
	GFP ² (Cterm)	723	F: ODR-10-CtermGFP ² JtF	CAAGTCCGACGATGGTGAGCAAGGGCGA (SEQ ID NO:37)	56.3
			R: attB2 GFP ² Reverse	GTTACTTGTACAGCTCGTC (SEQ ID NO:38)	
	(3') Odr10::GFP ² (Cterm)	1030	F: ODR-10-MidIC3RLuc(h)Jt2F	AAGAACGAGCAGCGAGCGCTACAGAAACA (SEQ ID NO:39)	54.7
			R: attB2 GFP ² Reverse	GTTACTTGTACAGCTCGTC (SEQ ID NO:40)	
	Odr10::RLuc(h)@AA240-241::GFP ² (Cterm)	2675	F: attB1 ODR-10Forward	AACCATGTCGGGAGAATTGTG (SEQ ID NO:41)	53.0
			R: attB2 GFP ² Reverse	GTTACTTGTACAGCTCGTC (SEQ ID NO:42)	

Components were then purified and placed in a paired reaction to denature at 94°C, anneal 52°C (at overlapping primer sites) and extend 68°C for 5min for the required pairs. This was then used as template for PCR using the most 5' and 3' primers of the pairs. This was repeated until the full length constructs were made. They were then cloned into pGEM-T for sequencing. Error free clones were subcloned into pDONR201 (Invitrogen) using ApaLI. These were then subcloned into pYES-DEST52 (Invitrogen) using Gateway® technology (attB sites were included in original 5' and 3' primers) for subsequent expression in *S. cerevisiae*.

Construction of OGOR Mutant (H110Y)

Site-directed mutagenesis was carried out with OGOR in pDONR201 vector (see above) as the double stranded template. The histidine 110 to tyrosine (H110Y) mutation was performed using the Stratagene Quickchange site directed mutagenesis kit according to standard protocols using the following primers; 5'-CACCAGTTTTGTTGTCTCAGGAGTTTATTTTGTTCGATATTTTGCAACTT-3' (WT) (SEQ ID NO:43) and 5'-AAGTTGCAAAATATCGATAAACAATAAACTCCTGAGACAACAAACTGTG-3' (H110Y antisense) (SEQ ID NO:44).

PCR was performed with Pfx50™ standard ingredients (Invitrogen) and conditions were as follows 94°C 2mins, 16 cycles of 94°C 30secs, 55°C 1 minute, 68°C 6.8 minutes. Following sequencing the OGOR mutant was then subcloned into pYES-DEST52 (Invitrogen) using Gateway® technology (5' and 3' attB sites were included in original OGOR sequence) for subsequent expression in *S. cerevisiae*.

Solution Preparations

20 % (w/v) Glucose - Add 20 g of glucose to 100 mL of deionized water, heat on hot-plate (50 °C) until dissolved and filter purify (0.2 µm filters) solution.

20 % (w/v) Raffinose - Add 20 g of glucose to 100 mL of deionized water, heat on hot-plate (50 °C) until dissolved and filter purify (0.2 µm filters) solution.

20 % (w/v) Galactose - Add 20 g of galactose to 100 mL of deionized water, heat on hot-plate (50 °C) until dissolved and filter purify (0.2 µm filters) solution.

YPD medium - Add 20g of bacteriological peptone, 10g of yeast extract to 1 L of deionized water. Autoclave for 15 minutes.

YPD plates - Add 20g of bacteriological peptone, 10g of yeast extract and 20 g of agar to 1 L of deionized water. Autoclave for 15 minutes. Following autoclaving add 20 mL of 20 % glucose and pour agar plates.

Yeast Synthetic Drop-Out Media without Uracil (SCMM-U) medium - Add 6.7 g of yeast nitrogen base without amino acids (Product no. Y 0626, Sigma) and 1.92 g of yeast synthetic drop-out media supplement without uracil (Product no. Y 1501) to 1 L of deionized water. Autoclave for 15 minutes.

SCMM-U plates - Add 1.34 g of yeast nitrogen base without amino acids (Product no. Y 0626, Sigma), 0.384 g of yeast synthetic drop-out media supplement without uracil (Product no. Y 1501, Sigma) and 4 g of agar to 180 mL of deionized water. Autoclave for 15 minutes. Following autoclaving add 20 mL of 20% glucose and pour agar plates.

1 × Sodium phosphate buffer (1 × PBS, pH 7.4.) – A 10 × stock solution was prepared by dissolving 82.33 g of sodium phosphate dibasic (0.58 M), 23.45g of sodium phosphate monobasic (0.17 M) and 40 g sodium chloride (NaCl) in deionized water. The stock solution was diluted to a 1 × PBS solution in deionized water.

Coelenterazine 400a - Dissolve 1 mg of Coelenterazine 400a (Clz400a, Biosynth) in 10.20 mL of pure ethanol to make a 250 µM stock solution. Pipette 40 or 400 µL aliquots of Coelenterazine 400a into microcentrifuge tubes and then dry down with a SpeedVac[®] Plus SC110A (Savant). Store aliquots at –80 °C. Reconstitute samples in 100 or 1000 µL (40 or 400 µL aliquots, respectively) of absolute ethanol to give a concentration of 50 µM.

Odorant Preparation - A 1 % stock solution of the odorants diacetyl, benzaldehyde and octanal were made up in the respective solvents water, ethanol and DMSO. The odorants were serially diluted in water to give the desired final concentration. The same dilutions of solvents without the addition of the odorants were also prepared.

Plasmid Transformation Protocol

Yeast transformations were carried out using a yeast transformation kit (YEAST-1, Sigma). A YPD plate was streaked with INVSC1 (Invitrogen) *S. cerevisiae*

strain and incubated at 28 °C for 2-3 days. Scrape a loop of InVSC1 cells from the YPD plate into a microcentrifuge tube. Resuspend cells in 0.5 mL of transformation buffer (Product code T 0809) and spin for 5 seconds. Remove the supernatant, leaving 50 - 100 µL of the buffer in the tube. Add 10 µL of 10 mg/mL salmon testes DNA (Product code D 9156) to the tube. Add 1 µg of the pYES-DEST52 – OR plasmid DNA to be studied and vortex for 10 seconds. Add 600 µL of PLATE buffer (product code 8966) and vortex. Incubate for 4 hours at room temperature. Heat shock the sample for 15 minutes in a 42 °C heat block. Spin for 3 seconds in a microcentrifuge and remove the supernatant. Resuspend cells in 500 µL of sterile water. Plate 100 µL on SCMM-U plate. Incubate at 28 °C for 2-3 days until colonies appear.

Expression Protocol

Inoculate a single colony containing the pYES-DEST52 – OR construct into 15 mL of SCMM-U media containing 2 % glucose. Grow overnight at 28 °C with shaking (200 rpm).

The OD₆₀₀ of the overnight culture was determined. The amount of overnight culture required to obtain an OD₆₀₀ of 0.4 in 30 mL of induction medium (SCMM-U, 2% galactose, 2% raffinose) was removed and the cells pelleted at 1500 x g for 5 minutes. The cells were resuspended in 1 mL of induction medium and inoculated into 29 mL of induction medium. Grow at 15 °C with shaking (200 rpm) for 72 hours. The culture was removed from the flask and the cells were centrifuged at 1500 x g for 5 minutes at 4 °C. Decant the supernatant and resuspend cells in 1 mL of sterile water. Transfer cells to a sterile microcentrifuge tube and centrifuge samples for 1 minute at 10,000 x g. Remove the supernatant and carry out membrane isolation.

Membrane Preparations

Cells were harvested by centrifugation at 1500 x g (4 °C) for 5 minutes, washed in water and resuspended in 4 mL of Dulbecco's phosphate buffered saline (D-PBS) or 1 x PBS, containing 1000 mg/L glucose, 36 mg/L sodium pyruvate, calcium and magnesium (Invitrogen). The cells were lysed by French press (~ 18000 psi) and the soluble protein fractions were isolated by centrifugation at 9300 x g (4 °C) for 15 minutes. Following this the soluble protein fraction was transferred to 13.15 mL polycarbonate thick wall centrifuge tubes and ultracentrifuged at 40,000 rpm (Beckman Coulter L-80 ultra-centrifuge) for 1 hour at 4 °C. The supernatant was decanted and the membrane pellet resuspended in 1 mL of D-PBD or 1 x PBS, and left overnight at 4 °C to solubilise.

Spectral Measurements

All spectral scans were recorded with a plate-reading SpectraMax M2 spectrofluorimeter (Molecular Devices). 100 μ L aliquots of membrane preparations sample were scanned using 96-well plates (Perkin-Elmer). Fluorescence spectral scans recorded from 450 to 600 nm with an excitation wavelength of 420 nm using a 455 nm emission cut-off filter.

Simultaneous Dual Emission Detection

Simultaneous dual emission RET measurements were carried out with a POLARstar OPTIMA microplate reader (BMG LabTech). Simultaneous emission measurements used a BRET² filter set (410-80/515-30) with the set respective gains for each channel (3300/4095).

RET Analysis Protocol

Normalization of Sample Concentration

To assess the relative concentrations of BRET² tagged receptor samples the fluorescence intensity of the sample was determined from spectral scans and the sample amount normalized by the OGOR fluorescence intensity. To convert GFP² intensity into concentration purified GFP² protein was assayed at different concentrations to produce a calibration graph relating concentration to fluorescence intensity. GFP² proteins were purified using cobalt affinity chromatography according to the supplied instructions (BD Talon (BD Biosciences, Clontech)). Rearranging the line of best fit equation ($y = 271x + 233.31$) results in conversion of fluorescence intensity to concentration. An estimated concentration of 5 or 10 nM was used for assays in a final volume of 100 μ L.

Selectivity

RET analysis was carried out in 96-well plates (Perkin-Elmer) and involved incubating the specified dual tagged receptor protein (OGOR) for 45 minutes with 1 μ M of each particular odorant. The final volume was 100 μ L and included 10 μ L of odorant, receptor protein sample (see '*Normalization of sample concentration*' section), D-PBS (or 1 x PBS) and 5 μ L of Clz400a (5 μ M). A background signal was recorded by assaying a sample of D-PBS (or 1 x PBS). During the incubation time the 96-well plate wells were sealed with TopsealTM - A (Packard) with each sample area individually sealed. Non odorants samples (water, pyruvate, citric acid, lactic acid)

were prepared and assayed first. Following this odorants solutions were prepared in the fume hood and assayed in the following order: 2-butanone, 2,3 – pentanedione, 2,3-butanediol and diacetyl.

For BRET² measurements Clz400a substrate (5 μ M) was added following the 45 minute incubation time and the signal recorded using a 0.50s integration time over a 5 second period. Following addition of Clz400a the well was re-sealed while the signal was recorded to reduce cross-contamination of samples. The assays were sequentially carried out in the order the samples were added to the wells.

BRET² ratio is calculated as emission ratio measured as ((emission at 515 nm for receptor sample)-(emission at 515 nm for D-PBD (or 1 x PBS)))/(emission at 410 nm for receptor sample)- (emission at 410 nm for D-PBD) (or 1 x PBS)).

Dose Response Curve

The OGOR concentration was normalized to 10 nM by GFP² intensity. A dose response curve was constructed by varying odorant concentrations over the concentration range as indicated in the text. The lowest concentration was always assayed first and the highest last.

A sigmoidal dose response curve was fitted, and EC₅₀ calculated, by non-linear regression analysis using GraphPad Prism for Windows XP.

RESULTS

Ligand Response and Selectivity

The constructs produced have the BRET² donor and acceptor inserted within the third intracellular loop and at the C-terminus of the odorant receptor (Figure 1). Diacetyl binding by ODR-10 would cause an increase in the BRET² ratio if the donor and acceptor components moved apart or an increase in the signal if the components moved closer together.

The BRET² signal was recorded following incubation of OGOR with 10 nM or 1 μ M of the following ligands: water, pyruvate, citric acid, lactic acid, 2-butanone, 2,3 – pentanedione, 2,3-butanediol and diacetyl (Figures 2a and b). The largest change in BRET² signal occurred upon incubating OGOR with μ M concentrations of diacetyl, with a 37.5 % difference in the signal compared to the solvent (water) response (Figure 3a). This is the first example of monitoring ligand binding using a dual-labelled BRET² tagged receptor in a cell-free assay format.

The change in the BRET² ratio upon addition of both nM and μ M concentrations of diacetyl to OGOR was significantly different ($P > 0.05$) to the control

response (water) (Figures 3a and b). The response of OGOR to diacetyl stimulation was the only response which was significantly different to the control response compared to all other ligands tested at both nM and μ M concentrations. These results confirm that ODR-10 selectively binds diacetyl. Diacetyl was previously confirmed to be the only volatile compound to produce a Ca^{2+} elevation response in ODR-10 expressing HEK 293 cells (Zhang et al., 1997).

The largest change in the BRET^2 response to ligand binding of 37.5% is substantially greater than the observed change in the FRET signal ($\sim 5\%$) upon binding of 10 μ M norepinephrine by the α_{2A} receptor (Lohse et al., 2003) and 1 μ M PTH by PTHR ($\sim 20\%$) (Villardaga et al., 2003). The decrease in BRET^2 signal upon addition of diacetyl suggests that the BRET^2 components move apart upon odorant binding. This is the first demonstration that this BRET^2 transduction system exhibits superior sensitivity compared to a FRET transduction system for monitoring intramolecular changes.

Dose Response

The effect of changing odorant concentrations on the amplitude of the change in the BRET^2 signal of OGOR (Figure 4) provides the first demonstration of a dose-dependent response. The EC_{50} value was calculated to be 3.55 fM diacetyl, which is equivalent to 0.31 parts per quadrillion (ppq). The apparent affinity of ODR-10 for diacetyl when expressed in human cells, and monitored by calcium imaging technique, was calculated to be 2.3 μ M (~ 0.2 part per million (ppm)), an EC_{50} value consistent with chemotaxis results (Zhang et al., 1997).

The cell free assay presented here is more than nine orders of magnitude more sensitive for diacetyl quantification compared to whole cell assays and existing chemical detection systems such as fluorescence detection (Li et al., 2009) and a gas chromatographic technique with flame ionization detection (GC-FID) (Macciola et al., 2008).

Negative Control - OGOR Mutation (H110Y)

An ideal negative control for the OGOR response to diacetyl would place the BRET^2 components the same distance apart as in the OGOR receptor but the receptor would be unresponsive to diacetyl itself. Replacing the histidine with a tyrosine at position 110 in the 3rd membrane spanning residue of ODR-10 resulted in a strongly defective chemotaxis response to diacetyl (Troemel et al., 1995; Sengupta et al., 1996).

The introduction of a histidine 110 to tyrosine (H110Y) mutation to the OGOR construct reduced the response to μM concentrations of diacetyl from 32.4% for OGOR to 4.1% (Figure 5). This reduced response to diacetyl was not significantly different ($P < 0.05$) from the solvent (water) response indicating the mutation caused a loss of function. This infers that the response of OGOR to diacetyl is due to diacetyl interacting with the ODR-10 receptor and not non-specifically with the BRET² components themselves.

EXAMPLE 2 - COMPARISON OF DUAL-LABELLED FRET ODR-10 (OCOY) TO DUAL-LABELLED BRET² ODR-10 (OGOR)

To compare the sensitivity of the BRET² system to the FRET system for monitoring GPCR activation the BRET² components used to tag the ODR-10 receptor (OGOR) were replaced with FRET components resulting in the insertion of CFP into the 3rd intracellular loop and YFP at the C-terminus (OCOY). The CFP (mCFP) (SEQ ID NO:45) and YFP (mCitrine) (SEQ ID NO:46) derivatives were both monomeric and codon optimized (EUROSCARF) for yeast expression (SEQ ID NOs 47 and 48 respectively).

MATERIALS AND METHODS

The OCOY sequence flanked by *Kpn*I and *Xho*I restriction sites was synthesised by Genscript. The OCOY sequence was inserted into the *Kpn*I and *Xho*I sites of the pENTR11 vector. These were then recombined into pYES-DEST52 (Invitrogen) using Gateway[®] technology for subsequent expression in *S. cerevisiae*. The OCOY coding sequence is provided as SEQ ID NO:49, whereas the amino acid sequence is provided as SEQ ID NO:50.

OCOY Expression

The same expression protocol was used for the expression of OCOY in InVSC1 as for OGOR expression.

Concentration Normalization

To assess the relative concentrations of dual-tagged receptor samples the fluorescence intensity of the sample was determined from spectral scans and the sample amount normalized by the OCOY fluorescence intensity. The YFP intensity (530 nm) was normalized to 721.32 a.u. for OCOY. 50 μL of OCOY was pipetted into the appropriate well and the volume made up to 100 μL with $1 \times \text{PBS}$.

RESULTS

Ligand Response

There was a 7.6% reduction in FRET ratio (intensity at 520 nm/ intensity at 480 nm) of OCOY in response to μM concentrations of diacetyl compared to a 32.4% reduction for OGOR (Figure 6). The OCOY response was shown to be significantly different ($P < 0.05$) to the solvent (water) response. OGOR was shown to be more than four times more sensitive for monitoring diacetyl binding than OCOY.

The Förster distance (R_0), the RET probe separation corresponding to 50% of the maximum RET efficiency, for the BRET² system was recently determined to be 7.5 nm, the largest R_0 value determined for any genetically encoded RET pair (Dacres et al., 2009). The R_0 value for the FRET system was previously determined to be 4.8 nm (Evers et al., 2006) indicating that the BRET² system is able to probe a larger distance range (3.8 – 11.3 nm) than the FRET system (2.4 – 7.2 nm). The measured transfer efficiency for OGOR changed from 64.3% to 47% upon the addition of diacetyl (1 μM) indicating a distance change of 6.8 nm to 7.6 nm. A system with a Förster distance of 4.8 nm, such as the FRET system, would only exhibit a transfer efficiency change of 11.3% to 6.0% upon addition of diacetyl for this distance change. This confirms that the BRET² system is more suitable, in terms of detection sensitivity, for the measurement of this distance change in this distance range.

OCOY Dose Response Curve

Following the confirmation that the OCOY response to diacetyl was significantly different to the solvent (water) response a dose response was plotted. To generate this data spectral scans were recorded upon the addition of different concentrations of diacetyl (Figure 7). As the concentration of diacetyl increased from 1×10^{-21} M to 1×10^{-10} M there was a decrease in the YFP emission intensity and an accompanying increase in CFP emission intensity (Figure 7). Scaling the OCOY response with respect to the normalized OGOR response curve (Figure 8) confirmed that BRET² detection is more sensitive than FRET detection for monitoring diacetyl binding by ODR-10. The calculated log EC50 value for the FRET detection system was -16.43 ± 0.9741 M (mean $\pm$ SEM, $n=5$) which is not significantly different ($P < 0.05$) to the calculated log EC50 value of -14.43 ± 0.5468 (mean $\pm$ SEM, $n=12$) for the BRET² system. This demonstrates that the ODR-10 affinity for diacetyl is statistically similar for both detection systems inferring that diacetyl is specifically interacting with the ODR-10 receptor and not with the RET components themselves.

EXAMPLE 3 – DUAL-TAGGED Str112 (TGTR)

MATERIALS AND METHODS

The TGTR sequence flanked by *Nco*I and *Not*I restriction sites was synthesised by Genscript. The TGTR sequence was inserted into the *Nco*I and *Not*I sites of the pENTR11 vector. These were then recombined into pYES-DEST52 (Invitrogen) using Gateway[®] technology for subsequent expression in *S. cerevisiae*.

TGTR Expression

The same expression protocol was used for the expression of TGTR in InVSC1 as for OGOR expression. The TGTR coding sequence is provided as SEQ ID NO:51, whereas the amino acid sequence is provided as SEQ ID NO:52.

RET Analysis Protocol

The same RET analysis protocol as described for the OGOR selectivity studies. 1 μ M of the ligands pyruvic acid, citric acid, ethyl acetate, acetoin and diacetyl was assayed with 10 nM of TGTR.

Preparation of Bacterial Extract Assays

The bacterial strain OP50 was grown in LB overnight at 37°C with shaking (200 rpm). *E.coli* strain OP50 is usually used as a food source for nematode growth in the laboratory (Brenner, 1974). Two assays were performed using the OP50 bacterial culture. The first assay was the addition of 10 μ L of the bacterial culture or 10 μ L of LB to 10 nM TGTR. The second assay required that 1 mL of the bacterial culture was placed in a microcentrifuge tube and centrifuged at 10000 $\times$ g for 1 minute. 10 μ L of the supernatant, following decanting into a fresh microcentrifuge tube, or 10 μ L of LB was added to 10 nM TGTR. Following bacterial sample addition the same protocol was followed as for the OGOR RET analysis.

RESULTS

The response of TGTR to the addition of 10 μ L of OP50 bacterial supernatant or bacterial culture in LB was significantly different ($P \leq 0.05$) to that of LB alone (Figure 9). Stimulating the Str112 receptor to a complex odorant mixture as released from OP50 during growth causes an increase in the BRET² ratio suggesting that the BRET² components move towards each other upon odorant binding.

A number of ligands were tested individually (Figure 10) and both pyruvic acid and acetoin produced significantly higher BRET² signals ($P \leq 0.05$) compared to the response of TGTR to water. This confirms that upon ligand binding the BRET² components move towards each other. An increase of 20.8% in the BRET² signal in response to acetoin is four times greater than the response of the FRET tagged α_{2A} adrenergic receptor to norepinephrine (Lohse et al., 2003). This is the first demonstration of odorant binding by the Str112 nematode receptor and also the first example of monitoring odorant binding by BRET² tagged Str112.

EXAMPLE 4 – RECEPTOR CHIMERAS

An ODR-10 transduction cassette is engineered so the ODR-10 N-terminus (aa1-32) and IC3 to C terminus (aa225 –aa339) with BRET tags flank a multiple cloning site (Figure 11). The chimeric receptors are expressed in yeast. Ligand binding regions of ORs are shuffled “in-frame” into this cassette and these chimeric receptors can be used to assess ligand binding by BRET.

EXAMPLE 5 – OLIGOMERIZATION OF OLFACTORY RECEPTORS

Odr10 labelled with Rluc at the C-terminus (SEQ ID NO:17) and Odr10 labelled with GFP2 at the C-terminus (SEQ ID NO:19) were co-expressed in yeast to show receptor oligomerization and BRET modulation.

MATERIALS AND METHODS

Transformant Culture and Tagged-Gene Induction Conditions

A colony of transformed yeast cells was grown in yeast synthetic drop-out medium (SCMM, Sigma) lacking appropriate nutrients (such as uracil (U), tryptophan (T)) to select for plasmid-containing cells with 2% glucose for overnight at 28°C with shaking 190 rpm; SCMM-U-T for Invsc1 co-expressed *pYesDest52-Odr10-Rluc* and *pDestpESC-Odr10-GFP2* (Invsc1/OR/OG), SCMM-U for Invsc1 expresses *pVV214-odr10-Rluc* (Invsc1/OR) alone and *pYesDest52 odr10-GFP2* (Invsc1/OG) alone respectively.

After overnight culture, OD600 was determined and the cells were suspended in induction medium (with 2% galactose and 1% raffinose instead of glucose as the culture medium) to give a final OD600 of 0.4. This induction culture was incubated for 24 hours with shaking at 15°C to induce fusion receptor expression. The culture was then pelleted and washed twice with cold phosphate-buffered saline (PBS). Cell pellet can be stored at -80°C and suspended in PBS buffer just before the BRET² assay.

Quantification of Yeast Cells for BRET² Assay

First Invsc1/OR/OG was quantified by GFP intensity (about 3000 RLU or c.p.s in 100 μ l per well) by direct excitation of GFP² at Ex420nm in a white 96-well microplate (Perkin Elmer) using a SpectraMax M2 spectrofluorometer (Molecular Devices). The Renilla luciferase activity of the quantified Invsc1/OR/OG cells was determined by adding luciferin coelenterazine native (final concentration 5 μ M) into a total volume of 100 μ l cell in a 96-well white microplate and measuring luminescence signals immediately (Polarstar Optima, BMGLABTECH).

Invsc1/OG was normalised to have the similar GFP intensity as Invsc1/OR/OG. Invsc1/OR was normalised to have the similar Rluc activity as Invsc1/OR/OG. Negative control (host strain) Invsc1 was quantified to have same cell density as Invsc1/OR/OG.

Microplate BRET² Cell Based Assay

Assay procedure was modified from Issad and Jockers (2006) and conducted in a 96-well white microplate in a total volume of 100 μ l and two repeat for each sample. Three biological independent assays will be conducted and data are pooled. Coelenterazine h DeepBlueC substrate (Biosynth AG) was added at a final concentration of 10 μ M, and readings were performed with a dual wavelength lumino/fluorometer microplate reader (BMGLabtech). The following optimized filter settings were used to measure Rluc light emission (410 $\pm$ 80 nm) and GFP² light emission (515 $\pm$ 30 nm). The BRET ratio was defined as the difference of the emission at 515nm/410nm of co-expressed Rluc and GFP2 fusion proteins and the emission at the 515nm/410nm of the Rluc fusion protein alone. Results were expressed in milliBRET units, 1 milliBRET corresponding to the BRET ratio value multiplied by 1000 (Ayoub, 2002). Illumination of control cells (host strain Invsc1) that do not express a Rluc or GFP2 fusion at the same settings results in detection of cell autofluorescence. Subtraction of the autofluorescence from all tested samples was taken place before BRET ratio values were calculated.

Crude Membrane Preparation, Solubilisation, and Immunoprecipitation

Properly induced yeast cells (GFP² level was not more than 2 fold over background of host strain Invsc1 cells) were washed three times with ice-cold Buffer A (75 mM tris-HCl, pH7.4, 12 mM MgCl₂ and 2 mM EDTA) and the final pellet was suspended in Buffer B (Buffer A + protease inhibitor cocktail, complete Mini EDTA-

free (Roche Applied Science)). Then the yeast cells are disrupted using a French Press and centrifuged for 15 mins at 10,000 x g at 4°C. The supernatant was ultracentrifuged for 1 hour at 130000 x g and the pellet was suspended in cold Buffer B.

Membrane protein solubilisation and immunoprecipitation procedures were modified according to the method described by Ayoub et al. (2002). Crude membrane was solubilised with 0.5% digitonin (Sigma) and this mixture was stirred for 3h at 4°C. Non-solubilised membrane proteins were removed by centrifugation at 18,000 x g for 30 mins at 4°C. The digitonin concentration was adjusted to 0.2% using cold Buffer B and the polyclonal anti-GFP antibodies (Sapphire Bioscience, Cat No 120-29000) were added to a final dilution of 1:1000. Immune complex formation was allowed to proceed for 12h at 4°C with gentle agitation and Protein A-agarose suspension (Sigma) was added to a final volume of 1:10 (agarose suspension:sample) for incubation for another 6h with gentle agitation at 4°C. After centrifugation for 1 min at 5000 x g, supernatant was decanted and the agarose beads washed five times with 0.5 ml of cold Buffer C (Buffer B + 0.2% digitonin). Precipitates were analysed by assessing luciferase activity in a luminometer (BMGLabtech) using coelenterazine as substrate (Biosynth AG, Switzerland).

RESULTS

Visualisation of Nematode odr-10 in Yeast Cells – Confocal Microscopy

Confocal image of yeast strain *Invsc1* co-expressed odr-10-Rluc and odr-10-GFP² after 24 hour induction reveals that GFP² fusion protein mostly only expressed on the membrane of the cells and no over-expression of tagged odr-10 observed. About 32% of the cells expressed tagged odr-10 protein. Increasing induction time up to 48 hours, confocal image shows GFP² over-expression in the cells and aggregated GFP² particles observed in the cytosol of the cells (Figure 12).

Detection of Constitutive odr-10 Oligomers in Living Yeast Cells by BRET²

BRET² experiment results shows that significant energy transfer was observed in yeast cells co-expressing odr-10-Rluc and odr-10-GFP² (Figure 13) indicating that odr-10 forms homo-oligomers. No significant energy transfer was obtained in the sample at which half yeast cells expressed odr-10-Rluc and another half cells expressed odr-10-GFP².

Detection of Constitutive Odr-10 Oligomers in Living Yeast Cells by Immunoprecipitation

Oligomerisation of Odr-10 in the living yeast cells was confirmed by the pairwise expression of receptor-Rluc and –GFP² fusion, followed by precipitation using anti-green fluorescence protein antibodies and measuring co-immunoprecipitated luciferase activity. The results represented in Figure 14 indicate that Odr-10 forms oligomers in the cells. To rule out the possibility that co-immunoprecipitation could result from receptor-independent, interaction between the GFP² and the Rluc, co-immunoprecipitation was also carried out using (1) odr-10-Rluc/GFP², (2) the mixture of solubilised membranes which either expressed receptor-GFP² or receptor-Rluc. Results from those samples in which less than 20% of luciferase activity was recovered comparing to co-expression of odr-10-GFP² and odr-10-Rluc in the same cells suggested the interaction between co-expressing odr-10-GFP² and odr-10-Rluc fusion proteins was specific.

EXAMPLE 6 – BRET² TAGGED MOUSE α_{2A} ADRENERGIC RECEPTOR

The mouse α_{2A} adrenergic receptor (SEQ ID NO:56) was engineered so that the GFP² was inserted into the 3rd intracellular loop with its N-terminus following Ala250 and its C-terminus adjacent to Arg372. RLuc was fused to Val461 in the C-terminus of the receptor (amino acid sequence provided as SEQ ID NO:54 and encoding open reading frame as SEQ ID NO:53).

The dual-tagged adrenergic receptors are expressed in yeast. These receptors can be used to monitor ligand binding by the mouse α_{2A} adrenergic receptor via changes in the BRET² ratio.

EXAMPLE 7 – WHOLE-CELL VS CELL-FREE BRET ASSAY

Comparison of the cell-free assay system of the invention to a whole cell assay system demonstrates that the intensity of the BRET² signal was more than forty time greater, in terms of light output when measured in the RLuc channel, for the cell-free assay compared to the whole-cell assay (Figure 15). Assaying 1 μ M of diacetyl resulted in no significant change ($P \leq 0.05$) in the BRET² signal using the whole cell assay, whereas a significant decrease ($P \leq 0.05$) of 52 % was observed using a cell-free assay system (Figure 16).

81732212

67

It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

The present application claims priority from US 61/148,271 filed 29 January 2009.

Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this application.

REFERENCES

- Aloni et al. (2006) *Genome Biol.* 7:R88.
- Ayoub et al. (2002) *J. Biol. Chem.* 277:21522-28.
- Brenner (1974) *Genetics* 77:71-94.
- Buck and Axel *Cell* (1991) 65: 175-187.
- Celic et al. (2003) *Biochemistry* 42: 3004-3017.
- Charest et al. (2005) *EMBO Reports* 6: 334-340.
- Cuppen et al. (2003) *Comp Funct Genomics* 4:479-491.
- Dacres et al. (2009) *Anal. Biochem.* 385:194-202.
- Day et al. (2004) *Luminescence* 19:8-20.
- de Wet et al. (1987) *Mol. Cell. Biol.* 2987:725-737.
- Evers et al. (2006) *Biochemistry* 45: 13183–13192.
- Feldmesser et al. (2006) *BMC Genomics*.7:121.
- Frishman and Argos (1997) *Proteins* 27:329-335.
- Fuchs et al. (2001) *Human Genetics* 108:1-13.
- Gaillard et al. (2004) *Cellular and Molecular Life Sciences* 61: 456-469.
- Ghanouni et al. (2001) *proc. Natl. Acad. Sci. USA* 98:5997-96002.
- Glusman et al (2001) *Genome Res.* 11:685-702.
- Glusman et al. (2000a) *Mammalian Genome* 11: 1016-1023
- Glusman et al. (2000b) *Genomics* 63: 227-245.
- Graschopf et al. (2001) *J. Biol. Chem.* 276:16216-16222.
- Greer and Szalay (2002) *Luminescence* 17:43-74.
- Harayama (1998) *Trends Biotechnol.* 16:76-82.
- Hastings (1996) *Gene* 173:5-11.
- Hoffman et al. (2005) *Nature Methods* 2:171-176.
- Hofmann et al. (2009) *Trends Biochem Sci* 34:540-552.
- Hofmann and Stoffel (1993) *Biol. Chem.* 374:166.
- Hushpulian et al. (2007) *Biotransformation* 25:2-4.
- Inouye et al. (1997) *Biochem. J.* 233:349-353.
- Issad and Jockers (2008) *Methods Mol. Biol.* 332:195-209.
- Jansen et al. (1999) *Nat. Genet.* 21:414-419.
- Kaiser et al. (2008) *Proc Natl Acad Sci U S A* 105:15726-31.
- Klein et al. (1984) *Biochim. Biophys. Acta* 787:221-226
- Kobilka et al. (2007) *Biochimica et Biophysica Acta* 1768: 794-807.
- Lander et al. (2001) *Nature* 409:860-921.

- Li et al. (2009) *Journal of Fluorescence* 19:601-606.
- Lisenbee et al. (2007) *Molecular Endocrinology* May15: 17505057.
- Lohse et al. (2003) *Life Sciences*. 74: 397-404.
- Lohse et al. (2007) *Current Opinion in Pharmacology* 7: 547-553.
- Lorenz et al. (1991) *Proc. Natl. Acad. Sci. USA* 88:4438-4442.
- Macciola et al (2008) *Food Control* 19:873-878.
- Milligan (1999) *Trends Pharmacol. Sci.* 20:118- 124.
- Moore et al. (1994) *Methods Enzymol.* 228:448-450 9.
- Nakanishi et al. (2006) *Biochemical and Biophysical Research Communications* 343:1191-1196.
- Needleman and Wunsch (1970) *J. Mol Biol.* 45:443-453.
- Neves et al. (2002) *Science* 296:1636-1639.
- Niimura and Nei (2003) *Proc. Natl. Acad. Sci. USA.* 100:12235-12240.
- Oldenburg (1998) *Annu. Rep. Med. Chem.* 33:301-311.
- Oldham abd Hamm (2008) *Nature* 9:60-71.
- Olender et al.(2004a) *Genet Mol Res.* 3:545-53.
- Olender et al.(2004b) *Genomics.* 83:361-72.
- Persson and Argos (1994) *J. Mol. Biol.* 237:182-192.
- Persson and Jergil (1994) *Analytical Biochemistry* 204: 131-136.
- Pfleger and Eidne (2006) *Nature Methods* 3:165-174.
- Pilpel and Lancet (1999) *Protein Science* 8: 969-77.
- Piston et al. (2007) *TRENDS in Biochemical Sciences* 32: 407-414.
- Pope (1999) *Drug Discovery Today* 4:350-362.
- Rieder and Emr (2001) *Curr. Protocol. Cell. Biol.* Ch. 3; Unit 3.8.
- Robertson (1998) *Genome Research* 8:449-463.
- Robertson (2001) *Chem Senses* 26:151-159.
- Rochais et al. (2007) *The Journal of Clinical Investigation* 117: 229-235.
- Sengupta et al. (1996) *Cell* 84:899-909.
- Sharon et al.(1998) *Ann N Y Acad Sci.* 30;855:182-93
- Spencer (1998) *Biotechnol. Bioeng.* 61:61-67.
- Strop et al. (2007) *J. Biol. Chem.* 283:1113-1119.
- Troemel et al. (1995) *Cell* 83: 207-218.
- Trueheart and Fink (1989) *Proc. Natl. Acad. Sci. USA.* 86:9916-9920.
- Tsien (1998) *Ann. Rev. Biochem.* 63:509-544.
- Verhaegen et al. (2002) *Anal. Chem.* 74: 4378-4385
- Villardaga (2003) *Nature Biotechnology* 21: 807-812.

- Viviani (2002) Cell. Mol. Life Sci. 59:1833-1850.
 von Heijne (1992) J.Mol.Biol. 225:487-494.
 Wang et al (1997) In Bioluminescence and chemiluminescence: molecular reporting with photons, Wiley, NY, pp 419-422.
 Xu et al. (1999) Proc. Natl. Acad. Sci. USA. 96:151-156.
 Young et al. (2002) J. Human Mol. Genet. 11:535-4.
 Zhang and Firestein (2002) Nat. Neurosci. 5:81.
 Zhang et al. (1997) PNAS 94: 12162-12167.
 Zozulya et al. (2001) Genome Biol. 2:0018.1-0018.12.

SEQUENCE LISTING IN ELECTRONIC FORM

In accordance with Section 111(1) of the Patent Rules, this description contains a sequence listing in electronic form in ASCII text format (file: 79314-66 Seq 04-JUL-11 v1.txt).

A copy of the sequence listing in electronic form is available from the Canadian Intellectual Property Office.

The sequences in the sequence listing in electronic form are reproduced in the following table.

SEQUENCE TABLE

<110> Commonwealth Scientific and Industrial Research Organisation

<120> Measuring G protein coupled receptor activation

<130> 508883

<140> PCT/AU2010/000080

<141> 2010-01-28

<150> 61/148,271

<151> 2009-01-29

<160> 56

<170> PatentIn version 3.5

<210> 1

<211> 339

<212> PRT

<213> Caenorhabditis elegans

70a

<400> 1

Met	Ser	Gly	Glu	Leu	Trp	Ile	Thr	Leu	Val	Asp	Thr	Ala	Asp	Ile	Val
1				5					10					15	
Gly	Val	Thr	Leu	Thr	Phe	Cys	Val	Asn	Ile	Val	Leu	Leu	Gly	Leu	Leu
			20					25					30		
Lys	Thr	Arg	Gly	Lys	Asn	Leu	Gly	Thr	Tyr	Lys	Tyr	Leu	Met	Ala	Phe
		35					40					45			
Phe	Ser	Val	Phe	Ser	Ile	Phe	Tyr	Ala	Ile	Ile	Glu	Phe	Ile	Leu	Arg
	50					55					60				
Pro	Ile	Met	His	Ile	Glu	Asn	Thr	Thr	Phe	Phe	Leu	Ile	Ser	Arg	Lys
65					70					75					80
Arg	Phe	Asn	Tyr	Ser	Thr	Lys	Leu	Gly	Lys	Ile	Asn	Ser	Ala	Phe	Tyr
			85					90					95		
Cys	Ala	Cys	Phe	Ala	Thr	Ser	Phe	Val	Val	Ser	Gly	Val	His	Phe	Val
			100					105					110		
Tyr	Arg	Tyr	Phe	Ala	Thr	Cys	Lys	Pro	Asn	Leu	Leu	Arg	Leu	Phe	Asn
	115						120					125			
Leu	Pro	Thr	Leu	Leu	Leu	Trp	Pro	Leu	Gly	Cys	Ser	Val	Pro	Val	Thr
	130					135					140				
Met	Trp	Ala	Ser	Val	Ser	Tyr	Phe	Leu	Tyr	Pro	Asp	Thr	Glu	Tyr	Thr
145					150					155					160
Glu	Ala	Ala	Val	Thr	Asn	Val	Leu	Asn	Asn	His	Tyr	Asn	Trp	Ile	Lys
			165					170						175	
Lys	Glu	Asn	Val	Ser	Tyr	Ile	Ala	Tyr	Val	Tyr	Tyr	Gln	Tyr	Glu	Asn
			180					185					190		
Gly	Val	Arg	His	Ile	Tyr	Leu	Lys	Asn	Leu	Leu	Gly	Cys	Phe	Val	His
	195					200					205				
Tyr	Phe	Val	Met	Ser	Met	Thr	Phe	Val	Val	Met	Phe	Tyr	Cys	Gly	Tyr
	210					215					220				
Ala	Thr	Trp	Lys	Thr	Met	Asn	Glu	His	Lys	Asp	Val	Ser	Asp	Arg	Thr
225					230					235					240
Arg	Ala	Leu	Gln	Lys	Gln	Leu	Phe	Lys	Ala	Leu	Val	Leu	Gln	Thr	Leu
			245					250					255		
Ile	Pro	Thr	Ile	Phe	Met	Tyr	Ala	Pro	Thr	Gly	Val	Met	Phe	Ile	Ala
		260						265					270		
Pro	Phe	Phe	Asp	Val	Asn	Leu	Asn	Ala	Asn	Ala	Asn	Phe	Ile	Val	Phe
	275					280					285				
Cys	Ser	Phe	Leu	Tyr	Pro	Gly	Leu	Asp	Pro	Leu	Ile	Leu	Ile	Leu	Ile
	290					295					300				
Ile	Arg	Asp	Phe	Arg	Arg	Thr	Ile	Phe	Asn	Phe	Leu	Cys	Gly	Lys	Lys
305					310				315						320
Asn	Ser	Val	Asp	Glu	Ser	Arg	Ser	Thr	Thr	Arg	Ala	Asn	Leu	Ser	Gln
			325					330					335		

Val Pro Thr

<210> 2

<211> 346

<212> PRT

<213> Caenorhabditis elegans

<400> 2

Met	Ser	Gly	Gln	Leu	Trp	Leu	Ala	Leu	Val	Asp	Ala	Ala	Asp	Met	Val
1				5					10					15	
Gly	Phe	Thr	Leu	Thr	Ile	Ser	Ile	Asn	Ile	Ile	Leu	Leu	Gly	Leu	Ile
			20					25					30		

70b

Arg	Thr	Arg	Gly	Lys	Thr	Leu	Gly	Thr	Tyr	Lys	Tyr	Leu	Met	Ser	Phe		
		35					40					45					
Phe	Ser	Phe	Phe	Ser	Ile	Phe	Tyr	Ala	Ile	Val	Glu	Ser	Ile	Leu	Arg		
	50					55					60						
Pro	Ile	Met	His	Ile	Glu	Asn	Thr	Thr	Phe	Phe	Leu	Ile	Ser	Arg	Lys		
65					70					75					80		
Arg	Phe	Asp	Tyr	Ser	Thr	Arg	Leu	Gly	Lys	Ile	Asn	Ser	Ala	Phe	Tyr		
				85					90					95			
Cys	Ala	Cys	Phe	Ala	Thr	Ser	Phe	Val	Leu	Ser	Ala	Val	His	Phe	Val		
			100					105					110				
Tyr	Arg	Tyr	Phe	Ala	Ala	Cys	Lys	Pro	Asn	Leu	Leu	Arg	Leu	Phe	Asn		
	115						120					125					
Leu	Pro	His	Leu	Leu	Leu	Trp	Pro	Leu	Met	Cys	Ser	Ile	Pro	Val	Thr		
	130					135					140						
Ala	Trp	Ala	Ser	Val	Ser	Tyr	Phe	Leu	Tyr	Pro	Asp	Thr	Glu	Tyr	Thr		
145					150					155					160		
Glu	Ala	Ala	Val	Thr	Tyr	Val	Leu	Lys	Thr	His	Tyr	Glu	Val	Ile	Lys		
				165					170					175			
Lys	Glu	Asn	Val	Ser	Tyr	Ile	Ala	Tyr	Val	Tyr	Tyr	Gln	Tyr	Glu	Asn		
			180					185					190				
Gly	Glu	Arg	His	Ile	Tyr	Ile	Lys	Asn	Leu	Leu	Gly	Cys	Phe	Val	His		
	195						200					205					
Tyr	Phe	Val	Met	Ser	Met	Thr	Phe	Val	Val	Val	Phe	Tyr	Cys	Gly	Phe		
	210				215						220						
Ser	Thr	Trp	Trp	Thr	Ile	Arg	Glu	His	Arg	Gly	Ala	Ser	Asp	Arg	Thr		
225				230						235					240		
Arg	His	Leu	His	Arg	Gln	Leu	Phe	Lys	Ala	Leu	Val	Phe	Gln	Thr	Leu		
				245				250						255			
Val	Pro	Ser	Ile	Phe	Met	Tyr	Ile	Pro	Thr	Gly	Val	Met	Phe	Ile	Ala		
			260					265					270				
Pro	Phe	Phe	Asp	Ile	Asn	Leu	Asn	Ala	Asn	Ala	Asn	Phe	Ile	Val	Phe		
	275					280						285					
Cys	Ser	Phe	Leu	Tyr	Pro	Gly	Leu	Asp	Pro	Leu	Ile	Leu	Ile	Phe	Ile		
	290					295					300						
Ile	Arg	Glu	Phe	Arg	Val	Thr	Ile	Leu	Asn	Ile	Ile	Arg	Gly	Asn	Glu		
305					310					315					320		
Arg	Gly	Asn	Ala	Val	Gly	Glu	Ala	Tyr	Ser	Thr	Ser	Arg	Ile	Lys	Ser		
				325				330						335			
Ser	Gln	Pro	Ala	Ala	Val	Asn	Leu	Ser	Gly								
			340					345									

<210> 3

<211> 341

<212> PRT

<213> Caenorhabditis elegans

<400> 3

Met	Ser	Asp	Arg	His	Trp	Leu	Asp	Ile	Thr	Thr	Tyr	Ser	Asp	His	Ile		
1				5					10					15			
Gly	Phe	Thr	Ile	Ser	Thr	Ile	Ala	Asn	Phe	Val	Leu	Ile	Leu	Leu	Leu		
			20					25					30				
Val	Phe	Arg	Pro	Thr	Lys	Ser	Tyr	Gly	Ser	Tyr	Lys	Tyr	Leu	Met	Ile		
		35					40					45					
Thr	Phe	Cys	Val	Phe	Ser	Leu	Phe	Tyr	Thr	Ser	Ile	Glu	Thr	Phe	Leu		
	50					55					60						

70c

```

Arg Pro Leu Ile His Ile Tyr Asp Asn Thr Ile Phe Val Ile Gln Arg
65          70          75          80
Lys Arg Phe Gln Tyr Ser Glu Gly Thr Ala Arg Ala Ile Ser Ser Thr
          85          90          95
Tyr Cys Gly Cys Tyr Ala Met Ser Phe Thr Leu Phe Ala Val His Phe
          100         105         110
Val Tyr Arg Tyr Tyr Ala Ala Cys Lys Pro Asp Asn Leu Arg Tyr Phe
          115         120         125
Gln Gly Cys Tyr Phe Val Ala Trp Val Phe Gly Ala Met Ala Val Ala
          130         135         140
Ala Ser Trp Gly Phe Ala Ala Phe Ile Leu Tyr Pro Glu Thr Glu Arg
145          150         155         160
Thr Arg Thr Ala Leu Ile His Val Ile Gln Thr Ser Tyr Glu Leu Asp
          165         170         175
Pro Glu Trp Val Gly Asn Val Pro Tyr Ser Tyr Trp Arg Thr Glu Asn
          180         185         190
Gly Val Glu Tyr Leu Asn Pro Arg Asn Val Ile Gly Ile Phe Gln His
          195         200         205
Gly Val Ile Met Ile Leu Ser Phe Gly Thr Val Phe Tyr Cys Gly Phe
          210         215         220
Asn Thr Tyr Lys Thr Leu Asn Gly Ser Leu Gly Val Ser Glu Lys Thr
225          230         235         240
Lys Glu Met His Thr Gln Leu Phe Lys Ala Leu Val Leu Gln Thr Ile
          245         250         255
Ile Pro Thr Thr Leu Met Tyr Ile Pro Thr Thr Met Leu Phe Val Thr
          260         265         270
Pro Phe Val Gly Leu Asn Ile Gly Cys Tyr Gly Asn Ile Thr Thr Ala
          275         280         285
Thr Val His Leu Tyr Pro Gly Ile Asp Pro Val Val Leu Ile Phe Ile
          290         295         300
Ile Arg Asp Phe Arg Gln Thr Ile Leu Arg Pro Phe Arg Cys Phe Tyr
305          310         315         320
Arg Ser Asn Ser Val Glu Asn Thr Ala Thr Ile Arg Gln Tyr Gln Gln
          325         330         335
Ser Ser Ser Lys Gly
          340

```

```

<210> 4
<211> 348
<212> PRT
<213> Caenorhabditis elegans

```

```

<400> 4
Met Ser Asp Ile Tyr Trp Ile Gln Ile Thr Glu Val Cys Ser Phe Val
1          5          10          15
Gly Phe Met Leu Ser Val Leu Gly Asn Ser Thr Leu Leu Val Leu Leu
          20          25          30
Ser Gly Lys Ser Ile Asp Gly Ile Gly Thr Tyr Arg Tyr Leu Met Ile
          35          40          45
Thr Phe Cys Val Phe Ser Leu Leu Phe Thr Ile Leu Glu Asp Phe Ile
          50          55          60
Arg Pro Leu Met His His Tyr Asn Asn Thr Ile Ile Val Leu Gln Arg
65          70          75          80
Lys Arg Phe Gln Phe Ser Asp Ser Thr Ala Arg Ile Leu Thr Val Ser
          85          90          95

```

70d

```

Tyr Cys Gly Cys Phe Ala Met Cys Phe Val Met Phe Ala Val His Phe
      100                      105                      110
Ile Tyr Arg Tyr Leu Val Ala Cys His Pro Thr Lys Leu His Tyr Phe
      115                      120                      125
Arg Pro Lys Asn Phe Ile Phe Trp Leu Ser Gly Met Leu Phe Ile Ala
      130                      135                      140
Gly Ser Trp Val Ala Ile Ala Tyr Val Phe Phe Gln Glu Asp Leu Glu
145                      150                      155                      160
Thr Arg Thr Asp Leu Val Phe Ile Leu Ser Thr Cys Tyr Asn Leu Thr
      165                      170                      175
Pro Asp Asp Val Gly His Val Pro Tyr Ala Phe Tyr Lys Thr Gln Gly
      180                      185                      190
Asn Thr Arg Val Ile Arg Trp Asp Asn Met Ile Gly Val Ile His His
      195                      200                      205
Met Ile Val Met Thr Ile Ser Ile Ser Ala Val Phe Tyr Phe Gly Ile
      210                      215                      220
Lys Thr Tyr Thr Arg Ile Met Ser Phe Lys Gly Lys Ser Gln Lys Thr
225                      230                      235                      240
Lys Asp Leu Gln Asn Gln Phe Phe Thr Ala Leu Val Ala Gln Thr Val
      245                      250                      255
Val Pro Leu Ile Phe Met Phe Ile Pro Asn Met Val Leu Thr Thr Ala
      260                      265                      270
Ala Leu Ile Asp Gly Thr Phe Gly Ser Trp Ala Asn Ile Thr Val Val
      275                      280                      285
Met Asn His Leu Tyr Pro Ala Ala Asp Pro Phe Val Ile Leu Phe Ile
      290                      295                      300
Ile Lys Gly Phe Arg Asn Ser Ile Arg Asn Val Ile Tyr Arg Cys Thr
305                      310                      315                      320
Lys Thr Lys Lys Ala Ser Val Ser Ser Val Val Arg Gly Ile Glu Ala
      325                      330                      335
Gln Ser Lys Lys Gln Ser Phe Ser Arg Val Asp Ile
      340                      345

```

<210> 5

<211> 334

<212> PRT

<213> Caenorhabditis elegans

<400> 5

```

Met Thr Asp Gln His Trp Val Ile Ile Thr Asp Ile Ala Gly Pro Ile
1      5                      10                      15
Gly Phe Ser Met Ser Ile Phe Ser Asn Ser Ile Leu Leu Phe Leu Ile
      20                      25                      30
Phe Ser His Ser Ser Pro Ile Lys Gly Pro Tyr Lys Arg Met Leu Ile
      35                      40                      45
Val Phe Cys Ile Phe Thr Val Phe Tyr Ser Phe Val Glu Val Met Leu
50      55                      60
Gln Pro Leu Ile His Ile Tyr Asp Asp Thr Leu Phe Leu Ile His Arg
65      70                      75                      80
Lys Arg Ile Asp Leu Pro Lys Trp Leu Thr Arg Leu Val Pro Thr Thr
      85                      90                      95
Tyr Cys Trp Cys Tyr Ala Met Ser Phe Ser Leu Phe Ala Leu Gln Phe
      100                      105                      110
Leu Tyr Arg Tyr Val Ala Val Cys Lys Pro Gln Tyr Val Asp Leu Phe
115                      120                      125

```

70e

Val	Gly	Cys	His	Phe	Tyr	Ala	Trp	Val	Val	Leu	Ile	Leu	Ser	Leu	Ala
130						135					140				
Thr	Ser	Trp	Gly	Leu	Thr	Ala	Ala	Phe	Met	Phe	Pro	Gln	Thr	Asp	Arg
145					150					155					160
Thr	Thr	Glu	Ile	Phe	Leu	His	Ile	Ile	Tyr	Ser	Ser	Tyr	Asp	Leu	Glu
				165					170					175	
Pro	Tyr	Trp	Thr	Asp	Tyr	Val	Ala	Tyr	Lys	Tyr	Phe	Asp	Thr	Asp	Glu
			180					185					190		
Asn	Asn	Val	Arg	Trp	Val	Asn	Val	Leu	Ser	Phe	Phe	Gly	Val	Leu	Gln
		195				200						205			
His	Gly	Ile	Val	Ile	Thr	Leu	Ser	Phe	Gly	Thr	Leu	Tyr	Tyr	Cys	Gly
210						215					220				
Ile	Asn	Thr	Tyr	Leu	Lys	Ile	Lys	Lys	His	Thr	Gly	Thr	Ser	Asn	Arg
225					230					235					240
Thr	Arg	Cys	Ile	Gln	Leu	Gln	Leu	Phe	Arg	Ala	Leu	Val	Ala	Gln	Thr
				245					250					255	
Ile	Leu	Pro	Met	Phe	Met	Met	Tyr	Ile	Pro	Val	Gly	Phe	Met	Phe	Ala
			260					265					270		
Cys	Pro	Tyr	Phe	Asp	Leu	Gln	Leu	Gly	Ala	Tyr	Thr	Asn	Tyr	Gln	Thr
		275					280					285			
Val	Met	Ala	Gln	Leu	Tyr	Pro	Gly	Ile	Asp	Pro	Phe	Val	Met	Leu	Phe
290						295					300				
Leu	Ile	Asp	Ser	Tyr	Arg	Ile	Thr	Ile	Phe	Gly	Trp	Leu	Cys	Pro	Arg
305					310					315					320
Phe	Val	Tyr	Val	Lys	Pro	Met	His	Ser	Thr	Tyr	Thr	Leu	Thr		
				325					330						

<210> 6
 <211> 350
 <212> PRT
 <213> Caenorhabditis elegans

<400> 6
 Met Thr Asp Arg Arg Trp Val Ala Ile Thr Asp Ile Ala Gly Pro Ile
 1 5 10 15
 Gly Phe Thr Met Ser Ile Phe Ser Asn Ser Val Leu Leu Ser Leu Ile
 20 25 30
 Phe Ser Ser Ser Ser Pro Ile Lys Gly Ala Tyr Lys Asn Met Leu Ile
 35 40 45
 Val Leu Cys Ile Phe Thr Met Phe Tyr Ser Phe Val Glu Ile Met Leu
 50 55 60
 Gln Pro Leu Ile His Ile Tyr Asp Asp Thr Leu Phe Leu Ile His Arg
 65 70 75 80
 Lys Arg Phe Asp Leu Ser Lys Gly Ile Thr Arg Leu Ile Pro Thr Thr
 85 90 95
 Tyr Cys Trp Cys Tyr Ala Met Ser Phe Ser Leu Phe Ala Leu Gln Phe
 100 105 110
 Leu Tyr Arg Tyr Val Ala Val Cys Lys Pro His Leu Val Val Phe Phe
 115 120 125
 Thr Gly Cys Tyr Phe Tyr Tyr Trp Leu Ala Leu Ile Leu Ser Leu Ala
 130 135 140
 Thr Ser Trp Gly Leu Thr Ala Ala Phe Met Phe Pro Gln Thr Asn Arg
 145 150 155 160
 Thr Thr Glu Ser Phe Asn Tyr Val Ile Lys Thr Ser Tyr Asp Leu Asp
 165 170 175

Pro	Tyr	Trp	Thr	Asp	Tyr	Val	Ala	Tyr	Lys	Tyr	Phe	Asp	Thr	Asp	Glu
			180					185					190		
Asn	His	Val	Arg	Trp	Val	Asn	Val	Leu	Ser	Leu	Phe	Gly	Val	Leu	Gln
		195					200					205			
His	Gly	Leu	Val	Ile	Thr	Leu	Ser	Phe	Gly	Thr	Leu	Phe	Tyr	Cys	Gly
	210					215					220				
Ile	Lys	Thr	Tyr	Leu	Ser	Ile	Thr	Glu	His	Val	Gly	Met	Ser	Ser	Lys
225					230					235					240
Thr	Arg	Ser	Leu	Gln	Leu	Gln	Leu	Phe	Arg	Ala	Leu	Val	Ala	Gln	Thr
				245					250					255	
Cys	Leu	Pro	Met	Leu	Met	Met	Tyr	Met	Pro	Ile	Gly	Phe	Met	Phe	Ser
			260					265					270		
Cys	Pro	Tyr	Phe	Asp	Leu	Gln	Leu	Gly	Ala	Val	Thr	Asn	Tyr	Gln	Thr
		275					280					285			
Val	Met	Ala	Gln	Leu	Tyr	Pro	Gly	Ile	Asp	Pro	Phe	Met	Leu	Leu	Phe
	290					295					300				
Leu	Ile	Asn	Ala	Tyr	Arg	Lys	Thr	Val	Leu	Ser	Leu	Ile	Cys	Pro	Asn
305					310					315					320
Phe	Ile	Gln	Lys	Lys	Tyr	Val	Gln	Thr	Ala	Thr	Thr	Arg	Asp	Gly	Thr
			325						330					335	
Asp	Ala	Ser	Ala	Thr	Met	Asn	Ser	Val	Lys	Ser	Thr	Gln	Leu		
			340					345					350		

<210> 7

<211> 1020

<212> DNA

<213> Caenorhabditis elegans

<400> 7

atgtcgggag	aattgtggat	taccctagtt	gacacagcgg	acattgtcgg	cgtcaccctc	60
acottctgtg	tcaacattgt	tcttctcgga	cttctgaaaa	cacgtggaaa	aaacttgggc	120
acttataaat	atctcatggc	gtttttctca	gtattctcga	ttttttacgc	catcatcgag	180
ttcatattac	gacctataat	gcattattgag	aacaccactt	tctttttgat	ctcaaggaaa	240
agattcaact	actccacca	acttggaaaa	atcaactctg	cgttttactg	tgcttgtttt	300
gccaccagtt	ttgttgtctc	aggagtccac	tttgtttatc	gatattttgc	aacttgcaaa	360
ccgaatctac	ttcgtttggt	caacttgcca	actcttctac	tttggccact	tggttgacgt	420
gtaccctgta	caatgtgggc	tagtgtctca	tattttttgt	atccagatac	cgagtacacg	480
gaagcggtg	tcaccaatgt	actaaataac	cactataact	ggatcaaaaa	ggagaatgta	540
tcgtacattg	catacgtcta	ttaccaatac	gaaaacggag	taaggcatat	ctacctcaaa	600
aacttgcttg	gatgctttgt	tcattacttt	gtcatgtcga	tgacgtttgt	tgtgatgttc	660
tactgcggat	atgccacgtg	gaaaactatg	aatgaacaca	aggatgtatc	tgatagaact	720
cgagcgctac	agaaacaact	tttcaaagct	ttagttcttc	agacactcat	cccaactatc	780
ttcatgtacg	ccccaaactg	agtcatgttc	atcgcaccgt	tttttgacgt	gaatttgaat	840
gcaaacgcca	atttcattgt	gttttgctca	tttctgtacc	cgggactcga	tccactcatt	900
ctgattttga	tcattcgtga	tttccgaaga	acaatattca	atttcttggtg	tggaaagaaa	960
aacagtgttg	atgaatcccg	ctcgacaaca	agagccaatt	tgtctcaagt	tccgacgtga	1020

<210> 8

<211> 1040

<212> DNA

<213> Caenorhabditis elegans

<400> 8

atgtctggtc	aattatgggt	ggccctcgtg	gatgctgccg	atatggtagg	attcactctc	60
------------	------------	------------	------------	------------	------------	----

70g

acgatctcca	tcaacatcat	tctactgggg	ctgattagaa	cacgtggaaa	aacgttggga	120
acgtacaaat	acttgatgag	cttcttctcg	ttcttctcaa	tcttttatgc	aatcgttgaa	180
tctattttga	gaccaataat	gcataatcgaa	aacacgacgt	tctttctgat	ttctcggaaa	240
cgcttcgatt	actcaactcg	ccttggtaaa	atcaactctg	ctttctactg	tgcttgtttt	300
gccacgagtt	ttgtcctgtc	tgcggtacac	tttgtgtatc	ggtaactttgc	cgcttgcaaa	360
ccgaatctgc	tacgcttggt	taaccttccg	catcttttac	tgtggccttt	gatgtgttcg	420
attcctgtga	ctgcgtgggc	aagtgtttct	tactttttgt	accagacac	cgagtacact	480
gaagcagcag	ttacatatgt	tctgaaaaca	cactacgagg	tgatcaaaaa	agaaaatgta	540
tcttatatcg	catacgtata	ctatcaatat	gaaaatgggg	agcgtcacat	ctacataaaa	600
aatttgcttg	gctgctttgt	acactacttc	gttatgtcaa	tgacatttgt	agttgtgttt	660
tactgcggat	tttctacatg	gtggacgatt	cgtgagcacc	gtggagcacc	tgataggaca	720
cgtcacctgc	atagacaatt	gtttaaggca	cttgtatttc	aaaccttgt	tccatcaata	780
tttatgtaca	tcccaactgg	tgtcatgttc	atcgctccct	tttctgacat	caacctgaat	840
gccaatgcaa	acttcacgt	tttttgctca	tttctctatc	caggtcttga	cccactaatt	900
ctcattttta	tcattcgcga	attcgggtca	ctattttgaa	tatcatcaga	ggaaatgagc	960
ggggaaatgc	tgttggcgaa	gcatactcaa	cttctcgaat	aaaatcatca	caacctgcag	1020
ctgttaatct	ttctggataa					1040

<210> 9

<211> 1026

<212> DNA

<213> Caenorhabditis elegans

<400> 9

atgtctgacc	gtcattgggt	cgacatcacc	acctaactcag	accacattgg	gtttacgatt	60
tccaccatcg	ccaatttcgt	tctgatcctt	ctgctagtct	tccgaccgac	caaatcatac	120
ggttcataca	agtacctgat	gatcacatc	tgcggtgtca	gcctctttta	cacctccatt	180
gaaacttttt	tgagacctct	catccatata	tacgacaata	cgatcttcgt	gattcagcgc	240
aagagattcc	agtactccga	gggtaccgct	agagccattt	catcgacctt	ctgcggctgc	300
tacgccatga	gcttcaccct	gttcgcgcgc	cactttgtct	accgttacta	tgccggcttgc	360
aaacccgaca	acctccgtta	cttccaagga	tgctactttg	tgcgatgggt	attcggagca	420
atggcggttg	cggcgagctg	gggggttcgca	gcgtttatcc	tgtacccgga	gaccgagagg	480
accaggacgg	cgttgatata	cgtcatacaa	acatccatag	agctggatcc	cgagtgggtg	540
ggaaatgttc	catatagcta	ttggcgacac	gaaaacggag	tggaaatacct	gaatcctcgc	600
aacgtcatcg	ggatctttca	acacggcgct	atcatgatcc	tctccttcgg	aacagtcttc	660
tactgcggat	tcaaacctta	taagactttg	aacggaagtc	tgggggtgtc	tgaaaaaaca	720
aaagaaatgc	acacccaatt	gttcaaggcc	ttgggtctac	agactatcat	ccctactaca	780
ctaattgtaca	tcccgcacaac	catgctcttt	gtcaccctcat	tcgttggaact	caacatcggc	840
tgttacggca	acatcactac	tgcacccgct	cattttgtatc	ctggaattga	cccagtcgtt	900
ttgatcttta	taatccgaga	cttccggcaa	acgattttta	gaccattcag	atgcttctac	960
cgttcaaata	gtgtcgaaaa	cactgccacc	ataaggcaat	accagcagag	cagctccaaa	1020
ggataa						1026

<210> 10

<211> 1047

<212> DNA

<213> Caenorhabditis elegans

<400> 10

atgtccgata	tatactggat	acaaattact	gaagtttgct	ccttcgctcg	atttatgctc	60
tcagttctag	ggaacagtac	acttttagta	ctgctcagtg	gaaaatccat	agatggaatt	120
ggcacctatc	ggtacttgat	gatcactttc	tgcgttttca	gtttattatt	tacgatatta	180
gaggatttta	tcagaccgct	gatgcatcac	tataacaata	ccataattgt	tttacaacgc	240
aagcggtttc	agttttctga	ttcaacggct	agaatcttga	cagctcttta	ctgcggctgt	300

70h

ttcgcgatgt	gcttcgtgat	gttcgccggt	catttcatct	atcgatatct	agttgcttgt	360
caccgcgaaa	aattgcacta	ttttcgaccc	aaaaatttca	ttttctggct	gtccggcatg	420
ttattcatag	caggaagctg	ggttgcaatt	gcatatgtct	tttttcaaga	agacctagaa	480
accaggacgg	atttggtatt	tattttgtca	acttggtata	atttaacgcc	agatgatgtc	540
ggacatgtac	cgtatgcttt	ttacaaaact	caaggaaata	cacgagtaat	tcgatgggat	600
aacatgattg	gagtaattca	tcatatgata	gttatgacaa	tctctataag	tgccgttttc	660
tactttggca	ttaaaaccta	cactcgaata	atgagtttca	agggaaaatc	ccagaaaacc	720
aaggatctcc	agaatcaatt	tttcaactgt	ctagttgctc	aaaccgtagt	ccctctgatt	780
ttcatgttta	tcccaaatat	ggtgctcact	acggcagccc	ttatagatgg	cacatttggc	840
tcattggcca	atattactgt	agttatgaat	catttgtatc	cggctgccga	tccattcgtt	900
atactgttca	ttattaaggg	gttccggaat	agtattagaa	atgttatata	tcgtgcaca	960
aaaacgaaaa	aagcatcggt	tagctcagtg	gtccgtggta	ttgaggctca	aagcaagaaa	1020
caatcttttt	ctcgagttga	tattttaa				1047

<210> 11

<211> 1005

<212> DNA

<213> Caenorhabditis elegans

<400> 11

atgactgata	aacactgggt	tattatcaca	gatattgctg	gtccaatcgg	attttcaatg	60
tccatttttt	caaactctat	tcttttgttt	ttgatatttt	cacattcctc	tccaataaaa	120
ggtccatata	aacgaatgct	catagtattt	tgcataattt	ccgtatttct	ctcatttgtc	180
gaagtcatgc	ttcagccact	aatccatatt	tacgacgaca	ctttattttt	gattcatcga	240
aagagaatag	acttgccaaa	atggttaaca	cgtttgggtc	ctactaccta	ttgttgggtg	300
tacgcaatga	gtttttcctt	gtttgcatta	caatttttat	atagatatgt	ggcagtatgc	360
aaaccgcaat	atgttgatct	ttttgtcgga	tgtcactttt	atgcttgggt	agttttgatc	420
ttatcactag	ccacgagctg	gggactcact	gcagctttca	tgttcccaca	aaccgaccga	480
acaactgaaa	tttttttgca	cataatttat	agttcatatg	acttgagacc	ttattggaca	540
gattatgttg	cttataaata	ctttgatact	gatgagaata	atgtgagatg	ggtcaatggt	600
cttagttttt	tcgggtgtct	tcagcacggg	attgtaatta	ctctaagttt	tggcaccctt	660
tattattgtg	gcataaacac	gtatctcaaa	ataaaaaaac	acactggaac	atcaaacaga	720
actcgatgta	ttcaactaca	acttttcaga	gctctgggtg	cacagacaat	tttaccatg	780
ttcatgatgt	atattcccgt	tggtttcatg	tttgcatgtc	catattttga	cttgcaatta	840
ggtgcatata	ccaattatca	aacagtcatg	gcacaacttt	atccgggaat	cgacccattt	900
gtgatgctgt	ttttgataga	ttcttataga	ataacaatat	ttggatgggt	atgtccaaga	960
tttgtttatg	taaagccgat	gcattccaca	tacaccctaa	cttga		1005

<210> 12

<211> 1053

<212> DNA

<213> Caenorhabditis elegans

<400> 12

atgaccgatc	gtcgctgggt	cgtatattacg	gacattgccg	gaccgattgg	gttcacaaatg	60
tcaatttttt	cgaactcggg	gctgttatcg	ttgatattct	caagcagctc	tccaattaaa	120
ggagcttaca	aaaatatggt	gatagtgttg	tgtatattca	ctatgttcta	ctcttttgtt	180
gaaataatgc	ttcaaccggt	gattcatatt	tatgatgaca	cgtgttctct	gatccaccgg	240
aaaagatttg	acctgtctaa	aggaattaca	cgtttgatac	ctacaacata	ttgttgggtg	300
tatgcaatga	gtttctcatt	attcgccctc	cagtttttgt	acagatatgt	ggcagtttgc	360
aaacotcact	tagttgtttt	ttttactgga	tgtatattct	attattgggt	ggcactcatc	420
ttatcacttg	ctacaagttg	ggggcttact	gcagctttta	tgttcccga	aaccaatcga	480
acaactgaaa	gcttcaacta	cgtaataaaa	acttcttatg	acttagatcc	ttattggacg	540
gattatgttg	cctataaata	ttttgacacc	gatgagaatc	atgtgagatg	ggtgaatggt	600

70i

```

cttagtttat ttggagtott gcagcacgga ttagtaatta cgttgagttt tggaacctta      660
ttctactgtg gaattaaaac ttatctcagc attactgaac atgttggaat gtccagcaag      720
accogaagtc ttcaacttca actattccgt gctttagttg ctcagacatg tcttccaatg      780
ctcatgatgt acatgccaat aggattcatg ttttcttgcc cttactttga tttgcaactt      840
ggagcagtca caaactatca aaccgtcatg gcacagttat acccaggaat cgacccattt      900
atgttgctat ttcttattaa cgcctacaga aagacagtgt taagcttgat ctgtcctaata      960
tttatccaga aaaaatatgt tcaaacggca actactcgtg atggcacaga tgcctcggca     1020
acaatgaatt ctgttaaatac tacacagtta taa                                  1053

```

<210> 13
 <211> 889
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> BRET construct

<400> 13
 Met Ser Gly Glu Leu Trp Ile Thr Leu Val Asp Thr Ala Asp Ile Val
 1 5 10 15
 Gly Val Thr Leu Thr Phe Cys Val Asn Ile Val Leu Leu Gly Leu Leu
 20 25 30
 Lys Thr Arg Gly Lys Asn Leu Gly Thr Tyr Lys Tyr Leu Met Ala Phe
 35 40 45
 Phe Ser Val Phe Ser Ile Phe Tyr Ala Ile Ile Glu Phe Ile Leu Arg
 50 55 60
 Pro Ile Met His Ile Glu Asn Thr Thr Phe Phe Leu Ile Ser Arg Lys
 65 70 75 80
 Arg Phe Asn Tyr Ser Thr Lys Leu Gly Lys Ile Asn Ser Ala Phe Tyr
 85 90 95
 Cys Ala Cys Phe Ala Thr Ser Phe Val Val Ser Gly Val His Phe Val
 100 105 110
 Tyr Arg Tyr Phe Ala Thr Cys Lys Pro Asn Leu Leu Arg Leu Phe Asn
 115 120 125
 Leu Pro Thr Leu Leu Leu Trp Pro Leu Gly Cys Ser Val Pro Val Thr
 130 135 140
 Met Trp Ala Ser Val Ser Tyr Phe Leu Tyr Pro Asp Thr Glu Tyr Thr
 145 150 155 160
 Glu Ala Ala Val Thr Asn Val Leu Asn Asn His Tyr Asn Trp Ile Lys
 165 170 175
 Lys Glu Asn Val Ser Tyr Ile Ala Tyr Val Tyr Tyr Gln Tyr Glu Asn
 180 185 190
 Gly Val Arg His Ile Tyr Leu Lys Asn Leu Leu Gly Cys Phe Val His
 195 200 205
 Tyr Phe Val Met Ser Met Thr Phe Val Val Met Phe Tyr Cys Gly Tyr
 210 215 220
 Ala Thr Trp Lys Thr Met Asn Glu His Lys Asp Val Ser Asp Arg Thr
 225 230 235 240
 Met Thr Ser Lys Val Tyr Asp Pro Glu Gln Arg Lys Arg Met Ile Thr
 245 250 255
 Gly Pro Gln Trp Trp Ala Arg Cys Lys Gln Met Asn Val Leu Asp Ser
 260 265 270
 Phe Ile Asn Tyr Tyr Asp Ser Glu Lys His Ala Glu Asn Ala Val Ile
 275 280 285

Phe	Leu	His	Gly	Asn	Ala	Ala	Ser	Ser	Tyr	Leu	Trp	Arg	His	Val	Val	
	290					295					300					
Pro	His	Ile	Glu	Pro	Val	Ala	Arg	Cys	Ile	Ile	Pro	Asp	Leu	Ile	Gly	
305					310					315					320	
Met	Gly	Lys	Ser	Gly	Lys	Ser	Gly	Asn	Gly	Ser	Tyr	Arg	Leu	Leu	Asp	
				325					330						335	
His	Tyr	Lys	Tyr	Leu	Thr	Ala	Trp	Phe	Glu	Leu	Leu	Asn	Leu	Pro	Lys	
			340					345					350			
Lys	Ile	Ile	Phe	Val	Gly	His	Asp	Trp	Gly	Ala	Cys	Leu	Ala	Phe	His	
		355					360					365				
Tyr	Ser	Tyr	Glu	His	Gln	Asp	Lys	Ile	Lys	Ala	Ile	Val	His	Ala	Glu	
	370					375					380					
Ser	Val	Val	Asp	Val	Ile	Glu	Ser	Trp	Asp	Glu	Trp	Pro	Asp	Ile	Glu	
385					390					395					400	
Glu	Asp	Ile	Ala	Leu	Ile	Lys	Ser	Glu	Glu	Gly	Glu	Lys	Met	Val	Leu	
				405				410						415		
Glu	Asn	Asn	Phe	Phe	Val	Glu	Thr	Met	Leu	Pro	Ser	Lys	Ile	Met	Arg	
			420					425					430			
Lys	Leu	Glu	Pro	Glu	Glu	Phe	Ala	Ala	Tyr	Leu	Glu	Pro	Phe	Lys	Glu	
		435				440						445				
Lys	Gly	Glu	Val	Arg	Arg	Pro	Thr	Leu	Ser	Trp	Pro	Arg	Glu	Ile	Pro	
	450					455					460					
Leu	Val	Lys	Gly	Gly	Lys	Pro	Asp	Val	Val	Gln	Ile	Val	Arg	Asn	Tyr	
465					470					475					480	
Asn	Ala	Tyr	Leu	Arg	Ala	Ser	Asp	Asp	Leu	Pro	Lys	Met	Phe	Ile	Glu	
				485				490						495		
Ser	Asp	Pro	Gly	Phe	Phe	Ser	Asn	Ala	Ile	Val	Glu	Gly	Ala	Lys	Lys	
			500					505					510			
Phe	Pro	Asn	Thr	Glu	Phe	Val	Lys	Val	Lys	Gly	Leu	His	Phe	Ser	Gln	
		515					520					525				
Glu	Asp	Ala	Pro	Asp	Glu	Met	Gly	Lys	Tyr	Ile	Lys	Ser	Phe	Val	Glu	
	530					535					540					
Arg	Val	Leu	Lys	Asn	Glu	Gln	Arg	Ala	Leu	Gln	Lys	Gln	Leu	Phe	Lys	
545					550					555					560	
Ala	Leu	Val	Leu	Gln	Thr	Leu	Ile	Pro	Thr	Ile	Phe	Met	Tyr	Ala	Pro	
				565				570						575		
Thr	Gly	Val	Met	Phe	Ile	Ala	Pro	Phe	Phe	Asp	Val	Asn	Leu	Asn	Ala	
			580					585					590			
Asn	Ala	Asn	Phe	Ile	Val	Phe	Cys	Ser	Phe	Leu	Tyr	Pro	Gly	Leu	Asp	
		595					600					605				
Pro	Leu	Ile	Leu	Ile	Leu	Ile	Ile	Arg	Asp	Phe	Arg	Arg	Thr	Ile	Phe	
	610					615					620					
Asn	Phe	Leu	Cys	Gly	Lys											

70k

```

Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg Thr Ile Phe Phe Lys
      740                      745                      750
Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val Lys Phe Glu Gly Asp
      755                      760                      765
Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile Asp Phe Lys Glu Asp
      770                      775                      780
Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn Tyr Asn Ser His Asn
785                      790                      795                      800
Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly Ile Lys Val Asn Phe
      805                      810                      815
Lys Ile Arg His Asn Ile Glu Asp Gly Ser Val Gln Leu Ala Asp His
      820                      825                      830
Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro Val Leu Leu Pro Asp
      835                      840                      845
Asn His Tyr Leu Ser Thr Gln Ser Ala Leu Ser Lys Asp Pro Asn Glu
      850                      855                      860
Lys Arg Asp His Met Val Leu Leu Glu Phe Val Thr Ala Ala Gly Ile
865                      870                      875                      880
Thr Leu Gly Met Asp Glu Leu Tyr Lys
      885

```

<210> 14
 <211> 2670
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> ORF encoding BRET construct of SEQ ID NO:13

<400> 14

```

atgtcgggag aattgtggat taccctagtt gacacagcgg acattgtcgg cgtcaccctc      60
accttctgtg tcaacattgt tcttctcgga cttctgaaaa cacgtggaaa aaacttgggc      120
acttataaat atctcatggc gtttttctca gtattctcga ttttttacgc catcatcgag      180
ttcatattac gacctataat gcatattgag aacaccactt tctttttgat ctcaaggaaa      240
agattcaact actccaccaa acttggaaaa atcaactctg cgttttactg tgcttgtttt      300
gccaccagtt ttgttgtctc aggagttcac tttgtttatc gatattttgc aacttgcaaa      360
ccgaatctac ttcgtttgtt caacttgcca actcttctac tttggccact tggttgcagt      420
gtaccctga caatgtgggc tagtgtctca tattttttgt atccagatac cgagtacacg      480
gaagcggctg tcaccaatgt actaaalaac cactataact ggatcaaaaa ggagaatgta      540
tcgtacattg catacgtcta ttaccaatac gaaaacggag taaggcatat ctacctcaaa      600
aacttgcttg gatgctttgt tcattacttt gtcatgtcga tgacgtttgt tgtgatgttc      660
tactgcggat atgccacgtg gaaaactatg aatgaacaca aggatgtatc tgatagaact      720
atgaccagca aggtgtacga ccccgagcag aggaagagga tgatcaccgg ccccagtg      780
tgggccaggt gcaagcagat gaacgtgctg gacagcttca tcaactacta cgacagcgag      840
aagcacgccg agaacgccgt gatcttcctg cacggcaacg ccgctagcag ctacctgtgg      900
aggcacgtgg tgccccacat cgagcccggt gccaggtgca tcatccccga tctgatcggc      960
atgggcaaga gcggcaagag cggcaacggc agctacaggc tgctggacca ctacaagtac     1020
ctgaccgcct ggttcgagct cctgaacctg cccaagaaga tcatcttcgt gggccacgac     1080
tggggcgctt gcctggcctt ccactacagc tacgagcacc aggacaagat caaggccatc     1140
gtgcacgccg agagcgtggt ggacgtgatc gagagctggg acgagtggcc agacatcgag     1200
gaggacatcg cctgatcaa gagcgaggag ggcgagaaga tgggtgctgga gaacaacttc     1260
ttcgtggaga ccatgctgcc cagcaagatc atgagaaagc tggagcccga ggagttcgcc     1320
gcctacctgg agcccttcaa ggagaagggc gaggtgagaa gaccaccctt gagctggccc     1380
agagagatcc ccctggtgaa gggcggcaag cccgacgtgg tgcagatcgt gagaaactac     1440
aacgcctacc tgagagccag cgacgacctg cccaagatgt tcatcgagag cgaccccggc     1500

```

```

ttcttcagca acgccatcgt ggagggcgcc aagaagttcc ccaacaccga gttcgtgaag 1560
gtgaaggggc tgcacttcag ccaggaggac gcccccgacg agatgggcaa gtacatcaag 1620
agcttcgtgg agagagtget gaagaacgag cagcgagcgc tacagaaaca acttttcaaa 1680
gcttttagttc ttcagacact catcccaact atcttcatgt acgccccaac tggagtcatg 1740
ttcatcgcac cgtttttttga cgtgaatttg aatgcaaacg ccaatttcat tgtgttttgc 1800
tcattttctgt acccgggact cgatccactc attctgattt tgatcattcg tgatttccga 1860
agaacaatat tcaattttctt gtgtggaaag aaaaacagtg ttgatgaatc ccgctcgaca 1920
acaagagcca atttgtctca agttccgacg atgggtgagca agggcgagga gctgttcacc 1980
ggggtggtgc ccactcctgt cgagctggac ggcgacgtaa acggccacaa gttcagcgtg 2040
tccggcgagg gcgagggcga tgcacactac ggcaagctga cctgaagtt catctgcacc 2100
accggcaagc tgcccgtgcc ctggcccacc ctctgacca cctgagcta cggcgtgcag 2160
tgcttcagcc gctacccgga ccacatgaag cagcacgact tcttcaagtc cgccatgcc 2220
gaaggctacg tccaggagcg caccatcttc ttcaaggacg acggcaacta caagaccgc 2280
gcgaggtga agttcgaggg cgacaccctg gtgaaccgca tcgagctgaa gggcatcgac 2340
ttcaaggagg acggcaacat cctggggcac aagctggagt acaactacaa cagccacaac 2400
gtctatatca tggccgacaa gcagaagaac ggcacaaagg tgaacttcaa gatccgccac 2460
aacatcgagg acggcagcgt gcagctcgcc gaccactacc agcagaacac ccccatcggc 2520
gacggccccg tgctgctgcc cgacaaccac tacctgagca ccagtcgcgc cctgagcaaa 2580
gaccccaacg agaagcgcga tcacatggtc ctgctggagt tcgtgaccgc cgccgggata 2640
actctcggca tggacgagct gtacaagtaa 2670

```

<210> 15
 <211> 889
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> BRET construct

<400> 15
 Met Ser Gly Glu Leu Trp Ile Thr Leu Val Asp Thr Ala Asp Ile Val
 1 5 10 15
 Gly Val Thr Leu Thr Phe Cys Val Asn Ile Val Leu Leu Gly Leu Leu
 20 25 30
 Lys Thr Arg Gly Lys Asn Leu Gly Thr Tyr Lys Tyr Leu Met Ala Phe
 35 40 45
 Phe Ser Val Phe Ser Ile Phe Tyr Ala Ile Ile Glu Phe Ile Leu Arg
 50 55 60
 Pro Ile Met His Ile Glu Asn Thr Thr Phe Phe Leu Ile Ser Arg Lys
 65 70 75 80
 Arg Phe Asn Tyr Ser Thr Lys Leu Gly Lys Ile Asn Ser Ala Phe Tyr
 85 90 95
 Cys Ala Cys Phe Ala Thr Ser Phe Val Val Ser Gly Val His Phe Val
 100 105 110
 Tyr Arg Tyr Phe Ala Thr Cys Lys Pro Asn Leu Leu Arg Leu Phe Asn
 115 120 125
 Leu Pro Thr Leu Leu Leu Trp Pro Leu Gly Cys Ser Val Pro Val Thr
 130 135 140
 Met Trp Ala Ser Val Ser Tyr Phe Leu Tyr Pro Asp Thr Glu Tyr Thr
 145 150 155 160
 Glu Ala Ala Val Thr Asn Val Leu Asn Asn His Tyr Asn Trp Ile Lys
 165 170 175
 Lys Glu Asn Val Ser Tyr Ile Ala Tyr Val Tyr Tyr Gln Tyr Glu Asn
 180 185 190

70m

Gly	Val	Arg	His	Ile	Tyr	Leu	Lys	Asn	Leu	Leu	Gly	Cys	Phe	Val	His
	195						200					205			
Tyr	Phe	Val	Met	Ser	Met	Thr	Phe	Val	Val	Met	Phe	Tyr	Cys	Gly	Tyr
	210					215					220				
Ala	Thr	Trp	Lys	Thr	Met	Asn	Glu	His	Lys	Asp	Val	Ser	Asp	Arg	Thr
225					230					235					240
Met	Val	Ser	Lys	Gly	Glu	Glu	Leu	Phe	Thr	Gly	Val	Val	Pro	Ile	Leu
			245						250					255	
Val	Glu	Leu	Asp	Gly	Asp	Val	Asn	Gly	His	Lys	Phe	Ser	Val	Ser	Gly
			260					265					270		
Glu	Gly	Glu	Gly	Asp	Ala	Thr	Tyr	Gly	Lys	Leu	Thr	Leu	Lys	Phe	Ile
	275						280					285			
Cys	Thr	Thr	Gly	Lys	Leu	Pro	Val	Pro	Trp	Pro	Thr	Leu	Val	Thr	Thr
	290					295					300				
Leu	Ser	Tyr	Gly	Val	Gln	Cys	Phe	Ser	Arg	Tyr	Pro	Asp	His	Met	Lys
305					310					315					320
Gln	His	Asp	Phe	Phe	Lys	Ser	Ala	Met	Pro	Glu	Gly	Tyr	Val	Gln	Glu
			325						330					335	
Arg	Thr	Ile	Phe	Phe	Lys	Asp	Asp	Gly	Asn	Tyr	Lys	Thr	Arg	Ala	Glu
			340					345					350		
Val	Lys	Phe	Glu	Gly	Asp	Thr	Leu	Val	Asn	Arg	Ile	Glu	Leu	Lys	Gly
	355						360					365			
Ile	Asp	Phe	Lys	Glu	Asp	Gly	Asn	Ile	Leu	Gly	His	Lys	Leu	Glu	Tyr
	370					375					380				
Asn	Tyr	Asn	Ser	His	Asn	Val	Tyr	Ile	Met	Ala	Asp	Lys	Gln	Lys	Asn
385					390					395					400
Gly	Ile	Lys	Val	Asn	Phe	Lys	Ile	Arg	His	Asn	Ile	Glu	Asp	Gly	Ser
			405					410						415	
Val	Gln	Leu	Ala	Asp	His	Tyr	Gln	Gln	Asn	Thr	Pro	Ile	Gly	Asp	Gly
			420					425					430		
Pro	Val	Leu	Leu	Pro	Asp	Asn	His	Tyr	Leu	Ser	Thr	Gln	Ser	Ala	Leu
	435					440						445			
Ser	Lys	Asp	Pro	Asn	Glu	Lys	Arg	Asp	His	Met	Val	Leu	Leu	Glu	Phe
	450					455					460				
Val	Thr	Ala	Ala	Gly	Ile	Thr	Leu	Gly	Met	Asp	Glu	Leu	Tyr	Lys	Arg
465					470					475					480
Ala	Leu	Gln	Lys	Gln	Leu	Phe	Lys	Ala	Leu	Val	Leu	Gln	Thr	Leu	Ile
			485					490						495	
Pro	Thr	Ile	Phe	Met	Tyr	Ala	Pro	Thr	Gly	Val	Met	Phe	Ile	Ala	Pro
			500					505					510		
Phe	Phe	Asp	Val	Asn	Leu	Asn	Ala	Asn	Ala	Asn	Phe	Ile	Val	Phe	Cys
	515					520					525				
Ser	Phe	Leu	Tyr	Pro	Gly	Leu	Asp	Pro	Leu	Ile	Leu	Ile	Leu	Ile	Ile
	530					535					540				
Arg	Asp	Phe	Arg	Arg	Thr	Ile	Phe	Asn	Phe	Leu	Cys	Gly	Lys	Lys	Asn
545					550					555					560
Ser	Val	Asp	Glu	Ser	Arg	Ser	Thr	Thr	Arg	Ala	Asn	Leu	Ser	Gln	Val
			565					570						575	
Pro	Thr	Met	Thr	Ser	Lys	Val	Tyr	Asp	Pro	Glu	Gln	Arg	Lys	Arg	Met
			580					585					590		
Ile	Thr	Gly	Pro	Gln	Trp	Trp	Ala	Arg	Cys	Lys	Gln	Met	Asn	Val	Leu
	595						600					605			
Asp	Ser	Phe	Ile	Asn	Tyr	Tyr	Asp	Ser	Glu	Lys	His	Ala	Glu	Asn	Ala
	610					615					620				
Val	Ile	Phe	Leu	His	Gly	Asn	Ala	Ala	Ser	Ser	Tyr	Leu	Trp	Arg	His
625					630					635					640

70n

Val Val Pro His Ile Glu Pro Val Ala Arg Cys Ile Ile Pro Asp Leu
 645 650 655
 Ile Gly Met Gly Lys Ser Gly Lys Ser Gly Asn Gly Ser Tyr Arg Leu
 660 665 670
 Leu Asp His Tyr Lys Tyr Leu Thr Ala Trp Phe Glu Leu Leu Asn Leu
 675 680 685
 Pro Lys Lys Ile Ile Phe Val Gly His Asp Trp Gly Ala Cys Leu Ala
 690 695 700
 Phe His Tyr Ser Tyr Glu His Gln Asp Lys Ile Lys Ala Ile Val His
 705 710 715 720
 Ala Glu Ser Val Val Asp Val Ile Glu Ser Trp Asp Glu Trp Pro Asp
 725 730 735
 Ile Glu Glu Asp Ile Ala Leu Ile Lys Ser Glu Glu Gly Glu Lys Met
 740 745 750
 Val Leu Glu Asn Asn Phe Phe Val Glu Thr Met Leu Pro Ser Lys Ile
 755 760 765
 Met Arg Lys Leu Glu Pro Glu Glu Phe Ala Ala Tyr Leu Glu Pro Phe
 770 775 780
 Lys Glu Lys Gly Glu Val Arg Arg Pro Thr Leu Ser Trp Pro Arg Glu
 785 790 795 800
 Ile Pro Leu Val Lys Gly Gly Lys Pro Asp Val Val Gln Ile Val Arg
 805 810 815
 Asn Tyr Asn Ala Tyr Leu Arg Ala Ser Asp Asp Leu Pro Lys Met Phe
 820 825 830
 Ile Glu Ser Asp Pro Gly Phe Phe Ser Asn Ala Ile Val Glu Gly Ala
 835 840 845
 Lys Lys Phe Pro Asn Thr Glu Phe Val Lys Val Lys Gly Leu His Phe
 850 855 860
 Ser Gln Glu Asp Ala Pro Asp Glu Met Gly Lys Tyr Ile Lys Ser Phe
 865 870 875 880
 Val Glu Arg Val Leu Lys Asn Glu Gln
 885

<210> 16

<211> 2670

<212> DNA

<213> Artificial Sequence

<220>

<223> ORF encoding BRET construct of SEQ ID NO:15

<400> 16

atgtcgggag aattgtggat taccctagtt gacacagcgg acattgtcgg cgtcaccctc 60
 accttctgtg tcaacattgt tcttctcgga cttctgaaaa cacgtggaaa aaacttgggc 120
 acttataaat atctcatggc gtttttctca gtattctcga ttttttacgc catcatcgag 180
 ttcattattac gacctataat gcatattgag aacaccactt tctttttgat ctcaaggaaa 240
 agattcaact actccaccaa acttggaata atcaactctg cgttttactg tgcttggttt 300
 gccaccagtt ttgttgtctc aggagttcac tttgtttatc gatattttgc aacttgcaaa 360
 ccgaatctac ttcgtttgtt caacttgcca actcttctac tttggccact tggttgcagt 420
 gtaccctgta caatgtgggc tagtgtctca tattttttgt atccagatac cgagtacacg 480
 gaagcggctg tcaccaatgt actaaataac cactataact ggatcaaaaa ggagaatgta 540
 tcgtacattg catacgtcta ttaccaatac gaaaacggag taaggcatat ctacctcaaa 600
 aacttgcttg gatgctttgt tcattacttt gtcatgtcga tgacgtttgt tgtgatgttc 660
 tactgcggat atgccacgtg gaaaactatg aatgaacaca aggatgtatc tgatagaact 720
 atggtgagca agggcgagga gctgttcacc ggggtggtgc ccatcctggt cgagctggac 780

```

ggcgacgtaa acggccacaa gttcagcgtg tccggcgagg gcgagggcga tgccacctac      840
ggcaagctga ccctgaagtt catctgcacc accggcaagc tgcccgtgcc ctggcccacc      900
ctcgtgacca ccctgagcta cggcgtgcag tgcttcagcc gctaccccga ccacatgaag      960
cagcacgact tcttcaagtc cgccatgccc gaaggctacg tccaggagcg caccatcttc     1020
ttcaaggacg acggcaacta caagaccgcg gccgaggtga agttcgaggg cgacaccctg     1080
gtgaaccgca tcgagctgaa gggcatcgac ttcaaggagg acggcaacat cctggggcac     1140
aagctggagt acaactacaa cagccacaac gtctatatca tggccgacaa gcagaagaac     1200
ggcatcaagg tgaacttcaa gatccgccac aacatcgagg acggcagcgt gcagctcgcc     1260
gaccactacc agcagaacac ccccatcggc gacggccccg tgctgctgcc cgacaaccac     1320
tacctgagca ccagtcgcg cctgagcaaa gaccccaacg agaagcgcgga tcacatggtc     1380
ctgctggagt tcgtgaccgc cgccgggata actctcggca tggacgagct gtacaagcga     1440
gcgctacaga aacaactttt caaagcttta gttcttcaga cactcatccc aactatcttc     1500
atgtacgccc caactggagt catgttcata gcaccgtttt ttgacgtgaa tttgaatgca     1560
aacgccaat ttcattgtgt ttgctcattt ctgtaccogg gactcgatcc actcattctg     1620
atthttgatc ttctgtatth ccgaagaaca atattcaatt tcttgtgtgg aaagaaaaac     1680
agtgttgatg aatcccgcgc gacaacaaga gccaatthgt ctcaagttcc gacgatgacc     1740
agcaaggtgt acgaccccga gcagaggaag aggatgatca ccggccccca gtggtgggac     1800
aggtgcaagc agatgaacgt gctggacagc ttcatcaact actacgacag cgagaagcac     1860
gccgagaacg ccgtgatctt cctgcacggc aacgccgcta gcagctacct gtggaggcac     1920
gtggtgcccc acatcgagcc cgtggccagg tgcatactcc ccgatctgat cggcatgggc     1980
aagagcggca agagcggcaa cggcagctac aggtctgctg accactacaa gtacctgacc     2040
gcctggttcg agctcctgaa cctgcccagg aagatcatct tcgtgggcca cgactggggc     2100
gcctgcctgg ccttccacta cagctacgag caccaggaca agatcaaggc catcgtgcac     2160
gccgagagcg tgggtggacgt gatcgagagc tgggacgagt ggccagacat cgaggaggac     2220
atcgccctga tcaagagcga ggagggcgag aagatggtgc tggagaacaa cttcttcgtg     2280
gagaccatgc tgcccagcaa gatcatgaga aagctggagc ccgaggagtt cgccgcctac     2340
ctggagccct tcaaggagaa gggcgaggtg agaagaccca cctgagctg gccagagag     2400
atccccctgg tgaagggcgg caagcccgcg gtggtgcaga tcgtgagaaa ctacaacgcc     2460
tacctgagag ccagcgacga cctgcccagg atgttcacgc agagcgaccc cggcttcttc     2520
agcaacgcca tcgtggaggg cgccaagaag ttcccccaaca ccgagttcgt gaaggtgaag     2580
ggcctgcact tcagccagga ggacgcccc gacgagatgg gcaagtacat caagagcttc     2640
gtggagagag tgctgaagaa cgagcagtaa                                     2670

```

<210> 17
 <211> 650
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> BRET construct

<400> 17
 Met Ser Gly Glu Leu Trp Ile Thr Leu Val Asp Thr Ala Asp Ile Val
 1 5 10 15
 Gly Val Thr Leu Thr Phe Cys Val Asn Ile Val Leu Leu Gly Leu Leu
 20 25 30
 Lys Thr Arg Gly Lys Asn Leu Gly Thr Tyr Lys Tyr Leu Met Ala Phe
 35 40 45
 Phe Ser Val Phe Ser Ile Phe Tyr Ala Ile Ile Glu Phe Ile Leu Arg
 50 55 60
 Pro Ile Met His Ile Glu Asn Thr Thr Phe Phe Leu Ile Ser Arg Lys
 65 70 75 80
 Arg Phe Asn Tyr Ser Thr Lys Leu Gly Lys Ile Asn Ser Ala Phe Tyr
 85 90 95

Cys	Ala	Cys	Phe	Ala	Thr	Ser	Phe	Val	Val	Ser	Gly	Val	His	Phe	Val
			100					105					110		
Tyr	Arg	Tyr	Phe	Ala	Thr	Cys	Lys	Pro	Asn	Leu	Leu	Arg	Leu	Phe	Asn
		115					120					125			
Leu	Pro	Thr	Leu	Leu	Leu	Trp	Pro	Leu	Gly	Cys	Ser	Val	Pro	Val	Thr
	130					135					140				
Met	Trp	Ala	Ser	Val	Ser	Tyr	Phe	Leu	Tyr	Pro	Asp	Thr	Glu	Tyr	Thr
145					150					155					160
Glu	Ala	Ala	Val	Thr	Asn	Val	Leu	Asn	Asn	His	Tyr	Asn	Trp	Ile	Lys
			165						170					175	
Lys	Glu	Asn	Val	Ser	Tyr	Ile	Ala	Tyr	Val	Tyr	Tyr	Gln	Tyr	Glu	Asn
		180						185					190		
Gly	Val	Arg	His	Ile	Tyr	Leu	Lys	Asn	Leu	Leu	Gly	Cys	Phe	Val	His
		195					200					205			
Tyr	Phe	Val	Met	Ser	Met	Thr	Phe	Val	Val	Met	Phe	Tyr	Cys	Gly	Tyr
	210				215					220					
Ala	Thr	Trp	Lys	Thr	Met	Asn	Glu	His	Lys	Asp	Val	Ser	Asp	Arg	Thr
225					230					235					240
Arg	Ala	Leu	Gln	Lys	Gln	Leu	Phe	Lys	Ala	Leu	Val	Leu	Gln	Thr	Leu
			245						250					255	
Ile	Pro	Thr	Ile	Phe	Met	Tyr	Ala	Pro	Thr	Gly	Val	Met	Phe	Ile	Ala
		260						265					270		
Pro	Phe	Phe	Asp	Val	Asn	Leu	Asn	Ala	Asn	Ala	Asn	Phe	Ile	Val	Phe
		275					280					285			
Cys	Ser	Phe	Leu	Tyr	Pro	Gly	Leu	Asp	Pro	Leu	Ile	Leu	Ile	Leu	Ile
	290					295					300				
Ile	Arg	Asp	Phe	Arg	Arg	Thr	Ile	Phe	Asn	Phe	Leu	Cys	Gly	Lys	Lys
305					310					315					320
Asn	Ser	Val	Asp	Glu	Ser	Arg	Ser	Thr	Thr	Arg	Ala	Asn	Leu	Ser	Gln
			325						330					335	
Val	Pro	Thr	Met	Thr	Ser	Lys	Val	Tyr	Asp	Pro	Glu	Gln	Arg	Lys	Arg
		340						345					350		
Met	Ile	Thr	Gly	Pro	Gln	Trp	Trp	Ala	Arg	Cys	Lys	Gln	Met	Asn	Val
		355				360						365			
Leu	Asp	Ser	Phe	Ile	Asn	Tyr	Tyr	Asp	Ser	Glu	Lys	His	Ala	Glu	Asn
	370					375					380				
Ala	Val	Ile	Phe	Leu	His	Gly	Asn	Ala	Ala	Ser	Ser	Tyr	Leu	Trp	Arg
385					390					395					400
His	Val	Val	Pro	His	Ile	Glu	Pro	Val	Ala	Arg	Cys	Ile	Ile	Pro	Asp
			405						410					415	
Leu	Ile	Gly	Met	Gly	Lys	Ser	Gly	Lys	Ser	Gly	Asn	Gly	Ser	Tyr	Arg
		420						425					430		
Leu	Leu	Asp	His	Tyr	Lys	Tyr	Leu	Thr	Ala	Trp	Phe	Glu	Leu	Leu	Asn
		435					440					445			
Leu	Pro	Lys													

70q

Phe Lys Glu Lys Gly Glu Val Arg Arg Pro Thr Leu Ser Trp Pro Arg
 545 550 555 560
 Glu Ile Pro Leu Val Lys Gly Gly Lys Pro Asp Val Val Gln Ile Val
 565 570 575
 Arg Asn Tyr Asn Ala Tyr Leu Arg Ala Ser Asp Asp Leu Pro Lys Met
 580 585 590
 Phe Ile Glu Ser Asp Pro Gly Phe Phe Ser Asn Ala Ile Val Glu Gly
 595 600 605
 Ala Lys Lys Phe Pro Asn Thr Glu Phe Val Lys Val Lys Gly Leu His
 610 615 620
 Phe Ser Gln Glu Asp Ala Pro Asp Glu Met Gly Lys Tyr Ile Lys Ser
 625 630 635 640
 Phe Val Glu Arg Val Leu Lys Asn Glu Gln
 645 650

<210> 18
 <211> 1953
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> ORF encoding BRET construct of SEQ ID NO:17

<400> 18
 atgtcgggag aattgtggat taccctagtt gacacagcgg acattgtcgg cgtcaccctc 60
 accttctgtg tcaacattgt tcttctcgga cttctgaaaa cacgtggaaa aaacttgggc 120
 acttataaat atctcatggc gtttttctca gtattctcga ttttttacgc catcatcgag 180
 ttcattattac gacctataat gcatattgag aacaccactt tctttttgat ctcaaggaaa 240
 agattcaact actccaccaa acttggaata atcaactctg cgttttactg tgcttggttt 300
 gccaccagtt ttgttggtctc aggagttcac tttgtttatc gatattttgc aacttgcaaa 360
 ccgaatctac ttctgtttgtt caacttgcca actcttctac tttggccact tgggtgcagt 420
 gtaccctgta caatgtgggc tagtgtctca tttttttgtt atccagatac cgagtacacg 480
 gaagcggctg tcaccaatgt actaaataac cactataact ggatcaaaaa ggagaatgta 540
 tcgtacattg catacgtcta ttaccaatac gaaaacggag taaggcatat ctacctcaa 600
 aacttgcttg gatgctttgt tcattacttt gtcatgtcga tgacgtttgt tgtgatgttc 660
 tactgcggat atgccacgtg gaaaactatg aatgaacaca aggatgtatc tgatagaact 720
 cgagcgtctac agaaacaact tttcaaagct ttagttcttc agacactcat cccaactatc 780
 ttcattgtacg cccaactgg agtcatgttc atcgcaccgt tttttgacgt gaatttgaat 840
 gcaaacgcca atttcattgt gttttgctca tttctgtacc cgggactcga tccactcatt 900
 ctgattttga tcattcgtga tttccgaaga acaatattca atttcttgtg tggaaagaaa 960
 aacagtgttg atgaatcccg ctgcacaaca agagccaatt tgtctcaagt tccgacgatg 1020
 accagcaagg tgtacgaccc cgagcagagg aagaggatga tcaccggccc ccagtgggtg 1080
 gccaggtgca agcagatgaa cgtgctggac agcttcatca actactacga cagcgagaag 1140
 cacgccgaga acgccgtgat ctctctgcac ggcaacgccg ctacgagcta cctgtggagg 1200
 caegtgggtc cccacatcga gcccggtggc aggtgcatca tccccgatct gatcggcatg 1260
 ggcaagagcg gcaagagcgg caacggcagc tacaggctgc tggaccacta caagtacctg 1320
 accgcctggg tcgagctcct gaacctgccc aagaagatca tcttcgtggg ccacgactgg 1380
 ggcgcctgcc tggccttcca ctacagctac gagcaccagg acaagatcaa ggccatcgtg 1440
 cacgccgaga gcgtgggtga cgtgatcgag agctgggacg agtggccaga catcgaggag 1500
 gacatcgcgc tgatcaagag cgaggagggc gagaagatgg tgctggagaa caacttcttc 1560
 gtggagacca tgctgcccag caagatcatg agaaagctgg agcccagga gttcgccgcc 1620
 tacctggagc ccttcaagga gaaggcgag gtgagaagac ccacctgag ctggcccaga 1680
 gagatcccc tggtgaaggg cggcaagccc gacgtggtgc agatcgtgag aaactacaac 1740
 gcctacctga gagccagcga cgacctgccc aagatgttca tcgagagcga ccccggttc 1800
 ttcagcaacg ccatcgtgga gggcgccaag aagttcccca acaccgagtt cgtgaagggtg 1860

70r

aagggcctgc acttcagcca ggaggacgcc cccgacgaga tgggcaagta catcaagagc 1920
 ttcgtggaga gagtgctgaa gaacgagcag taa 1953

<210> 19
 <211> 578
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> BRET construct

<400> 19
 Met Ser Gly Glu Leu Trp Ile Thr Leu Val Asp Thr Ala Asp Ile Val
 1 5 10 15
 Gly Val Thr Leu Thr Phe Cys Val Asn Ile Val Leu Leu Gly Leu Leu
 20 25 30
 Lys Thr Arg Gly Lys Asn Leu Gly Thr Tyr Lys Tyr Leu Met Ala Phe
 35 40 45
 Phe Ser Val Phe Ser Ile Phe Tyr Ala Ile Ile Glu Phe Ile Leu Arg
 50 55 60
 Pro Ile Met His Ile Glu Asn Thr Thr Phe Phe Leu Ile Ser Arg Lys
 65 70 75 80
 Arg Phe Asn Tyr Ser Thr Lys Leu Gly Lys Ile Asn Ser Ala Phe Tyr
 85 90 95
 Cys Ala Cys Phe Ala Thr Ser Phe Val Val Ser Gly Val His Phe Val
 100 105 110
 Tyr Arg Tyr Phe Ala Thr Cys Lys Pro Asn Leu Leu Arg Leu Phe Asn
 115 120 125
 Leu Pro Thr Leu Leu Leu Trp Pro Leu Gly Cys Ser Val Pro Val Thr
 130 135 140
 Met Trp Ala Ser Val Ser Tyr Phe Leu Tyr Pro Asp Thr Glu Tyr Thr
 145 150 155 160
 Glu Ala Ala Val Thr Asn Val Leu Asn Asn His Tyr Asn Trp Ile Lys
 165 170 175
 Lys Glu Asn Val Ser Tyr Ile Ala Tyr Val Tyr Tyr Gln Tyr Glu Asn
 180 185 190
 Gly Val Arg His Ile Tyr Leu Lys Asn Leu Leu Gly Cys Phe Val His
 195 200 205
 Tyr Phe Val Met Ser Met Thr Phe Val Val Met Phe Tyr Cys Gly Tyr
 210 215 220
 Ala Thr Trp Lys Thr Met Asn Glu His Lys Asp Val Ser Asp Arg Thr
 225 230 235 240
 Arg Ala Leu Gln Lys Gln Leu Phe Lys Ala Leu Val Leu Gln Thr Leu
 245 250 255
 Ile Pro Thr Ile Phe Met Tyr Ala Pro Thr Gly Val Met Phe Ile Ala
 260 265 270
 Pro Phe Phe Asp Val Asn Leu Asn Ala Asn Ala Asn Phe Ile Val Phe
 275 280 285
 Cys Ser Phe Leu Tyr Pro Gly Leu Asp Pro Leu Ile Leu Ile Leu Ile
 290 295 300
 Ile Arg Asp Phe Arg Arg Thr Ile Phe Asn Phe Leu Cys Gly Lys Lys
 305 310 315 320
 Asn Ser Val Asp Glu Ser Arg Ser Thr Thr Arg Ala Asn Leu Ser Gln
 325 330 335

70s

Val Pro Thr Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val
 340 345 350
 Pro Ile Leu Val Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser
 355 360 365
 Val Ser Gly Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu
 370 375 380
 Lys Phe Ile Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu
 385 390 395 400
 Val Thr Thr Leu Ser Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp
 405 410 415
 His Met Lys Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr
 420 425 430
 Val Gln Glu Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr
 435 440 445
 Arg Ala Glu Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu
 450 455 460
 Leu Lys Gly Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys
 465 470 475 480
 Leu Glu Tyr Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys
 485 490 495
 Gln Lys Asn Gly Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu
 500 505 510
 Asp Gly Ser Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile
 515 520 525
 Gly Asp Gly Pro Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln
 530 535 540
 Ser Ala Leu Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu
 545 550 555 560
 Leu Glu Phe Val Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu
 565 570 575
 Tyr Lys

<210> 20
 <211> 1737
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> ORF encoding BRET construct of SEQ ID NO:19

<400> 20
 atgtcgggag aattgtggat taccctagtt gacacagcgg acattgtcgg cgtcaccctc 60
 accttctgtg tcaacattgt tcttctcgga cttctgaaaa cacgtggaaa aaacttgggc 120
 acttataaat atctcatggc gtttttctca gtattctcga ttttttacgc catcatcgag 180
 ttcataattac gacctataat gcatattgag aacaccactt tctttttgat ctcaaggaaa 240
 agattcaact actccaccaa acttggaaaa atcaactctg cgttttactg tgcttgtttt 300
 gccaccagtt ttgttgtctc aggagttcac tttgtttatc gatattttgc aacttgcaaa 360
 ccgaatctac ttcgtttgtt caacttgcca actcttctac tttggccact tggttgcagt 420
 gtacccgtga caatgtgggc tagtgtctca tattttttgt atccagatac cgagtacacg 480
 gaagcggctg tcaccaatgt actaaataac cactataact ggatcaaaaa ggagaatgta 540
 tcgtacattg catacgtcta ttaccaatac gaaaacggag taaggcatat ctacctcaaa 600
 aacttgcttg gatgctttgt tcattacttt gtcatgtcga tgacgtttgt tgtgatgttc 660
 tactgcggat atgccacgtg gaaaactatg aatgaacaca aggatgtatc tgatagaact 720
 cgagcgctac agaaacaact tttcaaagct ttagttcttc agacaactcat cccaactatc 780
 ttcatgtaag ccccaactgg agtcatgttc atcgcaccgt tttttgacgt gaatttgaat 840

70t

```

gcaaacgcca atttcattgt gttttgctca tttctgtacc cgggactcga tccactcatt 900
ctgattttga tcattcgtga tttccgaaga acaatattca atttcttggtg tggaaagaaa 960
aacagtgttg atgaatcccg ctcgacaaca agagccaatt tgtctcaagt tccgacgatg 1020
gtgagcaagg gcgaggagct gttcacccgg gtggtgcccc tcttggtcga gctggacggc 1080
gacgtaaacg gccacaagtt cagcgtgtcc ggcgagggcg agggcgatgc cacctacggc 1140
aagctgaccc tgaagtccat ctgcaccacc ggcaagctgc ccgtgccctg gccaccctc 1200
gtgaccaccc tgagctacgg cgtgcagtg cttcagccgt accccgacca catgaagcag 1260
cacgacttct tcaagtccgc catgcccga ggctacgtcc aggagcgcac catcttcttc 1320
aaggacgacg gcaactacaa gacccgcgcc gaggtgaagt tcgagggcga caccctggtg 1380
aaccgcacgc agctgaaggg catcgacttc aaggaggacg gcaacatcct ggggcacaag 1440
ctggagtaca actacaacag ccacaacgtc tatatcatgg ccgacaagca gaagaacggc 1500
atcaaggtga acttcaagat ccgccacaac atcgaggacg gcagcgtgca gctcgccgac 1560
cactaccagc agaacacccc catcggcgac ggccccgtgc tgctgcccg caaccactac 1620
ctgagcaccc agtccgccct gagcaaagac cccaacgaga agcgcgatca catggtcctg 1680
ctggagttcg tgaccgccgc cgggatcact ctcggcattg acgagctgta caagtaa 1737

```

<210> 21
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligonucleotide primer

<400> 21
 agtctagaat gtcgggagaa ttgtggatta 30

<210> 22
 <211> 49
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligonucleotide primer

<400> 22
 ggggacaagt ttgtacaaaa aagcaggctt catcacgtcg gaacttgag 49

<210> 23
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligonucleotide primer

<400> 23
 aaccatgtcg ggagaattgt g 21

<210> 24
 <211> 29

70u

<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer

<400> 24
tgtagcgctc gcttgtacag ctcgccat 29

<210> 25
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer

<400> 25
gagctgtaca agcgagcgct acagaaacaa 30

<210> 26
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer

<400> 26
cttgctgggc atcgctggaa cttgagaca 29

<210> 27
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer

<400> 27
caagttccga cgatgaccag caaggtgta 29

<210> 28
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer

<400> 28
gttactgctc gttcttca 18

<210> 29
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer

<400> 29
gagctgtaca agcgagcgct acagaaacaa

30

<210> 30
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer

<400> 30
gttactgctc gttcttca

18

<210> 31
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer

<400> 31
aaccatgtcg ggagaattgt g

21

<210> 32
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer

<400> 32
gttactgctc gttcttca

18

<210> 33
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer

<400> 33
aaccatgtcg ggagaattgt g 21

<210> 34
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer

<400> 34
ctgtagcgct cgctgctcgt tcttcag 27

<210> 35
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer

<400> 35
aagaacgagc agcgagcgct acagaaaca 29

<210> 36
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer

<400> 36
cttgctcacc atcgtcggaa cttgagaca 29

<210> 37
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer

<400> 37
caagttccga cgatggtgag caagggcga 29

<210> 38
<211> 19
<212> DNA
<213> Artificial Sequence

70x

<220>
<223> Oligonucleotide primer

<400> 38
gttacttgta cagctcgtc 19

<210> 39
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer

<400> 39
aagaacgagc agcgagcgct acagaaaca 29

<210> 40
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer

<400> 40
gttacttgta cagctcgtc 19

<210> 41
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer

<400> 41
aaccatgtcg ggagaattgt g 21

<210> 42
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer

<400> 42
gttacttgta cagctcgtc 19

70y

<210> 43
 <211> 53
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligonucleotide primer

<400> 43
 caccagtttt gttgtctcag gagtttattt tgtttatcga tatttttgcaa ctt

53

<210> 44
 <211> 53
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligonucleotide primer

<400> 44
 aagttgcaaa atatcgataa acaaaataaa ctctgagac aacaaaactg gtg

53

<210> 45
 <211> 238
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> mCitrine derivative

<400> 45
 Met Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val
 1 5 10 15
 Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu
 20 25 30
 Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Cys
 35 40 45
 Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Leu
 50 55 60
 Gly Tyr Gly Leu Met Cys Phe Ala Arg Tyr Pro Asp His Met Lys Gln
 65 70 75 80
 His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg
 85 90 95
 Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val
 100 105 110
 Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile
 115 120 125
 Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn
 130 135 140
 Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly
 145 150 155 160
 Ile Lys Val Asn Phe Lys Tle Arg His Asn Ile Glu Asp Gly Ser Val
 165 170 175

70z

Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro
 180 185 190
 Val Leu Leu Pro Asp Asn His Tyr Leu Ser Tyr Gln Ser Arg Leu Ser
 195 200 205
 Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe Val
 210 215 220
 Thr Ala Ala Gly Ile Thr His Gly Met Asp Glu Leu Tyr Lys
 225 230 235

<210> 46
 <211> 238
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> mCFP derivative

<400> 46
 Met Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val
 1 5 10 15
 Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu
 20 25 30
 Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Cys
 35 40 45
 Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Leu
 50 55 60
 Thr Trp Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Gln
 65 70 75 80
 His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg
 85 90 95
 Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val
 100 105 110
 Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile
 115 120 125
 Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Ile
 130 135 140
 Tyr Asn Ser His Asn Val Tyr Ile Thr Ala Asp Lys Gln Lys Asn Gly
 145 150 155 160
 Ile Lys Ala Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser Val
 165 170 175
 Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro
 180 185 190
 Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Arg Leu Ser
 195 200 205
 Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe Val
 210 215 220
 Thr Ala Ala Gly Ile Thr His Gly Met Asp Glu Leu Tyr Lys
 225 230 235

<210> 47
 <211> 717
 <212> DNA
 <213> Artificial Sequence

70aa

<220>

<223> Codon optimized ORF encoding SEQ ID NO:45

<400> 47

atgtctaaag	gtgaagaatt	attcactggg	gttgtcccaa	ttttgggtga	attagatggg	60
gatgttaatg	gtcacaaatt	ttctgtctcc	gggaagggtg	aaggatgatgc	tacttacggg	120
aaattgacct	taaaatttat	ttgtactact	ggtaaattgc	cagttccatg	gccaacctta	180
gtcactactt	taggttatgg	tttgatgtgt	tttgctagat	accagatca	tatgaaacaa	240
catgactttt	tcaagtctgc	catgccagaa	ggttatgttc	aagaaagaac	tatTTTTTt	300
aaagatgacg	gtaactacaa	gaccagagct	gaagtcaagt	ttgaagggtga	taccttagtt	360
aatagaatcg	aattaaaagg	tattgatttt	aaagaagatg	gtaacatttt	aggtcacaaa	420
ttggaataca	actataactc	tcacaatggt	tacatcatgg	ctgacaaaca	aaagaatggg	480
atcaaagtta	acttcaaaat	tagacacaac	attgaagatg	gttctgttca	attagctgac	540
cattatcaac	aaaatactcc	aattgggtgat	gggccagtct	tggtaccaga	caaccattac	600
ttatcctatc	aatctagatt	atccaaagat	ccaaacgaaa	agagagacca	catgggtctg	660
ttagaatttg	ttactgctgc	tggtattacc	catgggtatg	atgaattgta	caaataa	717

<210> 48

<211> 717

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon optimized ORF encoding SEQ ID NO:46

<400> 48

atgtctaaag	gtgaagaatt	attcactggg	gttgtcccaa	ttttgggtga	attagatggg	60
gatgttaatg	gtcacaaatt	ttctgtctcc	gggaagggtg	aaggatgatgc	tacttacggg	120
aaattgacct	taaaatttat	ttgtactact	ggtaaattgc	cagttccatg	gccaacctta	180
gtcactactt	taacttgggg	tggtcaatgt	ttttctagat	accagatca	tatgaaacaa	240
catgactttt	tcaagtctgc	catgccagaa	ggttatgttc	aagaaagaac	tatTTTTTt	300
aaagatgacg	gtaactacaa	gaccagagct	gaagtcaagt	ttgaagggtga	taccttagtt	360
aatagaatcg	aattaaaagg	tattgatttt	aaagaagatg	gtaacatttt	aggtcacaaa	420
ttggaataca	tttataactc	tcacaatggt	tacatcactg	ctgacaaaca	aaagaatggg	480
atcaaagcta	acttcaaaat	tagacacaac	attgaagatg	gttctgttca	attagctgac	540
cattatcaac	aaaatactcc	aattgggtgat	gggccagtct	tggtaccaga	caaccattac	600
ttatccactc	aatctagatt	atccaaagat	ccaaacgaaa	agagagacca	catgggtctg	660
ttagaatttg	ttactgctgc	tggtattacc	catgggtatg	atgaattgta	caaataa	717

<210> 49

<211> 2448

<212> DNA

<213> Artificial Sequence

<220>

<223> ORF encoding FRET construct

<400> 49

atgtcgggag	aattgtggat	taccctagtt	gacacagcgg	acattgtcgg	cgtcaccctc	60
accttctgtg	tcaacattgt	tcttctcgga	cttctgaaaa	cacgtggaaa	aaacttgggc	120
acttataaat	atctcatggc	gtttttctca	gtattctcga	ttttttacgc	catcatcgag	180
ttcatattac	gacctataat	gcattattgag	aacaccactt	tctttttgat	ctcaaggaaa	240
agattcaact	actccaccaa	acttggaaaa	atcaactctg	cgttttactg	tgcttggttt	300
gccaccagtt	ttgttgtctc	aggagttcac	tttgtttatc	gatattttgc	aacttgcaaa	360

70bb

```

ccgaatctac ttcgtttggt caacttgcca actcttctac tttggccact tggttgcagt 420
gtaccggtga caatgtgggc tagtgtctca tttttttgt atccagatac cgagtacacg 480
gaagcggctg tcaccaatgt actaaataac cactataact ggatcaaaaa ggagaatgta 540
tcgtacattg catacgtcta ttaccaatac gaaaacggag taaggcatat ctacctcaa 600
aacttgcttg gatgctttgt tcattacttt gtcatgtcga tgacgtttgt tgtgatgttc 660
tactgcggt atgccacgtg gaaaactatg aatgaacaca aggatgtatc tgatagaact 720
atgtctaaag gtgaagaatt attcactggt gttgtcccaa ttttggttga attagatggt 780
gatgttaatg gtcacaaatt ttctgtctcc ggtgaagggt aaggatgatgc tacttacggt 840
aaattgacct taaaatttat ttgtactact ggtaaattgc cagttccatg gccaacctta 900
gtcactactt taacttgggg tgttcaatgt ttttctagat acccagatca tatgaaacaa 960
catgactttt tcaagtctgc catgccagaa gggtatgttc aagaaagaac ttttttttc 1020
aaagatgacg gtaactacaa gaccagagct gaagtcaagt ttgaagggtga taccttagtt 1080
aatagaatcg aattaaaagg tattgatttt aaagaagatg gtaacatttt aggtcacaaa 1140
ttggaataca ttataactc tcacaatgtt tacatcactg ctgacaaaca aaagaatggt 1200
atcaaagcta acttcaaaat tagacacaac attgaagatg gttctgttca attagctgac 1260
cattatcaac aaaatactcc aattggtgat ggtccagtct tgttaccaga caaccattac 1320
ttatccactc aatctagatt atccaaagat ccaaacgaaa agagagacca catggtcttg 1380
ttagaatttg ttactgctgc tgggtattacc catggtatgg atgaattgta caaacgagcg 1440
ctacagaaac aacttttcaa agcttttagtt cttcagacac tcatcccaac tatcttcatg 1500
tacgccccaa ctggagtcac gttcatcgca ccgttttttg acgtgaattt gaatgcaaac 1560
gccaatttca ttgtgttttg ctcatctctg taccggggac tcgatccact cattctgatt 1620
ttgatcatte gtgatttccg aagaacaata ttcaatttct tgtgtggaaa gaaaaacagt 1680
gttgatgaat cccgctcgac aacaagagcc aatttgtctc aagttccgac gatgtctaaa 1740
ggtgaagaat tattcactgg tgttgtccca attttggttg aattagatgg tgatgttaat 1800
ggtcacaaat tttctgtctc cgggtgaagg gaaggatgat ctacttacgg taaattgacc 1860
ttaaatttta tttgtactac tggtaaattg ccagttccat ggccaacctt agtcactact 1920
ttaggttatg gtttgatgtg ttttgctaga taccagatc atatgaaaca acatgacttt 1980
ttcaagtctg ccatgccaga aggttatgtt caagaaagaa ctattttttt caaagatgac 2040
ggtaactaca agaccagagc tgaagtcaag tttgaagggt ataccttagt taatagaatc 2100
gaattaaaag gtattgattt taaagaagat ggtaacattt taggtcacaa attggaatac 2160
aactataact ctcaaatgt ttacatcatg gctgacaaac aaaagaatgg tatcaaagtt 2220
aacttcaaaa ttagacacaa cattgaagat gggtctgttc aattagctga ccattatcaa 2280
caaaatactc caattggtga tgggtccagtc ttgttaccag acaaccatta cttatcctat 2340
caatctagat tatccaaaga tccaaacgaa aagagagacc acatggtctt gttagaattt 2400
gttactgctg ctggtattac ccatggtatg gatgaattgt acaaataa 2448

```

<210> 50
 <211> 815
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> FRETConstruct

<400> 50
 Met Ser Gly Glu Leu Trp Ile Thr Leu Val Asp Thr Ala Asp Ile Val
 1 5 10 15
 Gly Val Thr Leu Thr Phe Cys Val Asn Ile Val Leu Leu Gly Leu Leu
 20 25 30
 Lys Thr Arg Gly Lys Asn Leu Gly Thr Tyr Lys Tyr Leu Met Ala Phe
 35 40 45
 Phe Ser Val Phe Ser Ile Phe Tyr Ala Ile Ile Glu Phe Ile Leu Arg
 50 55 60
 Pro Ile Met His Ile Glu Asn Thr Thr Phe Phe Leu Ile Ser Arg Lys
 65 70 75 80

70cc

Arg	Phe	Asn	Tyr	Ser	Thr	Lys	Leu	Gly	Lys	Ile	Asn	Ser	Ala	Phe	Tyr
			85						90					95	
Cys	Ala	Cys	Phe	Ala	Thr	Ser	Phe	Val	Val	Ser	Gly	Val	His	Phe	Val
			100					105					110		
Tyr	Arg	Tyr	Phe	Ala	Thr	Cys	Lys	Pro	Asn	Leu	Leu	Arg	Leu	Phe	Asn
		115					120					125			
Leu	Pro	Thr	Leu	Leu	Leu	Trp	Pro	Leu	Gly	Cys	Ser	Val	Pro	Val	Thr
	130					135					140				
Met	Trp	Ala	Ser	Val	Ser	Tyr	Phe	Leu	Tyr	Pro	Asp	Thr	Glu	Tyr	Thr
145					150					155					160
Glu	Ala	Ala	Val	Thr	Asn	Val	Leu	Asn	Asn	His	Tyr	Asn	Trp	Ile	Lys
			165						170					175	
Lys	Glu	Asn	Val	Ser	Tyr	Ile	Ala	Tyr	Val	Tyr	Tyr	Gln	Tyr	Glu	Asn
		180					185					190			
Gly	Val	Arg	His	Ile	Tyr	Leu	Lys	Asn	Leu	Leu	Gly	Cys	Phe	Val	His
	195					200					205				
Tyr	Phe	Val	Met	Ser	Met	Thr	Phe	Val	Val	Met	Phe	Tyr	Cys	Gly	Tyr
	210					215					220				
Ala	Thr	Trp	Lys	Thr	Met	Asn	Glu	His	Lys	Asp	Val	Ser	Asp	Arg	Thr
225					230					235					240
Met	Ser	Lys	Gly	Glu	Glu	Leu	Phe	Thr	Gly	Val	Val	Pro	Ile	Leu	Val
			245						250					255	
Glu	Leu	Asp	Gly	Asp	Val	Asn	Gly	His	Lys	Phe	Ser	Val	Ser	Gly	Glu
		260					265					270			
Gly	Glu	Gly	Asp	Ala	Thr	Tyr	Gly	Lys	Leu	Thr	Leu	Lys	Phe	Ile	Cys
	275					280					285				
Thr	Thr	Gly	Lys	Leu	Pro	Val	Pro	Trp	Pro	Thr	Leu	Val	Thr	Thr	Leu
	290					295					300				
Thr	Trp	Gly	Val	Gln	Cys	Phe	Ser	Arg	Tyr	Pro	Asp	His	Met	Lys	Gln
305					310					315					320
His	Asp	Phe	Phe	Lys	Ser	Ala	Met	Pro	Glu	Gly	Tyr	Val	Gln	Glu	Arg
			325						330				335		
Thr	Ile	Phe	Phe	Lys	Asp	Asp	Gly	Asn	Tyr	Lys	Thr	Arg	Ala	Glu	Val
		340					345					350			
Lys	Phe	Glu	Gly	Asp	Thr	Leu	Val	Asn	Arg	Ile	Glu	Leu	Lys	Gly	Ile
	355					360					365				
Asp	Phe	Lys	Glu	Asp	Gly	Asn	Ile	Leu	Gly	His	Lys	Leu	Glu	Tyr	Ile
	370				375					380					
Tyr	Asn	Ser	His	Asn	Val	Tyr	Ile	Thr	Ala	Asp	Lys	Gln	Lys	Asn	Gly
385					390					395					400
Ile	Lys	Ala	Asn	Phe	Lys	Ile	Arg	His	Asn	Ile	Glu	Asp	Gly	Ser	Val
			405						410				415		
Gln	Leu	Ala	Asp	His	Tyr	Gln	Gln	Asn	Thr	Pro	Ile	Gly	Asp	Gly	Pro
		420					425					430			
Val	Leu	Leu	Pro	Asp	Asn	His	Tyr	Leu	Ser	Thr	Gln	Ser	Arg	Leu	Ser
	435						440					445			
Lys	Asp	Pro	Asn	Glu	Lys	Arg	Asp	His	Met	Val	Leu	Leu	Glu	Phe	Val
	450				455					460					
Thr	Ala	Ala	Gly	Ile	Thr	His	Gly	Met	Asp	Glu	Leu	Tyr	Lys	Arg	Ala
465					470					475					480
Leu	Gln	Lys	Gln	Leu	Phe	Lys	Ala	Leu	Val	Leu	Gln	Thr	Leu	Ile	Pro
			485						490				495		
Thr	Ile	Phe	Met	Tyr	Ala	Pro	Thr	Gly	Val	Met	Phe	Ile	Ala	Pro	Phe
		500						505				510			
Phe	Asp	Val	Asn	Leu	Asn	Ala	Asn	Ala	Asn	Phe	Ile	Val	Phe	Cys	Ser
	515						520					525			

70dd

Phe Leu Tyr Pro Gly Leu Asp Pro Leu Ile Leu Ile Leu Ile Ile Arg
 530 535 540
 Asp Phe Arg Arg Thr Ile Phe Asn Phe Leu Cys Gly Lys Lys Asn Ser
 545 550 555 560
 Val Asp Glu Ser Arg Ser Thr Thr Arg Ala Asn Leu Ser Gln Val Pro
 565 570 575
 Thr Met Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu
 580 585 590
 Val Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly
 595 600 605
 Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile
 610 615 620
 Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr
 625 630 635 640
 Leu Gly Tyr Gly Leu Met Cys Phe Ala Arg Tyr Pro Asp His Met Lys
 645 650 655
 Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu
 660 665 670
 Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu
 675 680 685
 Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly
 690 695 700
 Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr
 705 710 715 720
 Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn
 725 730 735
 Gly Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser
 740 745 750
 Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly
 755 760 765
 Pro Val Leu Leu Pro Asp Asn His Tyr Leu Ser Tyr Gln Ser Arg Leu
 770 775 780
 Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe
 785 790 795 800
 Val Thr Ala Ala Gly Ile Thr His Gly Met Asp Glu Leu Tyr Lys
 805 810 815

<210> 51

<211> 2694

<212> DNA

<213> Artificial Sequence

<220>

<223> ORF encoding BRET construct

<400> 51

atgggttctg gtcaattatg gttggcttta gttgatgctg cagatatggg ttggttttact 60
 ttgacaatct caattaatat ctttttggtta ggtttgatta gaactagagg taaaaccttg 120
 ggtacttaca agtacttgat gtctttcttt tctttctttt ctattttcta tgcaatcggt 180
 gaatctatct tgagaccaat catgcatatc gaaaacacta catttttctt aatctccaga 240
 aagagattcg attacagtac tagattgggt aaaattaatt cagctttcta ctgtgcttgt 300
 ttcgcaacat ccttcgtttt gagtgcagtt catttcgttt acagatactt cgctgcttgt 360
 aagcctaatt tggtgagatt gtttaactta cctcatttgt tattgtggcc attgatgtgt 420
 tcaattcctg ttactgcttg ggcactctgt tcatactttt tgtaccaga tacagaatat 480
 accgaagctg cagttaccta tgttttgaag actcattacg aagttattaa aaaggaaaac 540

70ee

```

gtttcttaca ttgcttacgt ttactaccaaa tacgaaaacg gtgaaagaca tatctatatt 600
aaaaacttat tgggttggtt cggttcattac ttcgttatgt ctatgacatt cggttggtgtt 660
ttctattgtg gtttctcaac ttggtggaca attagagaac atagagggtgc ttccgataga 720
acaatgggta gtaaggggtga agaattatcc accggtgttg ttccaatttt ggttgaatta 780
gatggtgacg ttaatgggtca taaattttcc gttagtgggtg aagggtgaagg tgacgcaaca 840
tacggtaaatt tgaccttgaa gtttatttgt accactggta aattgccagt tccttggcca 900
accttgggta caaccttaac ttatgggtgtt caatgttttt ccagataccc tgatcatatg 960
aagcaacatg atttctttaa gagtgctatg ccagaagggtt acgttcaaga aagaacaatt 1020
ttctttaagg atgatggtaa ctacaagact agagcagagg ttaagttcga aggtgacaca 1080
ttgggttaaca gaatcgaatt gaagggtatc gatttcaagg aagatggtaa catcttgggt 1140
cataagttgg aatacaatta caactcccat aacgtttaca tcatggctga taagcaaaag 1200
aatgggatta aagttaactt caagatcaga cataacatcg aagatgggtc agttcaattg 1260
gcagatcatt accaacaaaa cacccttatt ggtgacggtc ctgttttggt gccagataac 1320
cattacttat caactcaatc cgctttgagt aaggatccaa acgaaaagag agatcatatg 1380
gttttggttg aattcggtac tgctgcagggt atcacattgg gtatggatga attgtacaag 1440
agacatttgc atagacaatt gtttaaagct ttgggtttcc aaaccttgggt tccatcaatt 1500
tttatgtaca tccctactgg tggtatgttc atcgcaccat ttttcgatat caatttgaac 1560
gctaacgcaa acttcacgtt tttctgttca tttttgtatc ctgggttgga tccattgatc 1620
ttgattttca ttatcagaga attcagagtt acaattttaa acattattcg tggtaatgaa 1680
cgtggtaacg ctgttggtga agcatactct acctcaagaa ttaaattctc acaaccagct 1740
gcagtttaatt tgtctgggtat gacatcaaag gtttacgata ctgaacaaag aaaaagaatg 1800
attaccgggc cacaatgggtg ggctcggtgt aagcaaatga acgttttgga ttctttcatt 1860
aactactacg attcagaaaa gcacgtctga aacgctgtta ttttcttgca tggtaacgct 1920
gcacccagtt atttgtggag acatgttggt cctcatattg aaccagttgc tagatgtatc 1980
atccctgatt tgatcggtat gggtaaattc ggtaaattct gtaacgggtc ttacagattg 2040
ttggatcatt acaagtactt aactgcacgg ttcgaattgt tgaatttgcc aaagaaaatt 2100
atcttcggtg gtcacgattg gggcgcttgt ttggcatttc attactctta cgaacatcaa 2160
gataaaaatta aggcatacgt tcatgcagaa tccgttggtg atgttattga aagttgggat 2220
gaatggccag atatcgaaga agatatacgt ttaattaagt ccgaagaagg tgaaaagatg 2280
gttttggaaa acaacttttt cggttgaaact atgttgccca gtaagatcat gagaaagttg 2340
gaacctgaag aatttgctgc atatttgga ccattcaaag aaaagggtga agttagaaga 2400
cctacattat cttggcctag agaaattcca ttgggttaaag gtggtaaacc agatgttggt 2460
caaactggtt gaaactacaa cgcttactta agagcatctg atgatttgcc aaagatgttc 2520
atcgaatctg atcctgggtt cttttctaat gctattgttg aagggtgctaa gaaattccct 2580
aacacagaat tcgttaaggt taagggtttg catttctctc aagaagatgc tccagatgaa 2640
atgggttaaatt acatcaagtc atttgttgaa agagttttga aaaatgaaca ataa 2694

```

<210> 52

<211> 897

<212> PRT

<213> Artificial Sequence

<220>

<223> BRET Construct

<400> 52

```

Met Gly Ser Gly Gln Leu Trp Leu Ala Leu Val Asp Ala Ala Asp Met
1           5           10           15
Val Gly Phe Thr Leu Thr Ile Ser Ile Asn Ile Ile Leu Leu Gly Leu
20           25           30
Ile Arg Thr Arg Gly Lys Thr Leu Gly Thr Tyr Lys Tyr Leu Met Ser
35           40           45
Phe Phe Ser Phe Phe Ser Ile Phe Tyr Ala Ile Val Glu Ser Ile Leu
50           55           60

```

70ff

Arg	Pro	Ile	Met	His	Ile	Glu	Asn	Thr	Thr	Phe	Phe	Leu	Ile	Ser	Arg	65	70	75	80
Lys	Arg	Phe	Asp	Tyr	Ser	Thr	Arg	Leu	Gly	Lys	Ile	Asn	Ser	Ala	Phe	85	90	95	
Tyr	Cys	Ala	Cys	Phe	Ala	Thr	Ser	Phe	Val	Leu	Ser	Ala	Val	His	Phe	100	105	110	
Val	Tyr	Arg	Tyr	Phe	Ala	Ala	Cys	Lys	Pro	Asn	Leu	Leu	Arg	Leu	Phe	115	120	125	
Asn	Leu	Pro	His	Leu	Leu	Leu	Trp	Pro	Leu	Met	Cys	Ser	Ile	Pro	Val	130	135	140	
Thr	Ala	Trp	Ala	Ser	Val	Ser	Tyr	Phe	Leu	Tyr	Pro	Asp	Thr	Glu	Tyr	145	150	155	160
Thr	Glu	Ala	Ala	Val	Thr	Tyr	Val	Leu	Lys	Thr	His	Tyr	Glu	Val	Ile	165	170	175	
Lys	Lys	Glu	Asn	Val	Ser	Tyr	Ile	Ala	Tyr	Val	Tyr	Tyr	Gln	Tyr	Glu	180	185	190	
Asn	Gly	Glu	Arg	His	Ile	Tyr	Ile	Lys	Asn	Leu	Leu	Gly	Cys	Phe	Val	195	200	205	
His	Tyr	Phe	Val	Met	Ser	Met	Thr	Phe	Val	Val	Val	Phe	Tyr	Cys	Gly	210	215	220	
Phe	Ser	Thr	Trp	Trp	Thr	Ile	Arg	Glu	His	Arg	Gly	Ala	Ser	Asp	Arg	225	230	235	240
Thr	Met	Val	Ser	Lys	Gly	Glu	Glu	Leu	Phe	Thr	Gly	Val	Val	Pro	Ile	245	250	255	
Leu	Val	Glu	Leu	Asp	Gly	Asp	Val	Asn	Gly	His	Lys	Phe	Ser	Val	Ser	260	265	270	
Gly	Glu	Gly	Glu	Gly	Asp	Ala	Thr	Tyr	Gly	Lys	Leu	Thr	Leu	Lys	Phe	275	280	285	
Ile	Cys	Thr	Thr	Gly	Lys	Leu	Pro	Val	Pro	Trp	Pro	Thr	Leu	Val	Thr	290	295	300	
Thr	Leu	Thr	Tyr	Gly	Val	Gln	Cys	Phe	Ser	Arg	Tyr	Pro	Asp	His	Met	305	310	315	320
Lys	Gln	His	Asp	Phe	Phe	Lys	Ser	Ala	Met	Pro	Glu	Gly	Tyr	Val	Gln	325	330	335	
Glu	Arg	Thr	Ile	Phe	Phe	Lys	Asp	Asp	Gly	Asn	Tyr	Lys	Thr	Arg	Ala	340	345	350	
Glu	Val	Lys	Phe	Glu	Gly	Asp	Thr	Leu	Val	Asn	Arg	Ile	Glu	Leu	Lys	355	360	365	
Gly	Ile	Asp	Phe	Lys	Glu	Asp	Gly	Asn	Ile	Leu	Gly	His	Lys	Leu	Glu	370	375	380	
Tyr	Asn	Tyr	Asn	Ser	His	Asn	Val	Tyr	Ile	Met	Ala	Asp	Lys	Gln	Lys	385	390	395	400
Asn	Gly	Ile	Lys	Val	Asn	Phe	Lys	Ile	Arg	His	Asn	Ile	Glu	Asp	Gly	405	410	415	
Ser	Val	Gln	Leu	Ala	Asp	His	Tyr	Gln	Gln	Asn	Thr	Pro	Ile	Gly	Asp	420	425	430	
Gly	Pro	Val	Leu	Leu	Pro	Asp	Asn	His	Tyr	Leu	Ser	Thr	Gln	Ser	Ala	435	440	445	
Leu	Ser	Lys	Asp	Pro	Asn	Glu	Lys	Arg	Asp	His	Met	Val	Leu	Leu	Glu	450	455	460	
Phe	Val	Thr	Ala	Ala	Gly	Ile	Thr	Leu	Gly	Met	Asp	Glu	Leu	Tyr	Lys	465	470	475	480
Arg	His	Leu	His	Arg	Gln	Leu	Phe	Lys	Ala	Leu	Val	Phe	Gln	Thr	Leu	485	490	495	
Val	Pro	Ser	Ile	Phe	Met	Tyr	Ile	Pro	Thr	Gly	Val	Met	Phe	Ile	Ala	500	505	510	

70gg

Pro Phe Phe Asp Ile Asn Leu Asn Ala Asn Ala Asn Phe Ile Val Phe
 515 520 525
 Cys Ser Phe Leu Tyr Pro Gly Leu Asp Pro Leu Ile Leu Ile Phe Ile
 530 535 540
 Ile Arg Glu Phe Arg Val Thr Ile Leu Asn Ile Ile Arg Gly Asn Glu
 545 550 555 560
 Arg Gly Asn Ala Val Gly Glu Ala Tyr Ser Thr Ser Arg Ile Lys Ser
 565 570 575
 Ser Gln Pro Ala Ala Val Asn Leu Ser Gly Met Thr Ser Lys Val Tyr
 580 585 590
 Asp Pro Glu Gln Arg Lys Arg Met Ile Thr Gly Pro Gln Trp Trp Ala
 595 600 605
 Arg Cys Lys Gln Met Asn Val Leu Asp Ser Phe Ile Asn Tyr Tyr Asp
 610 615 620
 Ser Glu Lys His Ala Glu Asn Ala Val Ile Phe Leu His Gly Asn Ala
 625 630 635 640
 Ala Ser Ser Tyr Leu Trp Arg His Val Val Pro His Ile Glu Pro Val
 645 650 655
 Ala Arg Cys Ile Ile Pro Asp Leu Ile Gly Met Gly Lys Ser Gly Lys
 660 665 670
 Ser Gly Asn Gly Ser Tyr Arg Leu Leu Asp His Tyr Lys Tyr Leu Thr
 675 680 685
 Ala Trp Phe Glu Leu Leu Asn Leu Pro Lys Lys Ile Ile Phe Val Gly
 690 695 700
 His Asp Trp Gly Ala Cys Leu Ala Phe His Tyr Ser Tyr Glu His Gln
 705 710 715 720
 Asp Lys Ile Lys Ala Ile Val His Ala Glu Ser Val Val Asp Val Ile
 725 730 735
 Glu Ser Trp Asp Glu Trp Pro Asp Ile Glu Glu Asp Ile Ala Leu Ile
 740 745 750
 Lys Ser Glu Glu Gly Glu Lys Met Val Leu Glu Asn Asn Phe Phe Val
 755 760 765
 Glu Thr Met Leu Pro Ser Lys Ile Met Arg Lys Leu Glu Pro Glu Glu
 770 775 780
 Phe Ala Ala Tyr Leu Glu Pro Phe Lys Glu Lys Gly Glu Val Arg Arg
 785 790 795 800
 Pro Thr Leu Ser Trp Pro Arg Glu Ile Pro Leu Val Lys Gly Gly Lys
 805 810 815
 Pro Asp Val Val Gln Ile Val Arg Asn Tyr Asn Ala Tyr Leu Arg Ala
 820 825 830
 Ser Asp Asp Leu Pro Lys Met Phe Ile Glu Ser Asp Pro Gly Phe Phe
 835 840 845
 Ser Asn Ala Ile Val Glu Gly Ala Lys Lys Phe Pro Asn Thr Glu Phe
 850 855 860
 Val Lys Val Lys Gly Leu His Phe Ser Gln Glu Asp Ala Pro Asp Glu
 865 870 875 880
 Met Gly Lys Tyr Ile Lys Ser Phe Val Glu Arg Val Leu Lys Asn Glu
 885 890 895
 Gln

<210> 53

<211> 2673

<212> DNA

<213> Artificial Sequence

70hh

<220>

<223> ORF encoding 2A adrenergic receptor-BRET construct

<400> 53

atggggtatc	cttacgatgt	tccagattat	gcttcaatgg	gttccttaca	accagatgct	60
ggtaattctt	catggaacgg	tacagaagct	ccaggtggtg	gtaccagagc	aactccatac	120
tcattgcaag	ttacattgac	cttagtttgt	ttggctggtt	tgttgatggt	gtttactggt	180
ttcggtaacg	ttttggttat	tatcgcagtt	tttacatcta	gagctttgaa	ggcaccacaa	240
aatttgttct	tagttagttt	ggcttctgca	gatatcttgg	ttgctacatt	agttattcct	300
ttttctttgg	caaacgaagt	tatggggttat	tggtaacttcg	gtaaagtgtg	gtgtgaaata	360
tatttggtct	tggatgtttt	gttttgtact	tccagtatcg	ttcatttgtg	tgctatctct	420
ttggatagat	actggtcaat	cacacaagca	atcgaataca	atttgaagag	aaccccaaga	480
agaattaaag	ctatcatcgt	tactgtttgg	gttatttccg	cagttattag	ttttccacct	540
ttgatttcca	ttgaaaagaa	aggtgctggt	gggtggtcaac	aacctgcaga	accaagtgtg	600
aagattaatg	atcaaaagtg	gtatgttatt	tcttcatcca	ttgggttcttt	ctttgctcca	660
tgtttgatca	tgatcttggg	ttacgttaga	atctatcaaa	tcgctaagag	aagaactaga	720
gttccacctt	ctagaagagg	tccagatgca	atggtttcaa	aaggtgaaga	attgtttact	780
gggtgtgttc	ctattttggt	tgaattagat	ggtgacgtta	atggtcataa	gtttagtgtt	840
tctggtgaag	gtgaagggtga	cgctacatac	ggtaaattga	ccttgaagtt	tatttgtact	900
actggtaaat	tgccagttcc	ttggccaacc	ttggttacca	ctttaactta	tggtgttcaa	960
tgtttttcca	gatacccaga	tcatatgaag	caacatgatt	tctttaagag	tgctatgcct	1020
gaaggttacg	ttcaagaaag	aactattttc	tttaaggatg	atggtaacta	caagacaaga	1080
gcagagggtta	agtttgaagg	tgacaccttg	gttaacagaa	tcgaattgaa	gggtatcgat	1140
ttcaaggaag	atggtaacat	cttgggtcat	aagttggaat	acaattacaa	ctcccataac	1200
gtttacatca	tggctgataa	gcaaaagaat	ggatttaaag	tttaacttcaa	gatcagacat	1260
aacatcgaag	atggttcagt	tcaattggca	gatcattacc	aacaaaacac	accaattggt	1320
gacggtcctg	ttttgttacc	agataaccat	tacttgtcaa	cccaatccgc	tttaagtaaa	1380
gatcctaacg	aaaagagaga	tcatatgggt	ttgttggaat	tcgttactgc	tgcaaggatc	1440
acattgggta	tggatgaatt	gtacaagaga	tggagaggta	gacaaaacag	agaaaagaga	1500
ttcactttcg	ttttggctgt	tggtattggt	gttttcgttg	tttgttggtt	cccatttttc	1560
tttacttaca	cattgatcgc	agttgggtgt	cctgttccat	ctcaattggt	caacttcttt	1620
ttctggttcg	gttactgtaa	cagttctttg	aacctcagtt	tatatactat	tttcaatcat	1680
gatttcagaa	gagcttttaa	aaagattttg	tgtagagggt	acagaaagag	aatcgttatg	1740
acctetaagg	tttacgatcc	agaacaaaga	aagagaatga	ttactgggtc	tcaatggtgg	1800
gcacgttgta	agcaaatgaa	cgttttggat	tcttttatta	actactacga	ttcagaaaag	1860
catgctgaaa	acgcagttat	tttcttgcac	ggtaacgctg	catcatccta	tttgtggaga	1920
catgttggtc	ctcatattga	accagttgct	agatgtatca	tcccagattt	gatcgggatg	1980
ggtaaatctg	gtaaatctgg	taacgggtct	tacagattgt	tggatcatta	caagtacttg	2040
acagcatggt	tcgaattggt	gaatttgcca	aagaaaatta	tcttcgttgg	tcattgattg	2100
gggtgcttgt	tggcatlcca	ttactcatac	gaacatcaag	ataaaattaa	ggctatcggt	2160
catgcagaat	ccgttggtga	tggtattgaa	agttgggatg	aatggccaga	tatcgaagaa	2220
gatatcgctt	taattaagtc	tgaagaagg	gaaaagatgg	ttttggaaaa	caactttttc	2280
gttgaaacca	tgttgccctc	aaagatcatg	agaaagtgtg	aaccagaaga	attcgctgca	2340
tatttggaac	cttttaaaga	aaagggtgaa	gttagaagac	caactttgtc	atggcctaga	2400
gaaattccat	tagttaaagg	tggtaaacct	gatgttggtc	aaatcgltag	aaactacaac	2460
gcttacttga	gagcatctga	tgatttgcc	aagatgttca	tcgaatccga	tccaggtttc	2520
ttttctaag	ctattgttga	aggtgctaag	aaattcccaa	acactgaatt	cgtaaggtt	2580
aagggtttgc	atttctctca	agaagatgct	cctgatgaaa	tgggtaaata	catcaagtca	2640
ttcgttgaaa	gagttttgaa	aatgaacaa	taa			2673

<210> 54

<211> 890

<212> PRT

<213> Artificial Sequence

<220>

<223> 2A adrenergic receptor-BRET construct

<400> 54

Met	Gly	Tyr	Pro	Tyr	Asp	Val	Pro	Asp	Tyr	Ala	Ser	Met	Gly	Ser	Leu	1	5	10	15
Gln	Pro	Asp	Ala	Gly	Asn	Ser	Ser	Trp	Asn	Gly	Thr	Glu	Ala	Pro	Gly	20	25	30	
Gly	Gly	Thr	Arg	Ala	Thr	Pro	Tyr	Ser	Leu	Gln	Val	Thr	Leu	Thr	Leu	35	40	45	
Val	Cys	Leu	Ala	Gly	Leu	Leu	Met	Leu	Phe	Thr	Val	Phe	Gly	Asn	Val	50	55	60	
Leu	Val	Ile	Ile	Ala	Val	Phe	Thr	Ser	Arg	Ala	Leu	Lys	Ala	Pro	Gln	65	70	75	80
Asn	Leu	Phe	Leu	Val	Ser	Leu	Ala	Ser	Ala	Asp	Ile	Leu	Val	Ala	Thr	85	90	95	
Leu	Val	Ile	Pro	Phe	Ser	Leu	Ala	Asn	Glu	Val	Met	Gly	Tyr	Trp	Tyr	100	105	110	
Phe	Gly	Lys	Val	Trp	Cys	Glu	Ile	Tyr	Leu	Ala	Leu	Asp	Val	Leu	Phe	115	120	125	
Cys	Thr	Ser	Ser	Ile	Val	His	Leu	Cys	Ala	Ile	Ser	Leu	Asp	Arg	Tyr	130	135	140	
Trp	Ser	Ile	Thr	Gln	Ala	Ile	Glu	Tyr	Asn	Leu	Lys	Arg	Thr	Pro	Arg	145	150	155	160
Arg	Ile	Lys	Ala	Ile	Ile	Val	Thr	Val	Trp	Val	Ile	Ser	Ala	Val	Ile	165	170	175	
Ser	Phe	Pro	Pro	Leu	Ile	Ser	Ile	Glu	Lys	Lys	Gly	Ala	Gly	Gly	Gly	180	185	190	
Gln	Gln	Pro	Ala	Glu	Pro	Ser	Cys	Lys	Ile	Asn	Asp	Gln	Lys	Trp	Tyr	195	200	205	
Val	Ile	Ser	Ser	Ser	Ile	Gly	Ser	Phe	Phe	Ala	Pro	Cys	Leu	Ile	Met	210	215	220	
Ile	Leu	Val	Tyr	Val	Arg	Ile	Tyr	Gln	Ile	Ala	Lys	Arg	Arg	Thr	Arg	225	230	235	240
Val	Pro	Pro	Ser	Arg	Arg	Gly	Pro	Asp	Ala	Met	Val	Ser	Lys	Gly	Glu	245	250	255	
Glu	Leu	Phe	Thr	Gly	Val	Val	Pro	Ile	Leu	Val	Glu	Leu	Asp	Gly	Asp	260	265	270	
Val	Asn	Gly	His	Lys	Phe	Ser	Val	Ser	Gly	Glu	Gly	Glu	Gly	Asp	Ala	275	280	285	
Thr	Tyr	Gly	Lys	Leu	Thr	Leu	Lys	Phe	Ile	Cys	Thr	Thr	Gly	Lys	Leu	290	295	300	
Pro	Val	Pro	Trp	Pro	Thr	Leu	Val	Thr	Thr	Leu	Thr	Tyr	Gly	Val	Gln	305	310	315	320
Cys	Phe	Ser	Arg	Tyr	Pro	Asp	His	Met	Lys	Gln	His	Asp	Phe	Phe	Lys	325	330	335	
Ser	Ala	Met	Pro	Glu	Gly	Tyr	Val	Gln	Glu	Arg	Thr	Ile	Phe	Phe	Lys	340	345	350	
Asp	Asp	Gly	Asn	Tyr	Lys	Thr	Arg	Ala	Glu	Val	Lys	Phe	Glu	Gly	Asp	355	360	365	
Thr	Leu	Val	Asn	Arg	Ile	Glu	Leu	Lys	Gly	Ile	Asp	Phe	Lys	Glu	Asp	370	375	380	
Gly	Asn	Ile	Leu	Gly	His	Lys	Leu	Glu	Tyr	Asn	Tyr	Asn	Ser	His	Asn	385	390	395	400
Val	Tyr	Ile	Met	Ala	Asp	Lys	Gln	Lys	Asn	Gly	Ile	Lys	Val	Asn	Phe	405	410	415	

7011

Lys	Ile	Arg	His	Asn	Ile	Glu	Asp	Gly	Ser	Val	Gln	Leu	Ala	Asp	His
			420					425					430		
Tyr	Gln	Gln	Asn	Thr	Pro	Ile	Gly	Asp	Gly	Pro	Val	Leu	Leu	Pro	Asp
			435				440					445			
Asn	His	Tyr	Leu	Ser	Thr	Gln	Ser	Ala	Leu	Ser	Lys	Asp	Pro	Asn	Glu
			450			455					460				
Lys	Arg	Asp	His	Met	Val	Leu	Leu	Glu	Phe	Val	Thr	Ala	Ala	Gly	Ile
465					470					475					480
Thr	Leu	Gly	Met	Asp	Glu	Leu	Tyr	Lys	Arg	Trp	Arg	Gly	Arg	Gln	Asn
				485					490					495	
Arg	Glu	Lys	Arg	Phe	Thr	Phe	Val	Leu	Ala	Val	Val	Ile	Gly	Val	Phe
			500					505					510		
Val	Val	Cys	Trp	Phe	Pro	Phe	Phe	Phe	Thr	Tyr	Thr	Leu	Ile	Ala	Val
		515					520					525			
Gly	Cys	Pro	Val	Pro	Ser	Gln	Leu	Phe	Asn	Phe	Phe	Phe	Trp	Phe	Gly
	530					535					540				
Tyr	Cys	Asn	Ser	Ser	Leu	Asn	Pro	Val	Ile	Tyr	Thr	Ile	Phe	Asn	His
545					550					555					560
Asp	Phe	Arg	Arg	Ala	Phe	Lys	Lys	Ile	Leu	Cys	Arg	Gly	Asp	Arg	Lys
				565					570					575	
Arg	Ile	Val	Met	Thr	Ser	Lys	Val	Tyr	Asp	Pro	Glu	Gln	Arg	Lys	Arg
			580					585					590		
Met	Ile	Thr	Gly	Pro	Gln	Trp	Trp	Ala	Arg	Cys	Lys	Gln	Met	Asn	Val
		595					600					605			
Leu	Asp	Ser	Phe	Ile	Asn	Tyr	Tyr	Asp	Ser	Glu	Lys	His	Ala	Glu	Asn
	610					615					620				
Ala	Val	Ile	Phe	Leu	His	Gly	Asn	Ala	Ala	Ser	Ser	Tyr	Leu	Trp	Arg
625					630					635					640
His	Val	Val	Pro	His	Ile	Glu	Pro	Val	Ala	Arg	Cys	Ile	Ile	Pro	Asp
				645					650					655	
Leu	Ile	Gly	Met	Gly	Lys	Ser	Gly	Lys	Ser	Gly	Asn	Gly	Ser	Tyr	Arg
			660					665					670		
Leu	Leu	Asp	His	Tyr	Lys	Tyr	Leu	Thr	Ala	Trp	Phe	Glu	Leu	Leu	Asn
		675					680					685			
Leu	Pro	Lys	Lys	Ile	Ile	Phe	Val	Gly	His	Asp	Trp	Gly	Ala	Cys	Leu
	690					695					700				
Ala	Phe	His	Tyr	Ser	Tyr	Glu	His	Gln	Asp	Lys	Ile	Lys	Ala	Ile	Val
705					710					715					720
His	Ala	Glu	Ser	Val	Val	Asp	Val	Ile	Glu	Ser	Trp	Asp	Glu	Trp	Pro
				725					730					735	
Asp	Ile	Glu	Clu	Asp	Ile	Ala	Leu	Ile	Lys	Ser	Glu	Glu	Gly	Glu	Lys
			740					745					750		
Met	Val	Leu	Glu	Asn	Asn	Phe	Phe	Val	Glu	Thr	Met	Leu	Pro	Ser	Lys
		755					760					765			
Ile	Met	Arg	Lys												

70kk

Phe Ser Gln Glu Asp Ala Pro Asp Glu Met Gly Lys Tyr Ile Lys Ser
 865 870 875 880
 Phe Val Glu Arg Val Leu Lys Asn Glu Gln
 885 890

<210> 55
 <211> 1389
 <212> DNA
 <213> Mus musculus

<400> 55
 atgggctacc catacgacgt cccagactac gccagcatgg gctcactgca gccggatgcc 60
 ggcaacagca gctggaacgg gaccgaagcg cccggaggcg gcacccgagc caccoccttac 120
 tccttgcaagg tgacactgac gctgggtttgc ctggctggcc tgctcatgct gttcacagta 180
 tttggcaacg tgctgggttat tatcgcggtg ttcaccagtc gcgcgctcaa agtcccccac 240
 aacctcttcc tgggtgtccct ggcctcagcg gacatcctgg tggccacgct ggtcattccc 300
 ttttctttgg ccaacgaggt tatgggttac tggtaacttg gtaagggtgt gtgtgagatc 360
 tatttggttc tegacgtgct cttttgcacg tcgtccatag tgcacctgtg cgccatcagc 420
 cttgaccgct actggtecat cagcgaggcc atcgagtaca acctgaagcg cagcccgctg 480
 cgcacaaagg ccatcattgt caccgtgtgg gtcacatcgg ctgtcatctc ctccccgcca 540
 ctcatctcca tagagaagaa gggcgctggc ggccgggcagc agccggccga gccaaagtgc 600
 aagatcaacg accagaagtg gtatgtcacc tcctcgctcca tcggttcctt cttecgccct 660
 tgccatcaca tgatcctggg ctacgtgcgt atttaccaga tcgccaagcg tcgcacccgg 720
 tgccctccag ccgccggggg ccggacgcct cgttcgcgcg ccgccggggg ccgcgatcgc 780
 agggcccaacg ggctggggccc ggagcgcggc gcgggtccca ccggcgctga ggccggagccg 840
 ctgcccaccc agcttaacgg tgccccgggg gagcccgcg ccgccggggc ccgcgatggg 900
 gatgcgctgg acctagagga gagttcgctg tccgagcacg ccgagcgggc cccggggccc 960
 cgcagacccg accgcggccc ccgagccaag ggcaagaccc gggcgagtca ggtgaagccg 1020
 ggggacagtc tgccgcggcg cgggcccggg gccgcggggc cgggggcttc ggggtccggg 1080
 cacggagagg agcgcggcgg gggcgccaaa gcgtcgcgct ggcgcgggag gcaaaaccgg 1140
 gagaaacgct tcacgttcgt gctggcggtg gtgatcgggc tgttcgtggt gtgttggttt 1200
 ccgttctttt tcacctacac gtcacatagc gtcggctgcc ccgtgcccag ccagctcttc 1260
 aacttcttct tctgggttcg ctactgcaac agctcgctga acctgttat ctacaccatc 1320
 ttcaaccacg acttccgacg cgccttcaag aagatcctct gccgtgggga cagaaaacgc 1380
 atcgtgtga 1389

<210> 56
 <211> 462
 <212> PRT
 <213> Mus musculus

<400> 56
 Met Gly Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Met Gly Ser Leu
 1 5 10 15
 Gln Pro Asp Ala Gly Asn Ser Ser Trp Asn Gly Thr Glu Ala Pro Gly
 20 25 30
 Gly Gly Thr Arg Ala Thr Pro Tyr Ser Leu Gln Val Thr Leu Thr Leu
 35 40 45
 Val Cys Leu Ala Gly Leu Leu Met Leu Phe Thr Val Phe Gly Asn Val
 50 55 60
 Leu Val Ile Ile Ala Val Phe Thr Ser Arg Ala Leu Lys Ala Pro Gln
 65 70 75 80
 Asn Leu Phe Leu Val Ser Leu Ala Ser Ala Asp Ile Leu Val Ala Thr
 85 90 95

7011

Leu	Val	Ile	Pro	Phe	Ser	Leu	Ala	Asn	Glu	Val	Met	Gly	Tyr	Trp	Tyr
			100					105					110		
Phe	Gly	Lys	Val	Trp	Cys	Glu	Ile	Tyr	Leu	Ala	Leu	Asp	Val	Leu	Phe
		115					120					125			
Cys	Thr	Ser	Ser	Ile	Val	His	Leu	Cys	Ala	Ile	Ser	Leu	Asp	Arg	Tyr
	130					135					140				
Trp	Ser	Ile	Thr	Gln	Ala	Ile	Glu	Tyr	Asn	Leu	Lys	Arg	Thr	Pro	Arg
145					150					155					160
Arg	Ile	Lys	Ala	Ile	Ile	Val	Thr	Val	Trp	Val	Ile	Ser	Ala	Val	Ile
				165					170					175	
Ser	Phe	Pro	Pro	Leu	Ile	Ser	Ile	Glu	Lys	Lys	Gly	Ala	Gly	Gly	Gly
			180					185					190		
Gln	Gln	Pro	Ala	Glu	Pro	Ser	Cys	Lys	Ile	Asn	Asp	Gln	Lys	Trp	Tyr
		195					200					205			
Val	Ile	Ser	Ser	Ser	Ile	Gly	Ser	Phe	Phe	Ala	Pro	Cys	Leu	Ile	Met
	210					215					220				
Ile	Leu	Val	Tyr	Val	Arg	Ile	Tyr	Gln	Ile	Ala	Lys	Arg	Arg	Thr	Arg
225					230					235					240
Val	Pro	Pro	Ser	Arg	Arg	Gly	Pro	Asp	Ala	Cys	Ser	Ala	Pro	Pro	Gly
				245					250					255	
Gly	Ala	Asp	Arg	Arg	Pro	Asn	Gly	Leu	Gly	Pro	Glu	Arg	Gly	Ala	Gly
			260					265					270		
Pro	Thr	Gly	Ala	Glu	Ala	Glu	Pro	Leu	Pro	Thr	Gln	Leu	Asn	Gly	Ala
		275					280					285			
Pro	Gly	Glu	Pro	Ala	Pro	Ala	Gly	Pro	Arg	Asp	Gly	Asp	Ala	Leu	Asp
	290					295					300				
Leu	Glu	Glu	Ser	Ser	Ser	Ser	Glu	His	Ala	Glu	Arg	Pro	Pro	Gly	Pro
305					310					315					320
Arg	Arg	Pro	Asp	Arg	Gly	Pro	Arg	Ala	Lys	Gly	Lys	Thr	Arg	Ala	Ser
				325					330					335	
Gln	Val	Lys	Pro	Gly	Asp	Ser	Leu	Pro	Arg	Arg	Gly	Pro	Gly	Ala	Ala
			340					345					350		
Gly	Pro	Gly	Ala	Ser	Gly	Ser	Gly	His	Gly	Glu	Glu	Arg	Gly	Gly	Gly
		355					360					365			
Ala	Lys	Ala	Ser	Arg	Trp	Arg	Gly	Arg	Gln	Asn	Arg	Glu	Lys	Arg	Phe
	370					375					380				
Thr	Phe	Val	Leu	Ala	Val	Val	Ile	Gly	Val	Phe	Val	Val	Cys	Trp	Phe
385					390					395					400
Pro	Phe	Phe	Phe	Thr	Tyr	Thr	Leu	Ile	Ala	Val	Gly	Cys	Pro	Val	Pro
				405					410					415	
Ser	Gln	Leu	Phe	Asn	Phe	Phe	Phe	Trp	Phe	Gly	Tyr	Cys	Asn	Ser	Ser
			420					425					430		
Leu	Asn	Pro	Val	Ile	Tyr	Thr	Ile	Phe	Asn	His	Asp	Phe	Arg	Arg	Ala
		435					440					445			
Phe	Lys	Lys	Ile	Leu	Cys</										

81732212

71

CLAIMS:

1. A method of detecting a compound, the method comprising,
 - i) contacting a sample with a cell-free composition comprising at least one G protein coupled receptor embedded in a lipid bilayer, and which is capable of binding the compound, wherein the G protein coupled receptor comprises one or more subunits that are the same or different, each subunit being a G protein coupled receptor, and wherein the G protein coupled receptor comprises a bioluminescent protein and an acceptor molecule, and wherein the bioluminescent protein is a *Renilla* luciferase or a biologically active variant or fragment thereof, and the acceptor molecule is green fluorescent protein 2 (GFP²),
 - 10 ii) simultaneously or sequentially with step i) providing a substrate of the bioluminescent protein, and allowing the bioluminescent protein to modify the substrate, wherein the substrate is Coelenterazine 400a,
 - iii) determining if step ii) modulates bioluminescent resonance energy transfer (BRET) between the bioluminescent protein and the acceptor molecule,
 - 15 wherein the spatial location and/or dipole orientation of the bioluminescent protein relative to the acceptor molecule is altered when the compound binds the G protein coupled receptor, and wherein when expressed in a cell the N-terminus of the G protein coupled receptor, or subunits thereof, is outside the cell and the C-terminus inside the cell, and wherein the level of BRET is indicative of the relative amount of the compound in the sample,
 - 20 and wherein
 - 1) a subunit of the G protein coupled receptor which is capable of binding the compound comprises the bioluminescent protein and the acceptor molecule, and wherein the spatial location and/or dipole orientation of the bioluminescent protein relative to the acceptor molecule is altered when the compound binds the subunit, or

81732212

72

2) the G protein coupled receptor comprises a first subunit comprising the bioluminescent protein and the acceptor molecule, and a second subunit which is capable of binding the compound, and wherein the spatial location and/or dipole orientation of the bioluminescent protein relative to the acceptor molecule is altered when the compound binds
5 the second subunit,

and wherein in 1) and 2)

a) the bioluminescent protein forms part of the fifth non-transmembrane loop of the subunit, and the acceptor molecule forms part of the C-terminus, or

b) the acceptor molecule forms part of the fifth non-transmembrane loop of the
10 subunit, and the bioluminescent protein forms part of the C-terminus.

2. The method of claim 1, wherein the method is performed using microfluidics.

3. The method of claim 1 or claim 2, wherein the subunit is a chimera of a portion of two or more different G protein coupled receptor subunits, and wherein

i) the subunit comprises the N-terminus and at least a majority of the first
15 transmembrane domain of a first G protein coupled receptor subunit, at least a majority of the first non-transmembrane loop through to at least a majority of the fifth transmembrane domain of a second G protein coupled receptor subunit, and at least a majority of the fifth non-transmembrane loop through to the C-terminal end of the first G protein coupled receptor subunit, or

20 ii) the subunit comprises the N-terminus through to at least a majority of the fifth transmembrane domain of a first G protein coupled receptor subunit, and at least a majority of the fifth non-transmembrane loop through to the C-terminal end of a second G protein coupled receptor subunit.

81732212

73

4. The method according to any one of claims 1 to 3, wherein the cell-free composition was obtained by producing the G protein coupled receptor in a recombinant cell and disrupting the membrane of the cell.
5. The method of claim 4, wherein the recombinant cell is a yeast cell.
- 5 6. The method according to any one of claims 1 to 5, wherein the G protein coupled receptor is embedded in the lipid bilayer of a liposome.
7. The method according to any one of claims 1 to 6, wherein the G protein coupled receptor is an odorant receptor.
8. The method of claim 7, wherein the odorant receptor is a chordate receptor, a
10 nematode receptor, or a biologically active variant or fragment of any one thereof.
9. The method of claim 8, wherein the odorant receptor is a nematode receptor.
10. The method according to any one of claims 1 to 9 which provides at least a 10 fold more intense BRET signal than if the method used the same G protein coupled receptor present in an intact cell instead of being in a cell-free composition.
- 15 11. A method for screening for a compound that binds a G protein coupled receptor, the method comprising,
 - i) contacting a candidate compound with a cell-free composition comprising at least one G protein coupled receptor embedded in a lipid bilayer, and which is capable of binding the compound, wherein the G protein coupled receptor comprises one or more
20 subunits that are the same or different, each subunit being a G protein coupled receptor, and wherein the G protein coupled receptor comprises a bioluminescent protein and an acceptor molecule, and wherein the bioluminescent protein is a *Renilla* luciferase or a biologically active variant or fragment thereof, and the acceptor molecule is green fluorescent protein 2 (GFP²),

81732212

74

ii) simultaneously or sequentially with step i) providing a substrate of the bioluminescent protein, and allowing the bioluminescent protein to modify the substrate, wherein the substrate is Coelenterazine 400a,

5 iii) determining if step ii) modulates bioluminescent resonance energy transfer (BRET) between the bioluminescent protein and the acceptor molecule,

wherein a modulation of BRET indicates that the compound binds the G protein coupled receptor, and wherein when expressed in a cell the N-terminus of the G protein coupled receptor, or subunits thereof, is outside the cell and the C-terminus inside the cell, and wherein the level of BRET is indicative of the relative amount of the compound in the sample,

10 and wherein

1) a subunit of the G protein coupled receptor which is capable of binding the compound comprises the bioluminescent protein, and the acceptor molecule, and wherein the spatial location and/or dipole orientation of the bioluminescent protein relative to the acceptor molecule is altered when the compound binds the subunit, or


15 2) the G protein coupled receptor comprises a first subunit comprising the bioluminescent protein, and the acceptor molecule, and a second subunit which is capable of binding the compound, and wherein the spatial location and/or dipole orientation of the bioluminescent protein relative to the acceptor molecule is altered when the compound binds the second subunit,

20 and wherein in 1) and 2),



a) the bioluminescent protein forms part of the fifth non-transmembrane loop of the subunit, and the acceptor molecule forms part of the C-terminus, or

b) the acceptor molecule forms part of the fifth non-transmembrane loop of the subunit, and the bioluminescent protein forms part of the C-terminus.



1/16

**Figure 1**

2/16

A**B****Figure 2**

3/16

A**B****Figure 3**

4/16






Figure 4

5/16

**Figure 5**

6/16**Figure 6**

7/16




Figure 7

8/16




Figure 8

9/16






Figure 9

10/16**Figure 10**

11/16

**Figure 11**

12/16








Figure 12

13/16**Figure 13**

14/16**Figure 14**

15/16**Figure 15**

16/16**Figure 16**

